var title_f20_53_21328="SIS submucous myoma1";
var content_f20_53_21328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Saline infusion sonohysterogram of a submucous myoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A posterior mid-segment submucous myoma measuring 1.6 x 1.9cm is identified after infusion of saline. The distance from the back of the myoma to the serosal surface measures 1.2cm (calipers). The endometrium surrounding the fluid is thin, compatible with early proliferative phase.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_53_21328=[""].join("\n");
var outline_f20_53_21328=null;
var title_f20_53_21329="Multiple nerve root metastases";
var content_f20_53_21329=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F60153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F60153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple nerve root metastases",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T2-weighted sagittal MRI of the lower thoracic, lumbar, and sacral spine shows abnormal hyperintensity of multiple nerve roots in a patient with leptomeningeal metastases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Seward Rutkove, MD and Andrew Tarulli, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_53_21329=[""].join("\n");
var outline_f20_53_21329=null;
var title_f20_53_21330="Air plethysmography";
var content_f20_53_21330=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Air plethysmography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Air plethysmography indirectly measures changes in leg volume by quantifying air displacement within a polyurethane cuff wrapped around the calf.",
"    <br/>",
"    (A) The test begins with the patient supine. The limb being evaluated is elevated to drain the venous system. The cuff is placed on the lower leg and inflated to a low pressure to calibrate the equipment.",
"    <br/>",
"    (B) The patient is asked to stand, which fills the veins. The maximum volume achieved is the functional venous volume (VV). The time needed to fill 90 percent of the functional venous volume (90%VV) is the venous filling time (VFT90). The venous filling index (VFI) is 90%VV/VFT90.",
"    <br/>",
"    (C) With the limb filled with blood, the patient is asked to dorsiflex at the ankle (toe-up) which ejects blood from the leg (measured as the ejection volume [EV]). The ejection fraction (EF) is the ratio of ejection volume to the functional venous volume (EV/VV x 100%).",
"    <br/>",
"    (D) Next, the patient is asked to perform a series of consecutive dorsiflexion movements (toe-ups), which empties blood from the leg allowing the calculation of the residual volume (RV). The residual volume fraction is the ratio of the residual volume to the functional venous volume (RV/VV x 100%).",
"    <br/>",
"    (E) With the limb dependent and resting, the leg refills with blood.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Perrin M, Gillet JL, Guex JJ. Syndrome post-thrombotique. In: Encyclop&eacute;die M&eacute;dico-Chirurgicale, Elsevier, 2003. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_53_21330=[""].join("\n");
var outline_f20_53_21330=null;
var title_f20_53_21331="Breech7";
var content_f20_53_21331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Delivery of the head",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Often, delivery of the head is easily accomplished with continued expulsive forces from above, suprapubic pressure, and gentle traction. Cephalic flexion is maintained by pressure (heavy arrow) on the fetal maxilla (not mandible!)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gabbe, SG, Niebyl, JR, Simpson, JL (Eds). Obstetrics: Normal and Problem Pregnancies, 4th ed, Churchill Livingstone New York 2003. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_53_21331=[""].join("\n");
var outline_f20_53_21331=null;
var title_f20_53_21332="P6 acupressure point PI";
var content_f20_53_21332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F72347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F72347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    P6 acupressure point",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 376px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF4AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3EcH8aeM+ppOjGnDHXvTIHrn1PNOJwMk1CJMkKgyakVDkGRs+w6UALuJOEyc96cqE8u2fSnAADjAFKf1oGA9ulOGfWmg08dOtAwGeOaM8n+VB7mjvxxQIXPHXig5zQB6c06gYAe5oz7mgD8qO3WmAuc96U5yDR+dAxn3pAOB96DmkFOXmgABoGetHHrSZ5/xoAXmjJ9aQgde9GPXigBwPAHU+9Oxn1pqYPanfTigBp+p60xs4qVvX/JqM96AKzg4PWqk68Hmr7jPWq8q9aTEYt0hweuawtQhJz1/OunuI+D0rLuocg0MDzbxHZM8bMM5Fedaikkcv3mH48V7jqFiHDblzn1ridc0BWZ3UZPpUSRrTZ5lMZOgY/wDfRpq6hqEaeWt7cBOwLkgfnXSz6Twf3fArLuNOZAeDx3qJI6E+xzFx4t1LQ5hHqFtFqNo+THK37uQexYcce4p8njfR7qMh4LyFsdDhh9Mg/wBK0NS02DULJ7acEK3IYclD2NeWajZTafeS21yu2RDj2I7Ee1ChGQOtUp9dDpdR8VQksLC3kPo0zY/Qf41v/De9k1HTdUtp3d5o5VuFyx6Nwce2QOPevMq6/wCGFytv4hlR3CCW2dRnoSMN/Q05QSi7Cp1pSqLmOu1GGZAxjjQsOh/yat6G7rYIskssMhcsQg6jtzWjqVoFg80yKFIztx2pmmYjAAJAI3A+1c078p6dKKc00alqqlUP226Vu/z/ANK6rw7PscBrydtowBtyayNK3zbVAU8ZIOOea6rSYwdh8pUYDPAxx9a45XZ6kEkrGrFGws7iV2YgKTyfap/DcRWBN4JBUcVn+NL5dI8KXc2cKNkQP+07BR/Ot3w5Ik9pFtOcgcVjzNPU551bJmX4vtXn0y+uY5Zle3AZFQ4DAfeBH+eleI3N1eahcO1y80SMchEPJXsPWvoTxFAH0PUUHR4Zecf7Jrw23TyrfMY25wfMf7xH0rWc1FJo53eas3oVoo9hcorl1AJYg5I/z6VZyEgSSSSSPBzyx5HpUmJDtLTNlsZIHr296SRHDrtMi5J28gsT7DtWDm2UopbEFxcyRwu4Zo+u3fkED6ViyzS3BYiZ0j7yA4Nbbad5pczF2JOSG7f4077JCPkVd+CPl6A/gK0jUjAznTcinBqcKxJGzzgqoUDaW34GM8dSetWXuWKBo1nbPGC23HvjsP8A69WiiWwEs8scCoMqeP1qCS5kkCyWlu8pOf3jDYP17VPMpO6RSTirNjf9OZVzKlsvcISzY+p4BocJ5oMk0zMOPmkPP4f/AFqRUdt0l3MPmHKQfKv4v/hUIGw+Xa27O7DLFeBg9yxoXl/XzHtuWI5nRMQAxrjILE5/Lr+Zqo8uZCGkklOCCo5x+FSPauFZri48tMfMIxtA/HvTI2RkUWdviI/8t5shfr6mqT6ktO1mIHu5GPl4t4wOCXDP+Q4FMS5jjbary3UxPLbi2Pq3QU75CwBZrt8Y8tQFTPsP8TS3DDb5N3IFJHy29sMkn3x/Wq/r+uorWHPPKIi0jiScDmOLJ2ge5qoWnlAaaQxoeFjQkMf8+1TLbTnci/6LCmcKh3P+OeBQhhSZhApkm24eRuo9i3QfQU3Ky0J5b7kR+0OMbvs5zgDPzkeuP8ad+8Rf3ZeRh0eR8gH1z0oWQO21GkkbBBK/cH1PemSusa4fzJpCeI1Gf8/Wi7CysNi82adGjeR2BHz5IQH+ZP50VYGRIGun8uI4GwdQfc/4UVcbsho+rN3zYUFj7U9UY43tn2FKqgHjIp9e0eGAGMAdB2p4OBim57cU4DkUgAHOKdgCkBpc+lAC0ucjikAzinY4wcUxigHrS4757Ug4pfSkADnqcUvUUnIxTu9ABxu9KTvS4o70AKKBS/h1o70ALQKTrSigYpx3/EUnX0FKOvWkbk/SgQA8dKPrSd+nHtTgOKAFB9euKUZ465puMcdPanAc89aAHAU1hk8CnD0pevSgCBhxUTpVph+dRsvPNAGdLED24qjND7YradM9AKqyRAigDnbi3JB4rIu7Hfnj8K6+W34qjPbZosNaHBXmlKzE7cGuf1HSAASF/IV6ZcWmRgisi8sQc8cVLRrGdjx3UdNZGJC7TXG+LdCOp2u+Jf8ATIgTH/tj+7/hXuOqaSsmeO1cjqelBH4GAOai1ndF8yloz5uYFSQwIIOCDVrSr19N1K3vIwGaJw20/wAQ7j8RkV2PxD8Nm3ZtUtE/dscTqOx/v49D39/rXBir3Ri04s9/hlt9U8OWt5bN+4eIkZOMY6g+hGKp6SxuY7MwqWWXGMqSMZ9uorz3wNq9ykyaLNcg6beNsaJlLfM3GFI+6T+VesaPZpDfyeWvyQIscYBwEJ64/wAa4qvu6M9rDTVSPMtzpdM8Oa6IZpwLO4jUFkSMFHA/kTW/4OuU1KCL5Q0ZOeR6dc1o+FzKtszuTkDgk9asaHbJa3OooiBQXySPVgCT7da552smdiqSinGXyPJP2lte+yWei6LA2Gln+3SgHB2p8qfgSWP/AAGvQvhzqgn0e0mLcbAc18y/FvXv+Ei8f6ndISYIX+zQ4P8ABHxkfU5P416j8PNfe30i1hdSqxoACTkkepp4mg1Si+v+ZwYebq1px6HueqTxSaTcMrAhoplb24rxG1jcW6AEFyBwCOBXcLrKvoerxF8Ex+YrD1+7/WuDnuEhVdxVeAPmHP5DmuOd2lFHY4qm2mWAkYwry845Vfm/DNRySoXJiQKGxnC/zqrDNcXpJtoQYs/KZPlB46gdT+NK2nkgfbpmk4/1cZwo/Ad6z5UviYua690ZLdo7+Shd5c8pCQx/E9BUm2+KqdsFonU7jucjrRC1pbuYYIz5n92FNzD/AHm6LUjrdXBUOyQQ9NsQLMfqx/pmm2lstPMFd7v7ivNbWcUqvIvmMTuHmEuW+g61YZLqRowu2JWHIfnA7fKOM/jUai2tBsgXc5zk8sc+9IZGji33kv2cEHduPP0GO/0ou3/X6BsiVbO1jZzd3E0zZ+SMHcCfoOKS6aRwxLJCpAO9iCTxzx2/GprJYpYWeKMrkgYddrNjqSOtVNQuYRDGY4kCIcB5xsX8B1NWk5Mm6RAqB3L26mZhwZZThB/jUDqkku6WWa9fOAI8rGD/AJ9amZkaIPds+ScBXyq/UDrSPIRDhV+z2/RXYAD8B3q1f+v6/ITt/X9fmCo+A80gijQcpFwCPc5p0c8TPmyjIHOZGG0Y9Mn+lQwQlxwGdDyZJcDj2WpXMAkTzleSbHyIp3N+CjpRZbCRKwMaElzcSuNhVgBGO4x3zVGfAPl3hErdfJTp9No61o/ZmMQeZ1hTlvLQAsoPqegqEMsalbCIAHq7A/mT1NLmHy9RgjlaLbKVtohwqr976egqErJBJstIgn96Vjz/AIn9KCzCZABNcztnA4CoPfsP51JPFGxU3D78j/VDlSf6/jT2/r+vxDdFe3w9wvlOZnDZZ8jHXpmip2W4aVEYpCobhQOR+XA+lFWrMh3R9XA8ninYz1pO/wBaXt7+1e6fPDhQeD1pvWnj6UhgOeuc04U0Z70+gBaVcdqaDjnOKAfbNAx+etFJg8dvxpegHrTAWndPc03P5U7HakADpxS+tJ2paAFFHH4UCjOB2FMBaB7U3d83elpALS/0pKKBijgcD8aXHH69KbSj8RmgQo70oHYZ5FIMkY4/Ol7gUwHfU/nSZGcdu9MyWxzUi9OaQARn6+tG0dKWloAjKccVG6Zqx+dJii4yjJFkdKrSw5NabJntUbxg5oAxJoMZ4rOubYc4FdFLFmqNxDjOelAXORvbYDJxxXOapZB88YIrur2Dg1gXsAGf84qGguedX+mIytHNGJImUq6NyGU9QfavCPGfhmTw/rPlHcbCcloJPb+6T6jp+tfTGpxei5/rXG+JNEh8QWEmn3XG47opccxv2P09faktDW3MrHivhueG01/SX6qt1GxPYfMM171o8CwXF7G+ci6YDntxivEhpNxpt7cWF7Cba5t22SDvnsQfQjmvStF8TW7wxRag7JcKADLglZCP4jjlT6+tcdfc9TAvkTUj2nRJFW3xu5I5zjpWT408Qw+HPDWv6nuAkRCIQf4pSAqD8z+hrk7XxXbWsLCO7hZj0EALsfxPSuE+JmpS+ItEkiDsBbuJo4lBOcZBLH1wTXPFe0lGJ0YiSjByTPIYGxON/O7IOfevXvCl9anwzYu5K3EaGFwnzFtpwD7cY6142Dg5r1H4W3Fs9tqMVzGjPHsnjLYC46HOffFduLdqfN2PJwU3GrZdTropdSu7eSO2dLO2mADSfedgD09Bz/8ArpbXTLaJWJDzOT85LkB/rTnmluZCsSlkwcscpGo+vVvwoe1jMf76YyKMfJyFHqcD29a8iU33tc9e3M7vVk015tAFtEJudoWIYVfxPU/SmLBNMW+1spwMiGIEAeueef0pq3ccp8rT42l2gksvyoo/3un4DNRSRgJjUrnzM8rbW4Kg+n+038qlRt/Wo7p/1oOiuI0jEVogbBwRCAQOP4j0FOmiZXD310ypkbYYerf7x6mrM64tbYqy2EKIfOiYAk88Yx0GOoOeapxPg/8AEvgDLJktcSEgD8ep/Cl5r+vmO/Rj3mkWMCNEsoRwCQNx+i9vxqG3XfIht4XmZcBp5Dk9+c/0FTPDFHOv2tmnm6gYPzf8BHP4nFF5PKLbc8iWUZPJcDI+gHGfzoXZdf69RvTVk8btawSebcAeacsxGAPYdc1RnlknuA8QSG3VcK8inI9SAep9zUkUSjDRb9xxi4nyzufYdcflTWghgmDTb7i6PIUncfoF6CqjZO73Id2vIjiVHmMkcTon3TPcEkt/ug/4AUSx28LhrgvPP2B55+nQU6b7RKcysLePHKkZYj69vwpkRiJb7BBvxw0x4Ufif6Vfz/r1F/X9IdIklw4ad/IhGeB1cf73p9KYHEXyaZaxlpDywOAPdmqS5aBWRbjbcTH7qKDz/j+NDJLt/eulvCeSoODR0/r+mO3b+v8AIikwQWnJuZgeI4z8gP0/xp7GTyzNqDCKM4xEg/Qnv+FJFJvDJYIqhfvS7cL9c1E1vbW8gnupmkmHSRjnafRf/rD8aNNn/X+Qa7jQZHHlwIbSAjcHC4Zvov8AU01pobYDG4MwwGOWc+wFS5lueUIgiHJduXYe1QYhjLNCAzZy0rHv65/wqkuhN+qJsSu6STOLWIbSFBzIR7ntRVe3Bfypcb5A2DLM3yAE9QKKtJmcnfU+tx1NGKQ5zzjFOFe4eALTvamdDSg4xSGONLTevTj6U4djQAClGMUlLmgB1LjOKQH3NKvtTAVf50tJ7mng8UDE6etGT2I4oNGDj+VIAJpcGlxxQKAEoHIpRRjigBQM0djS4o/nQAUoHU5xSfQU4ZxjmgBO2CM84pwJz7etNHLDqacOO2B7GgA5HP404fnScDvQefagBQQelLTfYDApR9aAFFFBIFRs5bhDz0pAPOOATzSFc0InzZP86lHuBTAqunrVSePIPFabDg+tVZkzzQBgXMXByKwdQg64FdbcxE5FZN3B8p9aQHCajb5U7utY1pZF7gMenQYrs7+0LseKpQ2giPzD5jU2NYs474leCX1/Rhq2lxbtZsY/njUc3MA5K/7y9R+I9K8csrqDyAYEecnBwvTPua+s9LV0ZHTIZTnNeU/FPwXF4ZvT4i0m3jj0e7kzcoB8trMx646BGPT0PHcVlXhePMlqjroT15Wzzyysbm5K/aJfKiOT5aDHH863RZWcFnJCyoiNGVy2Rj8/eqEFxLIUFnGxGM+YwwuPXJq7BbQRky3sn2iQdmztU+vvXlzlLroegox6aniGt232TVJ4gMKGyB7Gui+HVzHD4gsxcFPKfdCd/QEjIP5gUvxOsxBrizxj93Ou5cDAx1/rXO6TcNb3KyJ96NhIPqDmvXmvaw9V+Z4SvSnr0f5HunmO7M1pG1y33d6/Ki8dSx5P4VBdRxRlRfyPPJkEWkCcfio5P1OKuNNPc2yyyXC2trKqyIISN5BAPLdB+FQwGUB47HybWA/emcZLn2HVj7mvCTt/X6/5HvvX+v0/zJJBMMG5KafaEDbGjAyn/wBlQfTJpqyGDI0208sNzJcSZLY7deWPtUgW2tUVZpJbq5djsL/NI30HQCpLmOVV3XU/2Zeu0ncx/wA+lRe+/wDX6sq33/18kVUEaSGS5d5pT0V1z+Sg4/MmpbqO6kjUz3C2EGPvnmX8OwotllEgFlAYlfh7m5PzH6L1pJ0hgfdIftV5wBg72X/gI4FPr/X/AAyH0CFNgEdnA0KseZJvmkk98dfzqKeSzinVQGubwchP9Y6/0XipZLWefeL2ZbS3zzHESXYf7TUsDxJEYtIhQRI3zY4GfUt/hk0vPf8Arqw8tv67Efk3ci772VbS3IztU7pCPTNSII4YiLGAAjjfKecfWobhYLdjJfzNK3aNVIGfZRyfqaljE81thUS2tlJYEqN5OPXr+FHTy/D/AIIktfP8f+AVJdsWJLuVpGJ+WJBkE+mOp/SlCzz7jck20AGQMZk/Lov6mi3uLeKWWKyDTTfxSn5j+JpPLJLNOyuVIJXnaD7k/wBau9v6/QVhEl2BlsoEyeWdm2qP+BdT+FMmVFiD3nly7cEO67Uz688mnedPdIFgRShOPMYERjHv1NPKxxyDmS6nUclvup/QCnsG43zpbkL5LIsZGAxXj8B3qEBI3YoHuJuhfPC/j2+gp8zvcSMrFpM/8sYlwGHu3p+VRRjy5CjnzZBytrb8IP8AeY9T+QqktCW/6/r/AIcaSZS0aL5xTrj5UH496aihl3lhdMDxjAjQe3rVhg8wMThZmPPkRnCr9T3phgVZk3nzfLx+4QbYo/qe/wCdUmhNdhkeJ2WVcbI3GXkO1VI9M8HFFNmkkaVSm27YONgZQsajPG0d6K0inYym2nofWWcHing1EDycU8fyr2jwh+fxpVHqabSjrSAU/WnA0yigY8EZp1Mz6U5elAC96cvBpKcvTn1oAXGVpV6470nQj27U4deKAFAp2KaOtLQMKXr9KSloAP50Dp70H2pcE0AH86UD14oA6E07px1oAaBTs4HpRjnOaB6cUAHfqaUDB7/hQPzowO9ABxjvS0EetIzBRz1oAXPFMeQD7vJpAWkOMfKevtTkQLz1PrigBAHbkkjPtUgAA46mjnNKO3SgAFPHemA4p6mgBSPyqF0yKsKM0pTIoAzZo8dqybuPriuglTOazrmEdxQBzk9v1qstpliSO9bU0POe1RCLPagpMjs4NoGRWn9kt72zns7+3jubK5QxzQyLlXU9QRTbeH1FaEKgDAoKbPmr4geGr7wh4hXT8GbTbkGSxu5OhTuh/wBpeBjuMGsKPy4jhw9zcA5EcYJI/Dt+lfVHifw7ZeKvD9xpGpblSQbopk4eCQdHU9v6jIr5tvtKvtB1O60d7Fba6tGxLK+dso7SKerAjn9D0ry8XQUPeitP6/A9PC13UXLLdHB/FSxnn0K1v5o1Vo5TGQDkgHpn9a8ut22yr78V7r4msobrw/qdo9w095JD5wBOPucnavbgn16V4NyD7iurCS5qK8tDhxcOWq/PU9r8F3lrN4fsGkBmvYswBSS7Lg8bV6DjHNb8sTthrmVLOM9I0wzn8eg/CuJ+FN080epWUbpGXVJ956gDggDv1FdlLLYWrq7ebPdD5VGCzN+A6V5eIjy1XFf1/kephZc1KMn/AFYtWpOx/sca2gJ2/aHXdI/uM9ar3HkWUhY5luj8u5zvlbnPHZRn/wDVVqKK6vTuvSbO3H3Y42xI4927fSoreOCBSmmW4ZySC+ev1brXNonr/Xqzotp/X5CQw3E5eS8Jiib+HflyP9o9voMU241GC2zDZL5kuOVQAZ+p6Cm3caZI1G4ZVX7yKcfy5p9oWu1Zba1+y20f/LR125PsP607K3M9vw/4IJv5/iM8tI4/P1QgFsEICCo/2cdz7mkaae+BaENawKcl5R8xHt6U8/ZYrgiKN7icnOX5/H0AqTyp5ZP9JuMJ/wA8YuB+J/wouuv9fIaj/X/BM9RbxXBisfMvrxuHc5bH+83QD2/SnzWUs7hryfeinmOA4Hbgn/8AVVlru2XNrYJvkj5KxnCL/vGqk8IkO+9uBIvZFyqA+mOrGq1vfb8ybK1t/wAhN6keVYRIRztAO2NPx6mopYoRn7QTcvkFVA+QH2Hc+5pbqR1gwAtpF/tgbiPYUiqIod+RCjHcZJfvsKuN7CbuNlmkkZQzFSeFii5cj8OlTrEYo0jlcxr1WKI8n/eNMAZFLQBbWFjkuR+8k98H+v5UsoESOWLWsDHG9jukkPsP8/Sm+yBb3Yl0ZGGx2kSIAbYITh2/HsKjljYOEaRY0I5gt1y/4tUsW2ANujaNWH8TZlc+p/u1SvJLifi3eOEE/MAvUf73rRFa2CW1x0k0XzRFvLXGBDEcE4/vN/Ske4MiBTwg42AYA/z71hENDOFkDQyNncQeSPUGpY5XhZVZvMQg4LHqT6V0exS21OZVXfVGtD99SNo56+lFVLa5hkuEHVi2Mde9FJR7jc0z646k8U8e9IevpQDXsngj8/Wl3c/40wHn159aXt1IpjHg85znNHfntTQcDgU7POPSkA4HPTpTgc00fpSqfSgY+nL1ptOX3oAeMdq57xV4x0jwxKlvfvJPfOu8W0ABZV7FieFB/Ot9JVWRdwBA+Y/Qc18n32rTavqd3qt2S895M0zZPQE/KPoFwB9Kwr1HHSJ04Wgq07S2R9HaT458O6kij7cLKY/8s7obf/Hhx+tdPH+9iEkJWWJujxsGU/iK+VIbghRtKg+prT0zVtQs3VtOurmFiesUhTn6Cs44iS3R2Ty5P4GfTGRnHeivGNN+I3iGzOy6e3v0HUXMeGH0Zcfrmuw0b4kabdkLqlpLp7n/AJaRnzo/xxyPyNaRrxe+hyzwdWGtr+h3IFLUNjc22oQibT7mG6i/vQuGx9R1FTHI6gj61snfVHK9NB3elximZPHpThk+tMA+tL+npSbWP8J/KlKsOSCKLAHp79aDhRk8CmGQdBz70gUtnPXP50AKzErhe/FKsQzlufbrT1AAwOlOoASgUY9KdSAQ0g60poAoAOpqRF/WlRemetPGAcdKYCgUo6ijrx2FKO9IZHIvHHNUrlM1fboTVaUdqYjKmj5quIxu5rQlXv2qAjHQcUAOiXAA5q1EKrR8DFWou1A0Woh2rlfiV4NTxbpaPbyvb6paAmKWMAmRP4ozn17Hsfxrq4+manXjnmpklJNMqMnF8yPkvTkj+0+VDb+TBI5triS8G2ZhyrKR1znPWvnzWrRrHV7y1kBDRSspB+tfbPxs8E3E5PiXQpktjGM6kgTJZAOJV9x39ue3Pyf8XrVIfGEt1CSYbyNLhW9cgZ/XNc2HpujOUG731X5ffsdOJmqsY1F6P+vvK3w7uvJ8RWKGUxLMTbvIOqhhx+uK9cSW3gm8rTraS4lUEME9fVmPA/zxXgemzNFOHQ4ZCJF+oOa+gLe4lu7SGayXybSdBKJD8obI59zzn0/GuXHx95SN8vldOAyeGZ/3mo3HkRcARRP1PoT3+gqyTO4ZLeNbWDj5mHX6Coo4YLe4VmDXN5j5HkG5gP8AZXoo9+KleC4uH3XTrGnJ2h+fxx/T9a852fp/X3nprT1Kjm1gkbYjXV2MDAGSfc9hSyR3N6A15cmGDoIIPvN9TVtmghiKxBQR2QY/Tr+NU3S4dHaXNrGfvbeWI927U731/P8AQLW0/r5k32i3tGFtAgL4yIIzlj/vN0FVblZHjeTUZo7a3UY8lDhfxbqaSF1QeVpluip1aZ+EHqSepNRRxxz3AkgzdNGf+PiYfu4/XaOn+etVGKWv/D/8D8yHJvT+v+CP8/8Adj7JDtt8Z81xsUn/AGVPX6mo7RfN3zrIEjxj7S6jc3+6D0FWGLSXAW2WW4nAy8shxGn4/wCFN2rIwkIe9w3Mr8RRnvg9M/maf9f1/XyBPuMYFY1dEJOCfOuO3uRUJiVSZlfMig5u7ocAd9o6flU7N5srfIbhBg+ZIuIVHb/ePsP0qvPLCZ2lG66mX7ryjCKfZelNJp2B2Y/zI4ttzk9MC7mTLEdyqVQXUkLEQNI7DrNJjcc/y/Ci6t47pzJceYXfoyNg1k3sRtZtjbn3KNjnn8x61vTpxlo9zCrUnHVbGvJIoJy6+YOowSTQGwABwTzyOay/MEOWJL9FB689T/8Aqqwtwu3DMqIcAHOSTVOnbYUat9yxKkZQrIm/P8OM/lVabT2PzQylW5ARxn9auI5c5jUc9WPf8KXOMksS3v8ApUqTjsU4xluZMDEzjJVZFk2t83Qj+f0opZQqayuYWxgE4P8AFnk0V0rVXORuzsfYOeT+tLu5phPNAOOtekeUSU4H3zUYIz61IDx7ikMUde9O7U0ZOMmnjP1NMBRz15p6nHQU36U7Pr2pAOHpSk4U0mR+FJIeOtIZSuJgkgz908GvlK/tGsNSurAjD287xfUA9fyr6i1DOG56d68O+KGltBraatGp8q4wkuP4ZB0P4j+VYVo3VzpwdTkqWfU52BgMRgjcw6Vrxu1vH8gBYDIrnrOQGb5jnaRj2FaU84HBbGdo+nNcrep71NXRvWFqZcZJkkzub61ofZdig4AJPb2rH0+6ZHAQgHPIFa1tcGYgDpyck9aB8rvdl6CMwskkUjRy9niYq35itqLxHrkCKINZufQLIA/8wawhKTIFHABBqT74YHOQMVO2xlKlGXxI2pPGPiNQQdV6HGRbx/4Vm3PjPxAzHzNauQueBGqLn8hWY6M6sozt9c1kXS+UBkcdj6VV2+pCw9NfZX3I6b/hI9cJAOq3+fTzzVyHxBrca+Y2q3g4/ilLfoa5DTrgSg4bI7sOa1wkYHDMzZ5PcUkmJ0obW/A7TTPHWowFBewwX8Z/i2+W4/EcfpXX6T4q0fUiqLcG0nP/ACyucLn6N0NeTRyjawb5VGDmoY5w7kRDIHHI4/Kto1ZROWrhYPbQ9+KuBnHynoRyKbn8/evF9P1jUbDAsL+eEf3EbK/keK6aw8d38WF1C3t7te7LmN/8P0rZVl1Rxyw8ltqeh54p1c3YeM9FusCaWWyc9p0+X/voZFdDbSx3UfmWk0Vwn96Jw38q0U4y2Zi4Sjuh+KcBSdODxThy1WSPBwBSjn0pBwKdQAdM+lOGcHNAH1paQxj9Kgk71M3Iz2qF/agRUlxg5qswq1KDk1Wbj60AC9RVmPjHFV1qxF2poZcjxU6/Wq6HvVhaAHdcggFTwQehHpXx1+1X4Lh8M3GkT6dGqaZOJFgRR/qsNuKfQb+Pb6V9i149+1Zo39q/CWa6Vcyabcxz5xztb5D+rg/hVQSbsxNtI+H7c4mQk8Hg17Z4Ga51Pwja7Z/IFo7W5lHLYHPGeBwRXh6nAPqDmvUPhVdXUzX+nW8qRrIq3W4jLLj5Tt7Z5FcONjenddDqwUuWrbvoegs0FjCsMR2l/wCNjukc+oHU1Er3F0csXtweMYDSsP5L+p+lJFNbWUrJZRveXrDDy/ef8W6D86USSOW+0ATSlseXEcqox/Ea8fl6/n/ke0pdBPOSKRo7CMPKPvux4HuxP/66gjQTMwBfUJM5Mh4hT2x3qRI0cmO6jLk/dtIOij/aI4H40+R/LCwyoqAH5LW2/kR3/lT223Fe+rK8sSS3casJdRdW2iBDtgiI7sRx+FOkKSOkcztdT4+S3gXbFF+PQ/U0+USPi3lWSEg4FrCw3Y/2z2pssnlx4kUiLHywx8Lj1Zvr6U9X/X9fh94W/r+v68gYidmWRzcFfvxRHbEP95+/+eKp3uqR28KQvIJmhXCQx8QxjPQZ60l0ovYUS4LfZ0+5EnygfQf41Vl03/n1kCqxyVlO8Mfb0NaQhH7X9f1/TIm5/ZX9f1/ww+TUWupd1xNlm4UE8CnBnAGwBcjGO59qw5MKcsMSRkggEgg+grUtjJJEjMQATywPQegraVNRV0YwquTsyU8EB8DPvzTpoIpoCkwGw8/MeQfX/wCtSKOD5IHHVjyf/rU1huC55b1HJ/CoNvUy7y3a1MKxSeZHIcAuMHIqOONvtJaJgwA2jAwM1a1lcLbEKrASEYP8P1qgFUyJllJzgk8jHYZFdEHzR1OOouWdkakJJAWM9uAo/XNTHO3CjnPzHNQ2wIUBuvUjGBUibixHVffp+HrWDOmOqKWoAb4HwN5cIDg8jOelFJcTCa9C7T5MfGc4LP7D2orphdRSOOq/e0PrncA2OD+NJnnn6Uw/ePpTlA/iNekeWOU+nT2qXGOAaYOvt6U7OfpSYx+cU4Hk0g6c04H0xSAcp9TzTvpTPzpRmmA4nsKOo5pCfXrThQBn3sfBPGCK4vxBp8d1BLDMm+JxtZfau/mTctYOpWu5Txx9KloD5z1TS59Fv5YpMvE/Mb4+8P8AGqzz+ZJH82TkZHrivWvE2jJdREFAzDpXlWp6RLbXR8nIXJyh/pXLKlrdHrYbGK1pGlp9xiRSSB6gVoW1wPlIcZB/OuRW6ltXCyAqw6E8A1ag1KNTksR2IHesXFo9KFWMkdtDdjdtHYk5I7VO0+XKRyH+8Tj8gDXLWmpwsTkgH1FWrG7EkkhDAgt6/hUWsaJp7HSLKFj2ByAB/Dziue1uflgGXJ5IAwcVpPfEpsUky7c/QeprKv8AM5U4EnGN3rVJmbjbUm0WZBFGAMKO1dNaX1sseIF3t3LHj/69cdBMY0WJfmUkA9uK6HT2BZSCADwTirXYxaL8gLNukO9jzgcAVHHFI24x8Z4wTxT5ZtoOBnb909zSWymddznjPQdjQhNOxYt9+SANzD0p6oXdtxPX8qURN5fy5H09ParKQiMAmRskZOaZElYj8sEHI5HbPU0sIa2kEkLSQzDo0TFT+YpzEHBTBU9yelDygIQvLHjJ7GixDibVh4x16zwHnivIhxsuEyf++hzXUaX490+fauqW8lhIf41PmR/pyK8ztWufJH2hhIwbqFxVpVSXCs4DfSnGco7GM6FN6W+49zgljnhSa3lSaFxlZI23KfxqTOO9eM6Nql74fuQ9jJmMn54W5jk+o7H3FeoeH9ctNcgLW2Y7hADJbsfmX3HqPeuinVUtHucdWi4arVGtntSgYpoPBp2a2MRrVDIPxNTGo5B70hFSUVWccn+lW5arOOaAGDqKni6DFQjr71LHzx2poaLsVWF/ziqsZzirKdBSAfWN4z0ga/4O1vSCATeWckSZ/v7TtP54NbNLGcSKaafK7iaufl7NGY7h0IIIJGD2rpvAF0sOv2AlWR4pH+zukb7WYN0GfTOKt/GjRf8AhH/ih4isAmyNLt3jX0RzvX/x1hXLWErwzF4iRIjCRCPUHIpVoX5ojhLlakfQTqY0EN26W0OSot7fqe+N3Un6VEnmLBHEcafbHmKJeZXHXgdv1NLblLu2jv7RRGJo1f7XcjLNlcnYPxPPAoM6RhRbKRu+/dSnLNjrgen5CvnbPb+v6+9n0Ka3GlZETyvNaxgc7toO+aT/AD+NQTT29guEf7Mz4JjjO+4f/eY8L+OfpTprhYnc27KsjZ3OTukP/AvT2FUPIWRsvbwhe7YGT9fWtIx6y/r+v6sS2+hCb5+Wt40t4mbcwHzl/XcTy2fSnfbgQJAQMnAwT/LtUd9aIscssUrq6rkY5U47Y/SqUbpgDdtjCcgAcHH610xjCSujncpQepsKQJMkh26f7R9OP8adGzFgSAuOp3DcR6ZqrbyD5Wjw3y7WAHQ+lSEEty3A7evtWTjY3jK5jyfLd3cIGMsWBcYYfSrWnuJNwkaUSgYweOBUd6oGp/MwVZ1ByF6Y9fU0tltWaQn5uMAnqR/hXQ9Y3OVe7OxoDey4OxVxg4/Sn8KCFUEjg9/zqMug3Apk/wB33pFDHK8D6d65rHUmijrcyFbaEB2GS7bV/LFVAzyynb8mRggY6e4pNRY/2lLuzlECqNvWpdNVFjkZvkkU4PbP0rpUbQOST5qhfGVGDktjoO1Q3VwYoWYsfNf5EVRnH1p3Jz5a4BP51Uv32zx4ZWMXRSeNx6/p3rKKvLU2lJqOhBbIyXEETB8nBPGQTnqaKtafbbTE+0ZLAlv8KK0c9TJQ01PrXHJo7+v1pOS340uMV6p5A4c9ealXp9KjHFOBycYpASZHbFPH6dqiHXFSL055pAO6YNLnFJ2pepouAvanD+dMHFOB56UwHdTVa6g35qxS5HfpQBzGoacGBGK4nX/D6Tq2Vw394CvVZkD/AHBnNZ0+mq2cjrUtXGnY+fNU0S7iYxlPMj7ZXNY0mmxBj51sVPtkYr6IudGjwQEAFYd94bhlOXiU+9S4G8arR4Q+lxg/uLmeLPbhx+Rp1lBcWOdt4sirkjem3Hsa9O1bwpAqs0alW9BXG6hoFyTJhCqqMg9sfWocDaOJknuR6BqDYYXBAuHOWwcjHbmta7VVTcvGc5xXE3cE9pKfJDOyjdkcACltNa1om1jvNPCrO22Ni235fUg1zSp21R6dKs5K0jeWB1m3LISvbPWtrTZWCDGPmxxVdYy4XOMqMjH86sJjhgOCcECkmbNGxb5dBvHJ7VaUbG+9g+3pVG1n3x7W4YH73cVdUiQZc/MB196PQl76mgkmYyArcd++acgFwpHt1PWqNucfKu44OcVowuJPlU4bvxmqWpnKy2HwoicAEcYNRMnOOwHU9x6VOclw2/jGDmmwp87NJxk9DVIxYsbgLsVMnr9KY9q2d7NjHpVnH9wDjjrTxllJwcdMVRCj3M9tzEDHHv2qa0mkglVoZWhuIzmORDhlP9fpVow4j6lQeciq80WSAhBC8nJrNjtoegaH4xgn2Qa0Utbk8LcD/VSfX+6f0rrh90NwVPIIOQR9a8WU7kxJjBHfvV/TdU1DTCv9mXjonQwyfPFj/dPT8MVca7jo9TnlhebWOh6yMDJyTk9+1RufWuRsvHEZGNUsHiI4Mlsd6/ip5H4ZrYtta02/wLS/gZ26I52P+RreNWMupyzozhui7IevP41A+DT5dy9VOP0qHcK0MhakT2qNfWpYVLMFUEmmhlmLoPWrCe2a5a48U2UErxxPEcMVDO338dSAO1OtPFsEvDmIOT9wAg/nWbqxTsaeym1ex1fYUpqK2mS4gjmiJMcgyD/Spe9WnfUzPjn9szRvsfxB07VkQiPUbJdzeskZKn/x0pXg0DYljY9PumvsH9svR/tnw90nVUUmTT77y2OOiSKc/wDjyoPxr45X/VnnocirnrZ+X/AJR7f4PjuG8C6VqNyqz2vny2CyFtwgdDuCEdmKsCPar7yvIzbgSQvGRxn2rW/ZZFj4n0Pxj4L1hs21wsWo26qPmjb7jyKexBEVUNX0y+8Pa1eaNrQUXNp0MYwJ4z92QZ7H+eR1Bry61Cyc13/r+u56eFxHMuR7kU1qggR5pAbpzkQr/AncsegPtUDkAsqE7M8KOQB9aes2WARSpPUAc4psoUt+6IAH4DP+NcuvU7UQSxCeF4sEE/Lz09c1ko0hSSJ2XzUb5cJj8h3rYY7cKADnkgc/nWXqaLDcpK25llJ5Xsa1pPWxlWjpzdiSynmDSI/7t2BBZAF4q8oQbT07c/561kM4jwDlgxLFQccdv8/Wr0bDHyAYYZBHOKc11Ipy6FbWCpubXaowCykg4P51WidvOfkoU5GRkkVevLfzrNxjA++GbjOOwrJDFkhmi2qRyVDd/SrhZxsZ1FadzaR0WNj0ZuuB+tSMpADOSqHt6/Wqkb4UMx3OyjHGAD7U5nZELSEZz93cMk+hJrJq7OlSsjO1PYb0OjKuIxuYnFPtY1YK/GOw3EioUeS7m8x0QruycDPI6D8KvSFIYHkfZkZ2LnAJ9MitZe7FR6nPFc0nPoNub1LYBFdVnbu38I96jghVSrgDOOSOQffNV0Kzt58rx5XGQF25+vtVj7Uu12JxGn3m9fYUnHlVluUpczu9iaW4W2aIdZmPAPRR64orIRzeXW7A3lwD8+QF9AKKuMIpakSlKT93Y+yu5xSg9MGmn7xpevtXos8ocfrSjBpAKev4cUAOFSDp6Uz6dacMDr0pAP7Ype9MzSk0AOpR0phYL1/Kmlix2jAoAkeTaPU+lKcscY4IpiJtGeSakzyKAHKAAMDijAIpu4AVDeXUNnbtPdSxwQL1kkbao/E0XGOeJfyqnPbmTiJCx9hXH658SbSFWTRrU3soz++mykQ+g6t+lcDqGs6z4gZm1PUJ2hJyIIm8qIf8BXr+OaylWS0Wp1U8JUnrsjtPE+uaXpkrwmT7bfDI+zQMDtP+23RfpyfauG1C6vdRxJdFYo8ZW3i4RT7/AN4/WobS0jjkKqoCgcdq0p1BtSuADjFc06rkd9DCxhra7OX0Hyplme4XdIW53DNP8U2s01vBdwpuNu2WUf3cc4qWaD7DeRSbdscqhXPYOOMn8Ksrc+RdGKXJjcblPY1DkdkY6WG6c63FpDJbuDhf0pk5a1kBIyjelWUsUtpRParhD95V/nVl0S5t8FcgjikXayI7aVZYQVwCR27VcgmzLg8+vuaxFMtvN5bYPHBHerySblyCfX/69Naks3Y5OFIPzdfrVm1nYScgLkAHjisSCcqQB6d60oX4Cj72Mg+1O9jNxNlF4DnBbPPH61YC/NxgAdfes+3uRkBSVUjBGetX4sEBlJPPftVJmTVmTiHJ4IK9Tu9KkbPm7S+fYUQlT1+9nueAKHYZAjHzdRgVSM2iG6JVNqgkZ6ntUATtnPsOBV+8wyZPloCM7Qcmqi5GCMY7DHNSXHYNnYjoAaQ7lIOeO4qW3DDO45PUk+lPcA8Dpk1IJW1Ioyc4Y5P6UPGkufMjVhnuOKjRtu70+nWnFwuQPlXqPSlyjciWG6urHH2G6nhHdQ2V/wC+TxVv/hLtUtQTLDa3kY67gY2P4jj9KyGcEdR15qu6LIecHHIwaqN1szGcIT3R01r8RtKLbb60vLU92TEq/wBD+lVfG3jKwvvDy2XhvUlmuL1zFMy5R4ogMt15GeB+deb+KYBaoZAF8snBIPSsHw1f7dUWWM8x9ffg8VftJ23CjhYOadjt/DX+mASMAqqcBR+ldcbGMxbjkHbwa5DwgUijNuzYZWOAfTOa9DwBYq+Rg8c1NOGh2VaijKxH8PdcltvEZ0O5lLQ3MTPAGOdsqcnHsy8/8B969MIIzkrx/tCvnbxVEC1/PCT5gUMjDqpUdq87m1ea905VRmUscuQeWHoaqNR000tTirYT2kuaLtc+i/jhBY658JfFlh9stmmjsmuwiSqWBhIl6Z77MfjXwLYWc17JLHbqGZInlYFgPlUFmPvgAnFe3eGlSLUWik4imVo5AP4kYYYH8DXkXiTTLnwt4ovdPErrJbSFVkU4LIw4P4qR+db0qzn7rWxzYnCOglK90z174CWWp+Df2idP8P3Twec8E1tcmF96SRmAzLhvTKofwr6O+LPgt/FWirPp8YXXbAF7ViMeev8AFCx9D1Hoce9fF/gXWLqT4j+Grw3EsNyk1vZ+dE5Rtu0RDkc/dwPpX09FfeI7ad0j1zUVAbHzyh8f99A1FSqoSaaumZ4ejOa5ouzR47bSFhl1aKRcq8bfeBBwQR2INSMykqrDYPTJOa7/AFPwzHqmpTX96rS3s7eZJIjCMufXC4GePSs658G2obcomTtjzSTjvXE0m9D04qVtTjGmGwrw3pgcD/Cq7RxyRtC7HDDB7kfia7AeDUMZVGnUDqoYc1CfBgfOy5nVsYzwSP0pbBZnAK4DGF2Y7Ny7+ox7elX7WddgKY3Dq2cj2rpJPAR3ITd3Lqo5yoHPrS/8IiysD585A5woA/IYrScosxhSmmclqMx+WIud0n32xyq+n41Vs41P7wlI0BKlRznFdkPB1u8rs8t2Gbrubt6cCnR+ErWM4RJMD+IyE4o5klZDdKbldnMrIAmANiAcsR0rMmk+0SKU+UD7q4z/AMCrvj4btAGDRZHcMxxTofDdtHu/0eMqOjBO31pRkk7lSpSkcXGViUB5FVR14H+c1Skl+1XIwkqoBjBHT8vXrXoiaJbxsMRK23tg/r2q1Hp8agbVCnPAK0c6i7jdBtWPPIYWcg+U7EDG3ae1V57S/urldtuUVc4EjAfia9QOnARqxUnPGUbmlSxXJ24HHRlxQp26DdG6seeWelXcZijVYwM5A3cZ/CivSYdMPVidxYHaT/L2opqfkJ00tj27HJqRR15pDjJxS16h4guKUe9NzSg8jPApAOzx704U0Ee1NMqjIUFiOwpATA4HYUxpOyAE00rKw+ZCqep4rB1rxXo2klobi73TjrDbje/4noPxNJyUdWOMXJ2irnQKuSS55p4k4wBn6V5nd/EiZx/xK9KjAPSS5csfxUYA/OsO88ZeI7xmX+0jbpjlbZFjA9s4z+tZutE6o4Oq99D2sCQjOw49SMVQ1DWdN04H+0NSs7cgZKvMNx/DrXhl1qGoXKEXd3d3APZ5WYH8M1jFWWVpCiggjAH86j299kbLAP7TPUNd+JaM7QaBalj0NzdLgD3VOv54+lcRqGo3WpXHnahdSXMx6GRshfoOg/CqEcYVNzEF27+9TJEBgnOT1rGdRvVndQwkIbIfDFuYBiSMfWrUEaxM3y8N6+tQxRhRwMrjk5q5AyFSgBLEd+1QdXLbQswY8mReNyn9BTpgrohxyG7U1CI1AkwQ3APrVm5TdEXXAKrkAc5pMwacZXM94VuIpY2G5S2celZ2o2EkJiYZdY8gfT0rRtZtrOHOCTnJP6VaMZk+XIyfu55zU2NkzHtDuT5GIx2b+VSCQox/dle5HUfUVYu7J1dnXHy4/GmIMyqJuvvTQcy3I3hEq4KjPr0xUMS7A0b5B9auPE+8qCNg647Ukqo65JIlHfNPzFcSMKrbWGV7E9quGQmMAnBHoKzXkYD7o9yO3vT0mcLtOSo65pozsbFpMCN2Q2OAO9W7eeRZsoPlJ5Wsa1A270IO77vP9K0oJcAAtkdRx+lO4cqZuRSNIOPlI9BnH41YjwsS7sDHUnkisyK4Axhm24yAeKsrOARjOW6HFUmZuKL0MRIw+5kXPJGA1NeMhskg89KmguBlQHK4GDu5qF5TMRHGuUHVh0+lJscEho+fkgDBqWOPcvSmREvIsa8L1wPSrZVR93oT09BU36A0VPJ52g/N0z7Vj65dLYICxAXrljXQRje7ZzkVw3xQBjtIo+hlcR8+5pkW5mokFrqP2yWNrgvHpwO5yn3pSDwo9v8ACu50zXmIRLOxgSEEfeXk1524222m2oHyuzMSMcbcAD6V33h2EK0O4YGBwKcLs2qUIRXvIfrR03xHHNpup2aW1xKpEN1H2btn/wCvXg3hpJrbXNQs7xdk9vMYZF9x/TvXumqRqkju/wAqo27ce3NeTeIrdLb4iyyrkrdwRzE+rDKn+VU7q6YU6ai7w2Ou01H4Zep5HHQ+tdCDqcsCRyXjbOyhQAaxdOuFEYXIwMdulbMFyzj7uBjoDWTsbNvsRT2hdGWQ7mZSCf6V4xZ20lpfXdq6kCN3QEjGcHivcw2xhv69h6V5d4yhaDxNO8CcMgbjoatWtYiV73M2zi8u+iY4AJHTtWT+0Hopjl0TXI1+W4hNrMQP405Un3Kn/wAdq0b4QvH5kbkqw6cVs/EJ7jxN8O74eUo+xBbyNV7BeG/8dJrSElGSMsRCVWk0ump4Rpl01jf2t6n34JUmX6qwP9K+4LiJJJ2lQZjkxIoPcMMj9DXwsh/dke+Pzr7O+Ht62s+APDd4rbmaxjic+rR/uz/6DTxK1TPNwT1cTWEYLEbeh4GaZJBxk4I75GKvPHziPAcdaY0bjG7P4965z0PMzzZg4wm3HQ+1QNZLE4cqXIOMjtWsybQEPGexPWmMoB6HI5GPWkkNMy5bRWAdeDUPkIVw+8npnHU1rKhABwB9e9Qyxu3z7B6dMUNXBdjNayBJJXI6HjmopLFFwxDL6nrWt5bY2gj8aYNzfKuSfaiwzLGnRunCnjoc4yKgFh5bEKo24z61siMqm3JHoDyKY0JLchSOuR1Bo5RXMjyYyMmM7hxtxR5Dcr5K9eCBWvJFv4Jw+OpHakSEiPBJK9dvoaXKPQyDbRBxgI2eTzyPwqU2u8fKEZugB7/Wr5UEgoyb1+8CORUTqykbQWB5DCmoiKkNsgPAw4PIB6e1FaCRcq7ZYnGc9aKqMdCGegk8k9qF3N91SfpXk+t/FC6mlePQrNIEBI8+5+d/qF6D9a4vV9Z1vUpVXUdSupwckKHKqf8AgIwK65V0tjzqeCqy1eh7hq3izQtJkaK81GHz16ww5lcfUL0/GucvPifpybvsWn3c5H8UzrEp/LJryq2t9g4Cg55zwatxxoSdxBGecCsnWkzqhgILfU6+5+JerT8WlnYWwPc7pG/p/KsW+8X+ILnIk1WeMEHCwgRj/wAdGazigOdhAAOM+tNmEJZAckr82efyqed9WbxwsI7RRVvby5lIa4mnuWABJllZs/nRCDvDEKMfNgUt4u+NnUBVTpzmo4ctKC2FqL6aG8aaSNJJPlwRjP6VICzbsZOeMDj9ahiAkGc4JH51oQqcDjaO+R0qW2aKKSIlU+UXwOBwPSsVJC05OM5/GtfUJTHBIB7d6wIZ1V9g+YnvQncJ6GpEMEFiQ2cgGr6P5gII5PQ1RgUkfNnjvWhA6KGLenYUjSKVrk3lICvzHIPfvUxUKQw4OfTFMjG51XqcAgnirMbbT8o3D+dBW2qEn2NGAVyc5yOpNSxxuVUqfl9M9alRRLGQwUHPA9KsRxFW4yf5ZouYydtTLubJmkBDAHrkHrUS3D20iCcdP4sZBFapRvOwwHIpzINhjkwysMcrSvoZ3IkmimVSAADSyxQmP5j8rcY9KoT2YVle2aQD0X+lNkW7R/kJdfQjvQkhejLAt4dxyTggYJqJk8mTavzsORxUJmkSVfMR1PTBp6SKHLb/AGwRVJ9g5WJOgly3JJ9KqtyuMnI46dKuiZQWDHA6gnvVeRgORwntRcag9iGGQxtkD8PWr8UofcTx7H1qkQrggk+1TQQux6Nz3PQ0cxoodWa0Up2jB/A1bguEZ9gzI4HIA6f0rJhgYN8z5A/hGQPxrUt9yqAoUAf3e9Cdg5Ua1ujTAeccL1wD1+tXjJwFwAO/PGKy7ecIATkCrSss3QMR+WapO6M+Rp3JLYfO0pJGBgYq6MBcAYXoTUYyeNoGKcCWPocdc0NXJu1qxwTaC/J9SK83+KNx5moaVbZJzLvb8B/9avTLd0ERDH5jwa8j+ID+Z43tUzkJGWI9sYppNImFpTRYgbDRMQCUPB9B3r0LQry3YRb5oQoHOXAPSuH022E6gqSNtdLp8ESR5AJdeOR2oUnF6G9SMZk2tXkU8M0UTK+48lTnvXmHjFyvjTTiRybPGf8AgdelT26ksUUBeprz/wAdxD/hL9DlQfIbeVefUEH+tJy5m7l00oxsi/YzmWV8MBGDj5j1Nb8EwZEH2tEBHOZOn4Cua0Tym3pIAxZuN3SupsbJ1U7LO3dR/EW61kk7lzaSsJHJCnzRNNKSeXVCR+ZrmvFiqNRs5GU7ZY3jJPHIIIrttsgBMtyiqcfuocAfhXN+OYt1hY3OCojuAv4MCKpKxLaaPPNYtzFIcqTj/Oa7HwX5Fzava3IBt7iJ4JB14ZcH+dYmrRGRjHGA5VQwx2HcVb0DzoGiiVFz97ketU31FBdDxe28NXVl4ybQtVjjguEYqyzBircZUjaQTkYI5r6S+ASyRfCfSA0gfzJ7hlGP9WPMI2/mCfxrgPi1pE41PQvEtkqeZbOlrdyvkRr8w2Mx9OSCfpXp/wANdMvPDWk3egak8LT2N9MVMOduxyGGMgEdc8+taVqsZRiup5McPKjXlG2ljr3Q7gW7c8DmkZmTAIGxunrT5mAI4J6dKQgEEkYI5xnpWV0dS2EdFdFJwWHTPakaHYC2MNjOev6UuAHXdkDPIzT3Y9mYYPpQtCbMiGMAOMgc1XY5btt9PSrYB4AIG70HSkdVRsjnPt0oQ7IprDgndgq3enNCcbsEAenFWhGgYHI3ZOO1KANjB88cnjoaVwbM9l2nGevQkcCmlMPjZkEdulXJIwwG3nPPWmPGeo4OMnNUJyKLpskwAcHk5PSnCNxxgcjrVlOMflmnDCHB78nNMTmVmhBBDKAe9Q+WNu5MYHFXWXJ5yR2zTSm3DKRnnrQUmVPJAZWwN3HfrRVuKPJBfBIPUCimgcjxZbdg7c/xGnSJtuRnAAU4p5lCOTKBnce/vTbq7QGIgHAPJ7YPah3udbsWYowIs8ZxVlYt0e0ZHHPoazBehEwzqufXvTX1S2Tl7hBnrlsYpWYN2NcQ4+8AAfekliXCMgGRkYJrHPiO2BCpIZSO0al/5VBJrsh+WLTLgsx43kL+eTRZkuaRpah5ZQbehI5JpluqAbywz6HtWO8eqXZwq29sB03HcatwaVdsMT6g2euI0x/jTasSp3NuKZcfMy5HA+lWXnh2hTKucdM1groKs+XnumzzkyEfypx0GzBzIsjD3lbJP51DszRN9CbV7hWj2rMijHJB5NcjDqkMF59mmyXZsoRzurfvNB07PyWgP1Zj/Wsu20SCDUGuI7OOEou1DyTk9etVDlsRPnbRuafqQOY956fMCOtX4WZzkNgds8is2xtldySOR3xnNaQt2QjHI/nUuxvT0WpPHPIpVW+Rv4eevtV+3ui+MEYx0z3qpDEGUBjyeMdafLC4IKYOBn/GpLdmacErK4JYDJ7VpxzZ+8Qrda5+3dT8rKTg85rUUqEXGRjvT3MZLuWUc+YN5LIePpUk2GBwPyqONw8YG0fTtTgroAXOc980O3UxcddCuPlfAyD6VNHOwznbkdferDpHk4AyTnJP8qpywEElGxjpk0bgrPcXcJHb5fmHI9qtLbq4BdV4655qmQ8YJwSeDx6VdS52/KcEH26U7DbaKv2KIyFtigemOD+FNFrGOka59xwavTOnloBwPfuKjRwznI3D0pWQ1JlIwIoO1UTHHFQqU3DgjGc84xWk6biOF2Y6VVYLkYxyeAKNi4siUyRsBuXnkgjnmrtqZfM2BCAeOWqONDE+7OT93JqyXUMp5GBycUWZSkX7aD+JhtPY561fiwAApDDviqEMnylg2fQ1OGA5yDn0qkiG7miJk+UnaPSgqPMUoM1UEoIwNp9fWpYH+cKxz709iORlpSroflxjODivF/EMnn/EG8BORFGFH4kV7NG33gD1rxjUP3njzWGGPldFGPzpt2iyKUf3h0GmOYsZbGa6K3nJRSWUDGcc8VzMqkQL5QLYYfmetbOl3Uaod5mXC4+VTyfSs72Z1SV1c3E2zxuPMUnGcg9a8/8AiEm280Vj98SSrx6YFdwtxG42os7rngsv9a5D4hxn+0NCbB2mSQHPrtFFxx93QXR41VwXAJPJFddbwwmJf3Ube5UGua0wKNvUHNdXaZ2DJA6Z69KpIxqSJljVAAAAO2AB/KsjxnZ/bPCepqgy8cYmQejId39K3SAmCE+bGcnmmSxCeKWB1O2VGQ575GDVW1JjI89slXULZX5WQpxhsA8dKns9KBmUO8pVcZBJ6enSqnhSBzZQL5hWSPMZI/2Tj+ldrBbz4PERbHduv61C7M1k1F6ENzp1rd6dcWN5BHJY3EZjdO7A/wBR1zT9HE0VzH9ourm7ncbJLi5YNJKcAAsQAOAAPwq+LcBN7qm4DnYuAP1zUb4zvXGUIORSceorprzNYF2O5j8p96nVgxx27mqyuuQSMg808SE8EdeDiixyuYMQm3OcZwe+2nB8tgk8e9MkIY9CAOx704geWCCRnn0xVWF7REu8FRg4/wA9KYS27Bbp0pisAVK7twBzmnnGOMk57CjYjmvsSRsSuDkjPNBXglRwMDFM2qCQAwx/OpgQDlgAO1LYLshGUzuXntRsDtuyST+NOlIJXH1+lJEOmVBIPr0plcuhGFw+ACfx4pfvjbgZXt6fjT2Q5Yjr7dKawb5QF5PGPSi4uVEJQg7geTxtpByxBXj0I704hscnjvQFJbKkjPvVENCKctzwR6UVKFJGM96KehJ88TW19PK7S3CIAT9xCaf/AGQ0oKzXdy3bGdtbpjAkLLx8xIyKcyAuS5Ab88mlc71HuY0fh23Jw4dz23yNn8anGi2Fs2428WT1O3dj861VRwM5JGKdIibCzgtg89qLk8q2KFtGqW4MaDABOOmKiWJ2mUyHk9eKv+YBb7FHLZ6jAqDzSs8YB3AUrlKnrqWoVKgDAU/XNXooxwpPvzVKF8/O5XPoB0q7bkMysQcH2/zxUPU0UbMmeMjA38CpfIjMTFuTjI9aRQztgt09OM0F8qw5B6DvUl2IntcoHj5b6/pWPdEPKS/ynd0rds7hUQB2U44x6fWsHVmDXDlfu5496paikNiTa5MZ4HPHeraStwrjK+nSsmObEoXP1P8AntWpA4faTxx0xVNWGncuRbd2EyGHI9jU0ed3zsQQe44qJIyRnOeetTqgBH3jz+FTcbJio3A7Sfp3qxbA5QOcewqG3VpDjIVSeueat7THwFzjgUiJMtwthQAoPPepvPRspIBjpxUFrMpVtyjPuOakISSPJQc980WMm9SKbKhgThF6NVdyVXG5sHpxUzyfIQScDj6ioPMO8lxhegxRawtWSQTNgggjA6elRBiCcE8HOPSpwoMhaPjjAHrVS4kMbjceec09gSfQleU4zjP4UxZzn5EJz61Gswk4QNkd+uaaW8x9p5Hc/wBKRpFWJ5Ll3QgE46Fl/lTQ7JwOmehGKlji5VEyFPU+lKqbXyOM8D3p21HcZJLtYMOWBqWGboGbPPr3psgxtwM/MeakRVZAF6+nrT3CPmXoZSGyBz6Z4qxHMABx74z0rMt4jyAxVs8fSriklgpGSvc96afcfKi+GBAIqSKT+I8P9apLJlfnJHYccVYRo2UYYZz2PSqC10StNtcPuAB4ORXlUGJfFOszcYNzjj2Fej3c4WNgW+UjqK8p0yYi4vnkYbnu5McehpP4TPkcZXOutW8xSmQuTnOOnNdHpvmxYbymYHIypHIPsa5vTNu4ZHJNdXZj5GcAsMYyP1qUtbjlLSxaWWSXdmJo07F2H8hXG/Edj5eiuSAVvCh/FDXZDuOMnvXG/FEFNGs5OcpfRsfoQR/WmlqC0QmnO25CDg/zrrdPB2D19Aa4fTptioW9M59K6WwuWGHySGHsP504mVTVnRkoIsKcd8E//XzTS2ZVOTjPHNZf2mYBSPnQepz/ACq7FcrMo7Edvem3oCVjz3Q98Gq6ja5AMN5KuDzwWJH86761P7vDEFsckfyri9YjNj46uG4Ed5Ekw+o+Vv5D86620mPkk5O0D73OKlbs1qO6TLmGKnAfI9elQkc8jGeoqMvEW2h03c5BwTj86RiQ/wApwF9u1N2SJjc1LRt8ERBG7G38uKmyQRgdTjiqWmNuWVSeM598GraqC38QHp61O6MJaNodKMngk44OaaNpVkBOeSD607ymDZBXb1B7Usce1lIbdkZPHeqWxk9RVG3r1I71KoyOjH68UyPGWOfx9KfGSxJ60gURp75UYycnPSk2bc8k5OAfSnSKI8sMA+vSkLEuA33c8elA7MI5F2YdtvOMk96kJXqWwSPWqNwiyrtJAIOelTrxtAOeMcDmhg0Sgg7grkkfhik5C5Ibcev+FRAso+vGaUnBBPJ9KLBqxrNu5yPpTSSCOCPTmnMwIPv+GKXO7nsPamLYQEhxjjn8jRSPlnGT34zRVIGeOlQZ3UNzuOeanZ9oCqy7R3qg1wqytgYXcee9Kky4yDgE4NSdvMaC5IDbycfrTiDIh3bQc8VRS7UMBt4HcUx9TgjGW4b6dKVib9S4jr5W1SMgkfSqE5VbqN1cbSckelV5NXhMhZWVSev0+lUbvUECA+ahCnPNUkJysdFhDggkDrx3q3A6jBAGBzzXHjxJp8G3deQA46FqSbxJb8mJLibOMCOMnJ/Gk4NoSqW6ncLdr2AA6nJqvJc7g5PP41zVtPqt6m6KxSGPpumkyfyFTR2N7P8A6698sekKBf1OalxRSqPoX5pJArHaoJ5znFc7qU00W6QTKdv8Lkc1rNoUMgzI08vs0h5qneeGbd1wtshPX5upq04rcJe0ktBNLu4rm3ilRSFbPJrqLBoiAHOPb0rjLPT5LDMCYWIcqmPu+w9q3bCOfALHHoTxSlYundaM6mFkz8igLj6VODE+AW2468daxbZ5A5XcrYHftTlnYyYTczd8Vmb8pqyBI2YxM2egGetWGuXkVQR0NZsYnCKT8uTye4p484MMPnt9RSJsi7LIFIbHzjgA1HG0pwN2Vz0qq8skg28k+tSRMwB4YM3qKETZLQsZYE8E0ofgZY+4PrUYkRDhy2fp0qKSUAg44HOaq1yWyWa5ER2jPHTmqzSNIw3YJ9T2pruXwWHFNUYOG5x6UhFiKNwp5wzHHvVqJPlO04HuOapw7txYA8VcRiDgfL3PpQOw4FkQAZ54x6U+NvmJP3sDj8KWHJO7qv8AOnsmcMARjtTQ/IiikG35s+uRVtSAB+Q4qtbruT5QSOdwParSqCgByBjnHFGw2TIhHzdsdRSXDEAsBwOopqkYUA9PfrUcjBiyknkY46U0xpEa3Qx8zHB96dDfgNyc8cDGcVi3TmNyq569KrPcNkYyDnPFKTOmnFG7dXQZW2nBJ7cjFeYadNuM7dR9pkxx711F3qPlQyMxIAU9eMVwXh+7803ABwftLd/XmnG7RjiNGkenaOSFQ7uR3rq9NYCX5uZDjaCOMdxxXF6XIVVd3UfrXaaOf9H3PuKZ+7xgVSOSTNUqCpOFAJ4CDj61y/xJt/O8I3bDloGjl/AOM10hkU4AO0DoCazfE8LXXh3U4CAS9tJtx6gZFUtwTOEeUW1qJCflUDnNbHh4y3jq0IC8dSMn61xOryNJp2m4YhZggYdK9C0VZEtYRbrGrN/fB7d81D0sNtbmu0sVqoV0eUnliSR/XioftBEu5VcLwMcflVV7a7L7JRahxuJXByBnGSc1YhhkIzM0O3sQ2Bj6etDehaS3M7xooZ9Iu4+GSRojkdmGf5imvdBlihZ+B91QcZP1rR1uPz/Dz5IZoXR159CP8a5nSfLn8WmKclkTaeew9AKlvS4Rtt2OmWRjHlPsiY6/u9360/ziETy/LdcdEXaar6pPGkL4iuQxcjAj4x9aign/ANHRI4LhmGRkptyKHsOKvqbekzBr35RjchBHoRzW2m0IcZB5+hrldHkb7fCxTYNxXBPrXUI46AcLwQR60omNVWkSA4YrsPOCRTiQAoJIIOCM9RVdnJbOcg9PYUqyDHzY4zxiqMmiTzPmOQcHp708ZUBjxn9arnLqV3+wPSp1fgDoR6+1Owm7BICMgoPXPU1GSGzg4A46ZzSAtzzkcmnsMqoz0GTQFxjDPBxnHIxSqBjjPHpSsAwAJ57+/wBKhQ8kdvrTBDmbPenNnbkHqaRpFDBsDGajclsACgCQ4PP5gUgYhTtJ65xTW4I7UxycEArzQIlU4IJ6j1oqFW+bA7GimhM+S7vxzOJZFgtVAyQC7k/pTbfX/El6MW0SRrnO7y8D8zW/Z6JZRzu3kRjDfexzW9DbxrHkKvocDtWrnFbIcKFWWs5fcc5a2Or3w/e3joh9WJ/QYrSh8Heau641C6bP91sf410tpGqELjnvitKOEOeCfy61m6j6aGqoR66nKQ+BtNA+d7tznJzOQP0qaPwZogb95a7xn+ORj/M11iQsidASB6dKay4ySBkjkjjFL2ku5Xso7JIxIdH0uyb/AEaxt4wBwVjAJ/rULQMZwVQIinHFbEgC3EasBwM81UupQFyDk5yaV7lqktCyhZFUL0A5B9Ks28fmc9APU1UtW8xM4ywq1bSFAFAPJ5xUs0jFLYt7BH0xkYpSVdgCBk9zUTsSwB/MdadIymMDI4FJFWsiheWOJPMAGwEc56VXdwhCs2D0OKuT3DBCuQcc7SOvFZMs6zEmRdrDt05qkiW1cvQurspDZI71at5PlBAHr1rng7BtsYxk5rUtoZZFHmSbVxwF70milK6NuK4A4dxt9B6UTSZceXkr3BOKqQW0cYwGJH51P8iDkEntmpYKOpIvmMhHCeu2pomeI8biR0PekhjErHLFcdhTwxEhAOV6daRatsRSSja2Tznv1qugYk5zjsOtSOgWUcHcR+FSKuASSBimrg0iIdcbafgjk8ZHGalGMbhkjHPrTJkMjADoozxVIyY6MZOVbJzxU8eNoUqd3U1FETGq8dTgsRVuH94N+eSce9MLk/kt5Z2HII6DqKkiYr8o7eoohPIOce9SsEy6kj14pEp9yqEBkLtlcnIHY1LKdoLA4IOTj0oOFGGJBHrVeS4VDnhl6c/rQXe4v2ghjxkr0PrUcj8tk9ccE9DVSSYeZwxVTxzUEswjOT82OooGnYTUDgiT+EVnPMJEypGe1SXN9E+fm+UdhXF69rq6eSIXWTJ4XuKFByehUsQqcbsm8V3/AJEJjDjJ61y/g+UyXF4Cf+Wyt+YrJ1TVJb+QtJuz7Ve8IhoLickEbypANdHs+WJ5ssX7Wqux6xpM54U4+grrLC+IRB5mOQPlwf8AGuAsLgRyJEuJJD74FdbpBcNG8koRc4LKoO38KyZ0JJ6HTLMVIDAkdt3NTyP5iSI+3DqVx9QRWcTkMjX0xYgkjaqg/hUsQjVNwdwRgfN0+tJsaSW55k9sbzw9bR8efbOY8jnBUkf0rsvCs01/YfZrqV4pNu07e4rnIFa28Qa1aOu0Gfzkxg5DDPH45rf0wIJQGLq4+ZXibBpNAzWW3W2n3NcTN82xkdA4I7VJbpErbY7ONtvVipOfwqYTag8g8mSymQDO+VCrZ644701WvVkLTT20ZZssIlyR+JosUrhrsKR6fMBGUzGWZVPb8K4q5D2fiG3uIQxSRApbrn64rstUkW20nUJUDSssLHe3OeK563jN3bxzWyl12gmM9QcdR/hSktLDjpqdNdzJLCpaV4mlxglTtz65/rVOLzI7eCO9uY0VWOQW5+o9RUC6nbSQra3TujhQuyUEA80+3msoHDWiwI4wMj52P0oWqCMWiaFwbpDCGCBwQzDGee2a6bzPlyoGc9K5qIsXZ2/hOfoa0YbrzDk4GeT2pLcir0NNnBC55C856fhUZkU/ewcjrVXzmcEMByPWo5Z2VBjoeKpGdjSSRQBkc9u9SpIcEA59vWs+CTI5/ECpC+GyuBRci2paDKxPPP8ASntJjI6DNUDJ/EPz9aeZDggEY+tMOVEwcYOSxGajDtliDwfWmiRQmeTUe4kBsYFCGWGwy57g/nSbiE4OSaiGVIIxTgyseoAHpQJkhcj5XO0jjNJIMevJqrNIiv8Ae6DniniXcBg9vzoB9yyCS4wAM470VCD8ykMQwPaimkiGeFxxpvZjySTkdqu4jMTbB8wB4FZEd2sc7tICVyQCDjvVtL2KRyFIBPGenFNpnZzI3bcrgZHTkEd6vRFQwbzNxA6ehrnbXUMgKSNw+U45GaspeJuIVwoxj6VNu43NdDbaberFeCc/jTJZSqhSVJI5rFk1OCJyZJlXJyAxANLDfPcn/QrS5uP+ucLN+oFNJEc1tWaNyQVz/EF6j2qjdTq0XQk+lDRauyEtpN8qn1hIz+dU5VuwNv2K7QHqDGelNRI9rHoyza3BjUY9Oa0IrjaoOBzzya54NeICGtpNuepGKgmu50P3AGHbdmm4Nh9Ygup0zXHz8tg+g5/Oqsty0YJMmCecA9654TX9wSsKM30FVZLa6mmKSzjcOqRnP5mmqT6mbxSekdWaN/fRAfPPz3yxrnbzUURiba6cN/dDZzW1aeG45j+/3NxkjOa17bQba3C+XAi89QO1F4xHarU8jlbDXbmLBvoXMWf9Yinj3Ndfp2qxvGrRPvQ9GXpTpNKVo+FB7D2rJFhLp7s8CjaxJYDofU/Wpcoy2N4QnH4tTrLW6U7eoOOT3rQjZHGMk4HT1rA0eRXUNnOehrYjeMYJHIySKzN0X45N0XCDPT3oQY52k+4HeqwmVQccE9KnWUAA5z7570rD2GHIILHBz9anIGADyvU0gZXI3Yww5NNiY/d5+UU9iW7iiPC4JwCM/wD66dt4bp7Y70SZTBccZ7U/eHUEAcelNGTdhY8ODxweox0qUIVQt0APPqKqw3GxnIOUJ6GknusMTnKn/apsVuxZV2jHzOSD0p0d1ubg4OMVlzXQJJB6c1Va4O5uT70bhe25qS3RJKn5ufXFV5HSQMpYJnt1xWc8+FB3gAjqBmqUtyGmEcbNJM3RIxlm9sCmoidVRLszhANku4g9D3rG1DU47dW88gHrxya108P6pLH5s6G1T+FCcyH3PpWVe+HmALTglvU8nNawpdzirY5bROJ1fVLq9DeQnkRc/Nn5mrC+yySMQAW9Sa7q90vGQF69hVRLBUBY8dvrXQo20Rwucp6yObg0zacuOa1NOiMVyCgAJOBV+RVReAKhtyftS9iOelTP4S6LtNG7YSmG8aMFTK3A3dMV2Gk/aQioFiccjG4riuMjiU3kUmGJyOVGSa7S0aKaSN/KmZl++iofmH+NcktD16dzatILwJg/Y4gT80mdxH61fi2LBzfCQP8A8s+MfWsqCG1ZmzFcABWOJWCID/WtWxFiB5VnGHY9ZFX5R+NSynrqcVr/APo3jSOXnbc2q84wCVJFb1vHFOoKrhs5Knv75rF8fEL4l0Zc/L5MnzfitX9GlJY7wMEUCa0udLCFZQFdSoHSWMNj8etSPEow2bdkH8SDFQ2EkLFWlbBJ2Ac9f61JNGVjJRFjlAJaNpCRj6dqOg4lbVFWbS76INuDQOPT+E1zXhaXFpbMTjKDDdq6UZkRoidqsrDGOORXH+FcrYxq4xtUofwOKnc1aO6XFyh8+OOXIwS8W7B+o6VG8MYUKqxkDAwi7f1ptiMFSu5vXqKsybAWKAO8Z4B296p6mUXZ2ICAFWLAUEHhR0rHtbtlXLPhuR1/SugmdVVVRBuGCQT0ryHV/ESab4h1G1YhTFOwwx9eRjPsaUI3uKrJJXZ6EdRYNw2cjirEdwsuSxPrmvNV8TQyMCsitz0Yj+laEPiBWxubGfeqcWjLmT2Z6BHdhMrzgdwetTG63BQ7hfcGuMh1uHqr9uOQKkGqxsQwfIpWHozrlvQoJYgbe9OF4OVyCfauXj1BfL4Ydc8c1JBfplhlc9fSmFkdMlw+7qNman+0YViq7h2Ge1cuLze/yuMY6f571YFwcIfMB9eaVwaOgS6Vhk4HYUrTKFwprEN0uVIPzA4IxzT4rtcnYrZ96L2JaNEN5nEhDEcdetWEAO0sOhwPasc3Jdg2cdiKlju1A2hvmHWhu6E0zVaQJMqkc9etFZnnZkUK2eQSBRVIho+Z7ia+id3mux949gMHNQw3upyn91IAg6u6/wAqtXEFvFO0s7s/zHlumfYUj+fOo2ARxYzufuPYVrzHJr3GS6veQAkzAOP9nH5Cov7V1a4HyzmFOpbHzH/CpzBGmX2jAH+skNQyM0nMGfUMRxQmugNy6s9W+A2tWkl5caFqsVu1/KTPZXMkatI5A+eLceenI/GvaZkVVADnB5xnFfHtml3DeRXVjJL9tgkEkUicbGByDmvc0+Iyz2MDPpdzLfNGDMnmBYg/fB5OPw71tGSsZOnObvFHcXUcDHADO56YyawtVi0+FCb24gts8fPJtY/h1rjL7xFrGooweYWMB4EVr8pP1bqazdPsYuWOGcnLO3JzUOquhvDAzesnY6Sebw+Hwsk1wewjjYg/icVUa7sl4tdJ+jzvjP4D/Go4IFVuRkj09anKEryAfTFZurJnTHBQW93/AF8jM1Ca5ukCzOEhOB5MK7F/Huar2tqkW5QoXPPFak8KK8ZI6ZxmoJVG9HUcZGSKjmvudcKKirRVi7Yx7Fzng9j3q3GgJ45z+lQRYEKLnFWUXB68fzrNq5rF2LGz5VXt6dapXVrkuyBl7cVdhnIGNqlSO/alkJcEEqoPv1osWp2OZWGW1mYRjcvX0P5VYS52uPvYPJrSuUAbaDgdazmkcEh40JHJHSmiHJdC5HciQnPQe9SrcDYCPXAHesV5xGF2ADJ5AOaBKTuK5GKfKw9omdQt2hVQ2Mg9aqyXCpLxxxjINYUdwQuSc846dKJrpnjKqTkYxRYi6Oga8LIqORx0JqGS+CZCNx6isLzSYwxLDPXNTWkNxdyeXawyzt6RIW/lVJGcqiWpo/bQp6jNRm8GdvHA59K0rHwNrt0QzQJaqR96dwMf8BGTXT6d8ObaPBvr6SZj1WFNg/M5q40mzlli4xPPpb49SwHbI7mr+k6VrWqY+wWE8if89pB5af8AfR/pXruleGtL08g2enQK46SSDe35mtloSw+clvatI0O5zVMY3sjzCz8AnIbWL8yHr5NoNoHsXPJ/ACun0zRLLTYtlnaxW6kclR8x+rHk1uzKsXJwKqSPxkn9K1UIrY451JT3Zl3sa8qoNYGo2ilCGHUd+a3764VSStcr4n1iHTbAzzhndzsiiXq7fXsPWq0RMItuyOW1ZY0ZgBk9s1zdwTk8HGeRVm4vNT1J2LSwW6E/diTcf++jWdq2nTwwGWO9mduu7dkE/Ss/aK+h2/VpxV2Ur6ZIVLMeRwAKzNLvDNqijoNjEVj31/cPc+XdfOc4DKMcVPYSCC/iYd22HJ9ab1RnH3ZI9IsgxCFMlgQeTXYWV0kNqVmG7PyghiDXD6XccqADnHWuusCE2ssfzHGSD1HtXHLuerTd9GakMUEy+YlqhZWwwlclsfSttJgkax+T5YAGCBwazgquFjljxLJySCQTgdDVk/NFJ5LYiPByclcd6zZ0LXc5D4ikf2vob8HIlB+ny1b0t8oM4GO9UfHsOLnQpHYsA8ke76rn+lWtPH7tQDwOn0qlrYm1tDp7Zsywq0mFbnO3IK+9STbYoiJvKZ5OCyE8f5GKi02eJMEjIb5SQuefU+3Y1ZkdwgBGI1G0ovQjtQKJXlWQSxs0nKdAP4q5HQCymaMjgTSAjPT5jXVESKy7c+WDlWPPHpXJ6Q3+m36bsYuZPp949fzqDbodjZhY0yp2Y43Dt/n0q44b5gAxxgZC/wBayreUoNhVVyMgnkGtRJCEJfbsBwdvUfjT6GWz1EdgzkAEMDya8a+Idh/xVd/KUJacJLnGMAqBz+VezyFkWQKV8vGCD+hrhPF+mvNrkEpLHdDt46Ag9T+dEJcr1M8SuanoeSnSGkmG2M5+u3j1qKXT3gB2SMGHXaxAH1rvdRjtrLEe4Fn5wo+Z/p6D3Nc3dQNdKxk2xRDIA9T7etbxqcx5jio+pyrX1/DIwtriQ4/vDP8APtVhPEOqQEhvKlbp0IrUnsFAURjYvq33m+tZc9uVUiNMsDgmrvF7mfNJapl+38Z3MJxLbkMO0bZrVg8aQFF8wtGGOPnU81xpi2kiPDOeWfHSpY7cZCKplcnPJ/pTcUVGtUXU9DtvE9tJhknUnt83GK0YNeGQVkBHXA715imnJkyXLBsnA47+mO9TCylUF2ke3jXptYhj9fSs3GJ0RrT7HrCazG4BEoTHBOec1bi1RQOJBnr1rxtLu6Rw3mlYeil/vP8ASrsWqXca7po9i+u7tScS1XuevJqLY+9wOpzViC6GFBPHUjNeUWniIB8yOVI659K2rbX0kOFmic55w/IpOBaqJnoy3WXTjjOOtFcVZ6wDIoYkgEck+9FKwnI4M24WeSWQqZCxJLEZAzUKyNLJtjTdgfNIw+Uf41ZntVlkZp2yCx+XoDzUMtwqER26F2BwFU4GKrdnPayGQWiM3mXRMsg5AP3RVq3gF1IIwfkHXA4qq6HINzIOAR5Y6f8A1zWppDNFId8flhuV3HBP+FPfculFcyTNiz09IFAwFHv6/Sr0EJDLjBYc9MYFRx3Ck4fAHrVy3kQsBnI9RSZ6kYotQwAxK23I5p1rEYyysMEE1PaTqY9hZcDpgdqiZ9lw4HU+vSosUkkXVAIXaPm6biaCAp3BsnPpVUSLxk54zxSyXGE6hQPXiixEncmuIw0R3Dc45A681nySeTAUKMHUnt1qxHdPK5S2jkmY8EIC38qtpoes3QAh0y5CkclxsH61SXYynUUV7zMyC5WQKWOMD0q2s+Mjccn0rUsvAerMw897S2U9mcu35D/Gui0/4fWyDN7fXEx7pCojX6Z5NV7OT6HPLFwi97nHm4VV6jp34pY3kmfEYaRiMYRSfp0r1Cz8M6TbYEOmwsR/FL85/WtiK0Ma7Y1SNR2QAD9KtUH3MJY/sjyD+xdXvP8AVaZcHPd12j9af/whOvyyhxFFH6rJMOn4Zr2IWxP3iT9aUWi/jVqgu5jLGze1jyN/h9rDBSJLIt3Hmnj9KfH4A1jjc1iMDgmU8fpXrgtl9KetuuOlP2MSfrdQ8ng+Gt47Zn1K0gHpHG0n+Faln8ONPiYG7v7qbp8sSiMf1NeiPGVwFUc1JDAvVsZ9KpUooh4io+pytl4N0e3O5NOjdv705Mn6HiuitrMQxCOJFjQfwxqFH6VoBQOgp3A4FWopbGTk3vqVktR1bFTrCo7U+lzTJFVQOgpsvTpTgainZVXnjNAGPft82SeBWNNPuk5PB6fSrupFpJCA2B1xWRcnZGQvHvS0EkZOs6j5TbVG4968+8R3rXuqReYMpEmEB6ZPJNdZq4Hm4IwDXGXJzetkAMOB3xWdR6WO7CRXPcnygjCt94jOAOQPWpRE1zaSoUZmQbhu78cYqrEHllO05k6ZJ5x3+lX7AeXcGePcIz8h3Vz3sei1zLU8u8VacVBl2Mp6muXmujFdRsVOY9uMHrivY/GtpCbVphkuQSRXimpf8fUn4VvB30POxEeV3PXNImICMPvnkmu40XY5h8zkKcgHoD6/0rgdGOIYyo5wP5Cu50JkEi/Lls54B9a5po7qTudTbPKmBNIZF6YI7+v4UshYlWAAkIwyjgGmZXLKcEsMjB5PrUjbXC9eM5Oe9ZM6loct8QvlsdEO4Ei8I6f7Bp2msWg4+ox3qj8RJT9r0KIYMZmkkIHHAXH9av6XtMUe0fL25/zmrtoiHLdG/ZqWA2MyAA/MuOlXJ224dkCsf4/7xqtDLtQLgEkYxjgVIiBtxJIB64yePQUnoENdRH/dbCM5JDba5G1ATXNUUf8APyxP48/1rsWjGUVDygGOO3pXLSkL4o1SIjBfZIB9V/8ArVF77mptwxgAFvm5+UfWr1sPlIAwoz8w7H+tUrdxHgAnPbvir0bqyIN6kqepOc49qfQi92W4yw35jC8dx94VzHjUTW+lJcWqjIkEZLc7VPpXTyMAFB3FunI6VW1uy+36Ld2pO1pUO0qeVOMjFSrX1KqR5otI8akRxJOWJll6k9enqf6VVniCgS3cm18YVT2+gq5JLDBABEN2wbdoJwD6lu5zWFcTkTHGZrjaTgdFHv6V0RbZ4ktNwmzICzt5MPp0ZvqazLiXcoJfZD0Cr1aoru+LvhyrOenoBVR7hIvmnYsTwAfWrUTK5dgiaZwiDZEOTjktWkiwiMxWqqzrwcnK/ie9Z1mTKu528uMHkA4J/GtGzmRpFEIEVuB948fkKUtjSBKsSoyZIluiOAB93/Cie3aa48pENxOPmK5/dr7ntV61hLoxTEEBHMmPmf39hVmJywNtpceNrYeY9z9e5rJytsdCiZcljHZoJrtxNcMeOMDPsPT3qrdWjznfcDbGvIXPH1NbE0lpZuXkmE90P4QdxBqvJ9ovnDCJYk9DyfrjpmknJ6l+zb0RiPayXL/uIysPQvj7/wDh9arS28cS7IIvNYdSo4FdhFpzuxMzs3Hf/Ctay09U4SMceg5quaxvHBtnnduLm3ljcyTq+4ELz60V7DaacSyAwBwSAdwFFP2nkN4FraR5NcBpJpDdny49xG1OpP8AOpY42WIkH7Oh/j4z/wDWokJFyxgiM77j82flHP6U14oxJvvZBJITxEOg/CmcSFhB2sLJfvHDSyHcc+1NCrFIcM9zdHoRzj+gqdwdpMuIoX74wagZ/LGLbbEh4Mhxk+woQbGhFfTwJi6KZBxtXkipo9VVPmMUgB7etY5niGdm7PTJbLGmzS7cBQPUqTVWvuWsRKOzOmGvxxowkEg2jqB1rv7PwHrF/Z2t5FfaYLe4jWWKQSO2VI9Avv0rxYyAp85+bHYcCvZ/2fPFCSiXwlfSfP8ANcacW/N4v/Zh+NXCkpbini6iWjN+y+HSrtOoarJIB1W3iCfqc10Fh4R0a0UeXYJMw/juGMh/Xiup8oDoMUoUDtWqpxXQ5J4ipPeRQitPKTbAiRIBwqKFH6U9LYyNls/U1oBelLt5HFXsYMrx2qA9OanESDoKeKUnAOe1IVxAB2FL+FM3k42g4p/PfNACjqKUA55oxx0pRxTHYUDvj8aPrSZ46GlxxzQAfrTwKB+FL35oAX8KX1zSdOtGfamA6imk45JpuS5IGQKAJC2Acf8A6qhkUtlm59OKmUY6cn1NMm+7QBz2pnDYHesK7OfTNberHnvWDc8njpUgjm9bbYTtAzjua4m8IXUHB4OB713GvgLCzDHSuJvCpvg2DtKj/wDXWdV6HbhH7xNp6+c7BR+8xwe2O5rbsLVYkQjcc8KRzj61jWUgjZiBhgMA46CujsFDy7ssGUAZ64Hp9a5ZHqR1MDx1bldKJX5mGckV4JqQIunyMc19HeLYh/ZMmFAAGcGvnzXYc6gFXq7YAreizgxsex6Jo+Hjix12A/oK7jQTuxgfMR+VcXpiKroMnjjJNdlpEmEOQwXp+NZTNqVzq4ZS04aToQFPuPrVnA3E8gk8DrWRbXAyEyXGM/U1NqmoCy0t5xjzfuxqerOelY9TtOO8UMb7xQwVg0VrH5KnPG4nLf0rY0xvLjRSMYGfoazrayKRKHOZeWdu5Y8k1sQR7VUKMcc/mOf0q7mT3NmDMioOqN19auKPJLKuWjJJGcD86y42KICWOf4SCf8APtV2AMsQzgkjLE5OD/XFTI0itB6OUJwMEngDr+Fcl4qtpbXWU1iBjlIljnTrlMn5vqCa61XQyqWx9TVTUYUummIC+XsMTDsRjtUrQuRWs7kSwq4wAwGGA7/5FatvIzRlSBwGODg4IrmtLDpGiDPA+YA1qxlxKjbQ4fcOTikmHLqbJPyjbk45z0FPaZjtZQMD0qrbTMwKNkDbkbvSrESfKVIGCPXvTWpbVkeG+ODPa+JdSsYyLe3STf5jd1YbvlH41x11OHJS1BWPuc8mvRfjTbfZtSsb9ziOaIwsf9ten5g/pXk88rzZI/dxAcY9K66equeBiI8tRoknn2DbEufUnoPrVKOb9+Gkbe5OAF5/CoJ5t3yxjCjv61f0e0kYGbAUdmb09q1tZXZzr3nZGpDltolUM3aJRwPqa27VUgjWS52vIfuRDqPSqOnQtI5MHKDq57mtq2W3sUa5uGLbB8zNzjPb/AVhNnXTj1LMxVbd7jVJFitwR+7Xqx9B6n9KzGvLnVG8m2X7LZ9BGh+ZvqaoXc9xrF6JWjIgUYjjHOPU/Wus8PaadylVBx0xUcvLq9zspQ5mR6Roiqo3x4J7V0NtpGAJFUADt6Vuadpg4ZmwwPT/ABro7azRYgjDryGB4HtUOVzvUIwRxsNjwpPp3FamnWQGCVLnHAUZya1LqyVGJUEEc+wqfT3jVHCSKkoHBI6ijdjnO0bohFnIrrvwBkfKCemaKoXuuR2k4junUSZ4VTkt9BRSdjJzfc8cHnyvIDtt7fccFeCearSXVvbDZAilsc7jyfqasXUYmmf7QzYB4jXgde9MjtIBkmNN49smtFbqeW72sjPmummlw252PUBSR9BSFJJGVHgkCddqLnbWxHkHag24HanrFlCM8d9vQf8A16rnt0J9nfdmGI5HO4QNheFUDpUqwXRAItyV6kNxW7gKADxjpkY+tJnJGxSD0wOfxodTyK9iu5jPb3SqC8YLZOFzz+NTae+pWFzBe2EYgvLaRZYnXqGBzWmPvE8yN69gPrTxl+nIPA29vxpe1aE6K7n1B4S16DxV4astZt1ETTDbcQ94Zh95f6j2IrWwBXgPwg8UL4d8TGwvZQNK1MiNz/DHL/A/t6H6+1fQbo0blWHI4NdkZKa5jjqQ5HYjA7072waD1NKTjPOfemZDC3OBzTQGLHJ4pxHOaWgAUYHH4UuffFNLZ4B5poHPzdqQEhODgUAZpOgzUTSEnAB5pjJS4Bx1PSmqW39MsO3bFNRMgbuKnwKAHD8Pxp/Q8VGDzS5waYD+3akLYwACWo7e1BAJz37UANVSxy2cVKoxwOntSe9KKBjqinxtp+fzqOb7vPpSYjndVBJyTxWBdSKjYPLegre1Vs9M8HnjpXPyJltzcnoAewpMEc5rsTSjJbaMZxXI3hxOi9igxiu41z/VgA84PWuGvPvoSWxg4P41nU2OrDaSC1l8uQEFs5yR6V0umPuUIGKgHO4cksewrllJbavGBya6HSJwAAWIB5OR0rlketTY3xhJjS5V3YGevWvDbmI3PiaCNckK4dh6Ac/0r13x1dCHTmYtnrxXmui25EpupM+ZM2ST2X0rWnornLiFzSsdTZJhgGBI6j/CuossrlXJ6dvSsGxBBGM5HfNdLaoZOQNu4c5NRI1o6su2j8qFPQ5ApZGGoX2/Obe3+WPPdu5qlMxQ+VGSoIy7+i+1W0KpEigALjoKzSOpvsI4Ug4GfSpInBLgLux+OTUMkmHHfjkUR/IBkjHXPpTM0rloS4AO7BAwOcDPc1tJMEt0VMgYGMd/esAFFZCF5HB/xrZiOYCXJztyu7mpZ0JaCTO/kjaflz35yaWN0WExNywXBI6UiuJFB52DjHrUJO1htAz1x6npUsJLoVrSP5icjPy5wOlWSREysDtZZDgEHGD3p8MTYQ8lgQ3A7Y7etI7eXLHI43qMnYp4HoRQkJbmlosnmxvjavlEY3Hr1zUs7nzOMMD97tis3QguHMrIQpKnzB35PWtB3Em9QBnAI9Aaa2NGtTkfizp4v/At8wQNJZFLtB9Dhv8Ax0mvm65naTjop5AFfXZiWWMi6UOkqGKVT0Kngj8q+U/GGjSeHvE2o6VLnNtMVUnunVT+KkGujDO90ePmNOzU16GfYwCecKx4HJrqLa3zt+0HEQ4EQ6fj61maLCBGTx5h546+1dTpVkk+Zrk42fdQ/wA61nI46Ub7FvT7eSdIorddikgFzwce1Z2qtHdaoLO1Ie1tSQzdd8nc/QdK19Z1BtL0tpLZVWWU+TEehzjkgewqj4Vs8SRlhnIOc96xX8zOyMbuxreHtPUt8yncDwBxmvQtEsfLg85F5TGV6ZFZGi2RWYHlhjjjtXcaVEsWFkx5bfK+P51lKWp6MfdRDcRCKNblQWiYgNnse1bFom+23Lz0wD/jVCOZbaWfTrsblcr5bHoyZqQpLp6Awhp7Qn/gSVlfU0ab0JL/ABIrH+LGCp7elcD4j1Xy7prewJlu1Hz4YBYh/tH19q6DxBqUdvpstzGzHd8qEDPzH0FecOqxxFSjRo3zmMfec98mk5GU5OKsQwqFuN0b+bduwWS4b7qrnoKKbsXdE10cIGGy3Tncc+lFUjibMh+Z32fKSxPHX/61IFPl4T5mzyB61UNxIJ5d2dpYnC89/Wm/bZ2XhThckdua6eVmHOuprssa2SlynnRy4KDqVI/oaZ5iqwAB9wv9TWPHNIqoCcZJwTxzVuG5LFV8vbk4yT1pOBUaiL4UK5APUnGTk07LMMJxx0qqjlAryg4Zshep/wDrCrMUm5uNpwORnIFQ00aJpjvKG0AgEkD5eeaeUYNucnYO2KnWA7f3hA3cntzSNglQoyejEn7tRcbTRFIBIpX+Bgcsa+hPhP4oPiXwyILqXfqunARTk9ZI/wCCT39D7ivn/duQAESFepA4FHhnxRdeFPG9lqdoWkSLMd3F0EsLfeX69x7gV0YeVpW6HPXjeJ9Zd+PXpRnr/KmwTwXlrBd2UgltbhBNDIOjKRkGgn611nAB6d6jbO4Ac5qSmk96BDRhc9+aUuB/hUbtgccc9aailuSP1pAPyZF4NSBR1PWgDGaWmNDuOtANIOPoaY7YOF6Hv6UXGSFgD70K3y5IwKiyRkHlu1OUM3OKYiQP8444qYVGqAcg/nT8jGQaAH/jSd6Sms2OFHOKBjiwXr3qtMWkHIwOlSBecvSzfd/lQIwNSHJx+tYUwyeOhFb+pLnmsSYc1LEjB1tMwnPUcZFcHfZOzA+UMQfrXoerpmBu3Brz69A2e248ZqKnwnVhviKyDncvOfU1qaXKpYryeev6Vk5Xkc4B/CpreUpJ+6wuO/8AdH+NcsketBlL4gzCWWCzX5lGWJznj6Vh2CZI+TsAK19TjEku4kE+rc8fWqcCBMDgE1a2MJ73NWzQg8niulhysK4Az1A/rWHaR5RSMHuTWoOVVU6sefpUSNaaJxFub94ox13evuaTJEYxkgndnOOP/r0qS4jBdhgEg1JdABdqnPGSB0yeg/CoOjoVWZvMYsQCOOPWrUTLLjDDB456YqpG6mRh0K1Yhbyh2wW4IoZMdx3mgSRgkZO4jvn3rWtWQWzSOhfA28+prIZCxVjjAIUD0960rbPlMGYY2ZJPfPp61D30OqKVtS5ZfvIyUwMDcc9GGahb5iVICkDOf5UyGQRhNpPGQA386A5YkcFjxjPWi1lcmW5ct3KMXGRtGSucbue360yaMFioKowIIU/UHFRRYUcY+Yfz71OCNiliqks2WYdPwpsztZ6C6cP30xBJyzHDgcCpuGDBeVGBUcEe1SWUjcByeqkdaktvm45Kk4I9c0lojS/UurGzIS38PU+teRfH/wANvNHZeJLaPLKq292AOw+45/8AQT/wGvXhhY8Dr2/DrTbqzh1CwktLqMS28yFJFPcHrVQlyNSOWtTVSLiz5f06KOFASN8p+6gPLexrqtLtp5zGLxV2lspCnAz6Z71Um0abQNdvNJlUyS27AmV+B5R5Vifp+tX0Et0rLbMUtFGGkHytJ649BXTN9jzKUHe3Y57XLl9R1QzYxBEfLiXHbPX6muz0C1BtkbuB1FcvqtktvIrQN+7P8OemK6/w4/7iMEjKjketRPbQ7aMPe1Ov0REfcF4ZeQSe/pXSWR+TKkbXXDZ9RWFpMYVsBTk4xzWxD+6kY8qpJLD0rnkd0kXfsaalJ5UxKSjDpIOqtj+VPupZYrdoJgRdRjkZ4cZ6irOngRqCSSFB2t3Ht71zPi/VEt7Tz5LhUZW8tT169QPWp8xX77HJa9qMd7qDR6cfMSNfnc/6uN/X3NYchRAy27+dMSN8p6A+1STDzIFjmY29ozY2Kcbvx70yRHMZBAgtcYSJPvN7moerucspOTK8Q8uZRGrXN2x+aZ+FXn17/QUURErtQYjiDdPx/WitEZS0OTnsZRPIIyXXcSzZxu56VMLWWQ480Lx0Hb0FXX5lbOeSSPbmpIE2q2ODjGRXS5M5o04mTd28luoLsWHqPWo1ff5Zw2McKfX3rfjijVP3i/QtzWNd2/kznaCwPKds/wD1qcZc2hM4cuqJVVM8sWYnsv51p2UkYV1EbKwOVU4OB7ntWSZP4H2hmb5toJ59BV+0VkIR4gMnPBwDSktNS4S1L4IYjcxlJPGOgNDKx+8cDPQdP0pyuoDgYUAdODz7VGJFK/uo8noWJ5rn1NwuJPKjZm+VAM4xk1zkZDTmR2faxyMLkmtG9mEzFGZ3WP7+zj8M+lVMqIi6xjHQc8iuimrI5ar5np0Pav2evFjGKTwpqU2TlptPLEcd3i/9mH417Qepr4306Se1mgvLB/Jubd1mil6FWByK+rvB3iKDxV4cttVgwsjfu7iIH/Vyj7w+ncexrphNS06o56sLJSNgnHpSDoetB6E0mefrVmJEU+ffn8KeMjvSt15puTngcetAh+e3egtiomkA4GCaCBu3Ekg9qAJN3GSQF96TopIB61Hgu3bHpVhAQM5pgIkfIyfwqYcfSmilz1oGP69P5UdDUbOqnHU0K525PHsKAJc9cmjhgDxx0qHdvBGenanxgjOTx2FAEn4cUyUcZpwHqaST7tAGJqQ4PH41hSjnt+NdDqK/Ie1c/JnNJiMrUQDCcnOOxrzvUVIWTkD5vSvS7pd0ZzXnOrAL9pHGQ2Rjmonsb0HaRhxZIxnGKuRAlVRBhT19zVWILuxjk8HNX7Jlz0z7E1zM9Wm9ChfI33T0xkZqCBR8uASe4rT1SPBLsv3u2Ov/ANaqETKD/tE80LYU1qativRQR07dSavyB4iC2COBkcfhVKxVVdfmH97ntV+7UvFxwcdR6etS9zSLKTSupAX95zyD2xW8sSPpplfJk4Xj9a59VLAKrALjvz+Jrc05gluoEhILbtvbHepe5v0KzcStjGff0pFxjcwzxzUvlDG4n5jzuoMTI7DJxj09qQouxGHw+MccAZ9O+a0bfasaxgFieQOoFZtvCZDhgT6nHetMW5jQBAcnpjIBpG8WRsXMhBcE9Cc8fSrUeGBUsQw6EfxGm+UUUnbz0JPU4pzYztHzY/i75pEyZFk8k4I54q/ArSxnkHaOn48VmzSkFeMLuycdT/kVoaZLhSm4KwO4A8ZHr9afkZSk0i4AfKLFfujgZzRaj5EODgEk4PU0y8k8pVjXKkDIB4xTbQnyeWII7dyai3Rlp3VzQaRSVCjqMEHnFWovkixjIHHvisyEMx+YlCvB9/rV5eQMnJ6898079CJdjj/ijoIv9PTUokMtxZDLKv8Ay1j7g+pHUfjXll3qyKqRxKUDDOWUjHtX0I2zynQ5AORXFaroltHOsrwq8YyHBHAJ7/StIztozJwueaLDJOqyLyF5z611Oj2mIQ8YAIIyO3401tNitdTdIObVx93PCk+hrodKgPlKUGCpxjpQ5aGkI2dzX0xQI0VsAk8OD1rUhIaZlIHQE4PHTFZtohQAlSoVskD0rZtoi2yTGcDDNjAIOetZN3N7FtgILYbeGDcg/wAq828Wut1rWxIi7Q5Klj8qk8k49a7/AFm7SO2+bgKOSTzgV5dPM13NNK+MuxYhR+nvUS02Mp7alYhY8GdRczqMK7fdX6CqkzySMWkPXuT/AJ/KrbOQAo4UDqRxVXUJoLC0lublsBMHk4z7Uoo53YjSM+apkLEBgRx1orlYvGMc9/ErwmOLzBzn3orf2M1ujldeF9GamyUSyHy2UFj2PrU0ccgyfLfGcEEHFFFaMqI4xyEozKx2k8lTWdq8EpaIhTxwTg8/hRRShuKq/dYKCYv9WwcnsvOKuWkLwI21HJZuPk5C/jRRVz0Ipu+pI8cj4DK+O+OcVV1BpYohEgILDHAxxRRUwV2XVdo3RSS3dbXasTe5OQasQWsuVV1Yjqq7egoopybM4JFiYi2gOVZpCOF25JNdL8IfFk3hvxWftYcaLqREN1uBxCw+5IPoTg+x9qKK0o+7Zin7z5XsfS7KQxxyOxHT60zDdwaKK6WcAvOeh5qOVXKELnOewoopiIwrDnb+NSrGxIzketFFDAmVcDoacARmiihjFwe+aaWOOB+NFFIBBu/iB3dKREZmOQee9FFUBKqbc4FSKDzwaKKQDsHoRQVJHT9KKKYGZfISp4NczcBg7DBB9xRRUsRyXjHxVp3hy1c3O64vWXMVnCfmb3Y/wr7/AJV5P4a13UNd1rWG1IbTJErxQoCEjAboPz696KKib0sa0laSZsJC5Y4R/wAqnt1mDkBCPqp4oornZ6kC5doxt2JDs+DkkcmsdUYbcKeOBxRRSQ5s2IImZkUqVYDNW5vMWAnBBAJOFNFFS1qVB6FeyUzuQ4ZVB4XbWstvLCmFDNntjgUUVL3OhSYRByuzBHTnbTiW3KQjHI5yOtFFD0IiPtVK3CjacA88e1a4h3uh+YYzwATRRUmyeiI5klDpwT8uCAOg9qimXLDCsvc8df8A61FFFtxSZFLHuGdrAngcd/enDdGilVPmqMEgdfrRRTsTbQWV5JiGlU7gMcCtS2Vlt18sEFhjO2iipmOLsh8MbBjhS7Hnmp4o5Y+ucDgcdBRRSS6kTbuTRjGSVbJ9qyNcie2W3vSGaMN5ci88hulFFUlcSk7nPXGnbJy0cTtE3Uen0q/pkeFCsWIGOTRRUPa50I3reJ9jNtGenTg1qwRskRO0gHpkdP8A61FFNqzJbOT8YTFrdYgr/M+MY5IHWuPljdwSA0cQOMheT7Ciisp6szqPWwx0bYVRCR6lf0ri/iKlw+lQbY38sTc9STxRRWuH0mjlxD9xnn0EUgnjzG/3h/CfWiiivUPIP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pressure or massage at the P6 acupressure point might help relieve motion sickness. The point is found three finger-widths away from the wrist, roughly in the middle of the forearm. The spot is shown in this picture by the tip of the pen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Judith A Smith, Pharm D, BCOP, FCCP, FISOPP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_53_21332=[""].join("\n");
var outline_f20_53_21332=null;
var title_f20_53_21333="Pannus invading cartilage in RA";
var content_f20_53_21333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F66979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F66979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pannus invading cartilage in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Articular surface of a joint obtained at the time of joint replacement surgery from a patient with rheumatoid arthritis. Pannus has replaced articular cartilage (left) and is invading the remaining cartilage (right, hematoxylin and eosin).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ellen M Gravallese, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_53_21333=[""].join("\n");
var outline_f20_53_21333=null;
var title_f20_53_21334="Incarcerated gravid uterus";
var content_f20_53_21334=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Incarcerated gravid uterus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/53/21334/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/53/21334/contributors\">",
"     Alex C Vidaeff, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/53/21334/contributors\">",
"     Karen M Schneider, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/53/21334/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/53/21334/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/53/21334/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/53/21334/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/53/21334/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/53/21334/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term incarcerated gravid uterus refers to a pregnant uterus that is entrapped in the pelvis by the sub-promontory sacrum (",
"    <a class=\"graphic graphic_figure graphicRef57272 graphicRef82473 \" href=\"UTD.htm?39/45/40664\">",
"     figure 1A-B",
"    </a>",
"    ). It has been reported to occur in 1 in 3000 to 10,000 pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299648\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In very early pregnancy, the uterus is retroverted (retroflexed) in up to 20 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/2\">",
"     2",
"    </a>",
"    ]. As the uterus enlarges during the first trimester, the fundus normally rises from the hollow of the sacrum to an anterior ventral position, spontaneously correcting any retroversion. In rare cases, however, the fundus becomes wedged below the sacral promontory, where it continues to enlarge [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/3\">",
"     3",
"    </a>",
"    ]. Concomitantly, the cervix becomes displaced cephalad against or above the symphysis pubis and pushes against the urethra and bladder, which interferes with normal voiding.",
"   </p>",
"   <p>",
"    Eventually, the posterior pelvis becomes too small to accommodate the increasing size of the fundus; this typically occurs when the pregnancy progresses beyond 20 weeks of gestation. At this point, the anterior lower uterine wall begins to thin and balloon into the upper abdomen, developing a sacculation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/4\">",
"     4",
"    </a>",
"    ]. This is termed &lsquo;inverted polarity&rsquo; because the anterior lower uterine wall becomes cephalad to the fundus, which is posterior-caudal. Concomitantly, both the bladder and the cervix are pulled up into the abdominal cavity, towards the umbilicus. The cervix can stretch to 10 cm or more in length, such that the internal os becomes located above the symphysis pubis, and occasionally above the bladder [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299734\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions that may inhibit the fundus of the enlarging uterus from ascending out of the sacral hollow include: adhesions related to previous pelvic surgery, pelvic inflammatory disease, or endometriosis; large fibroids; uterine malformation; or a deep sacral concavity with an overhanging promontory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laxity of the supporting tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Incarceration can also occur in the absence of predisposing factors, but this is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41499271\">",
"    <span class=\"h2\">",
"     Patient presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically, the patient presents at 14 to 16 weeks of gestation with symptoms related to pressure on the anatomic structures adjacent to the entrapped enlarging uterus. The most common symptoms are pain and progressive difficulty voiding. The pain may be abdominal, suprapubic, or in the back; or may be limited to pelvic discomfort or a feeling of pelvic fullness. Urinary symptoms include frequency, dysuria, sensation of incomplete emptying, voiding small volumes due to overflow incontinence, and, often, urinary retention. Gastrointestinal symptoms such as rectal pressure, tenesmus, and worsening constipation may occur due to compression of the rectum [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Vaginal bleeding has also been described. Symptoms can be intermittent, resolving for a period of time and then returning weeks later.",
"   </p>",
"   <p>",
"    Initial presentation in the third trimester is rare; only a few dozen cases have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/7\">",
"     7",
"    </a>",
"    ]. Cases of asymptomatic uterine incarceration are even rarer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/9-12\">",
"     9-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic retroversion with bladder outlet obstruction may first occur postpartum due to uterine enlargement combined with flaccid supporting tissues and other unknown factors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41499667\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key finding on physical examination is severe anterior displacement of the cervix behind the pubic symphysis, such that the clinician may not be able to visualize the cervix with a speculum or palpate the external os on pelvic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, the vagina is angulated anteriorly and a large, soft, smooth, nontender mass (the incarcerated uterus) fills the cul-de-sac.",
"   </p>",
"   <p>",
"    Initially, the uterus may be difficult to palpate abdominally, and later in pregnancy the fundal height may lag behind that expected for gestational age. The abdomen may appear full or distended due to an overdistended bladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36765994\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging can be a useful adjunct when the clinical presentation is suggestive of incarcerated uterus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41499621\">",
"    <span class=\"h3\">",
"     Ultrasound examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the first half of pregnancy, the cervix may be obscured or appear thin and elongated, pulled anterior to the uterus (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85819 \" href=\"UTD.htm?27/44/28357\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83558 \" href=\"UTD.htm?38/49/39698\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/2\">",
"     2",
"    </a>",
"    ]. The bladder is displaced superiorly. The fundus is located in the hollow of the sacrum; as a result, a fundal placenta may be mistaken for a placenta previa. The fetus may be seen posteriorly against the sacrum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H300081\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;On magnetic resonance imaging, the fundus is below the sacral promontory, the cervix in a cephalad and ventral position, and the vagina displaced almost parallel to the dorsal spine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/1\">",
"     1",
"    </a>",
"    ]. Characteristic magnetic resonance imaging findings midpregnancy include a &lsquo;free-standing,&rsquo; T-shaped multi-layer myometrium on sagittal images, and a small cleft-like cystic lesion between the bladder and the sacculation on axial images, corresponding to the elongated cervix and the caudal part of the uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, there is an asymmetrical thickening of the posterior uterine wall. The anterior wall appears much thinner than the posterior wall because of sacculation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41500140\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cephalad displacement of the cervix and upper vagina lifts the bladder neck and compresses the urethra, frequently causing urinary retention, sometimes with hydronephrosis. Urinary retention can lead to urinary tract infection and, rarely, bladder rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/6\">",
"     6",
"    </a>",
"    ]. In a review from 1894, Gottschalk described 67 cases of incarcerated sacculated uterus resulting in uremia, sepsis, peritonitis, and ultimately maternal death [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Malposition of the uterus can also compromise uterine arterial blood flow, increasing the risk of decidual bleeding, miscarriage, oligohydramnios, fetal growth restriction, and fetal demise [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/9\">",
"     9",
"    </a>",
"    ]. The rate of second trimester pregnancy loss has been reported to be as high as 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. There also appears to be increased risks of premature rupture of membranes and preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other complications described in case reports include uterine wall necrosis, uterine rupture, development of a cervicovaginal fistula, and rectal gangrene [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/6\">",
"     6",
"    </a>",
"    ]. Compression of pelvic veins may promote thrombosis, resulting in postpartum pulmonary embolism in the absence of thrombosis in the deep veins of the lower limbs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dystocia during labor inevitably occurs (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Delivery'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of incarcerated uterus is based on characteristic findings on physical and ultrasound examination after the first trimester: severe anterior displacement of the cervix and the uterus filling the posterior pelvis below the sacral promontory (",
"    <a class=\"graphic graphic_figure graphicRef57272 graphicRef82473 \" href=\"UTD.htm?39/45/40664\">",
"     figure 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Magnetic resonance imaging with either T1- or T2-weighted images can be useful in confirming uterine incarceration in cases of diagnostic uncertainty, especially later in pregnancy (see",
"    <a class=\"local\" href=\"#H300081\">",
"     'Magnetic resonance imaging'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. It also clarifies anatomic relationships, which can be severely distorted (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Delivery'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differential diagnosis of the physical findings includes a pelvic or adnexal mass extending into the cul-de-sac (eg, ectopic pregnancy, adnexal torsion, appendiceal abscess), a posterior fibroid, and some uterine anomalies (eg, uterus didelphys, unconnected rudimentary horn). These conditions are excluded by ultrasound examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because this condition is rare, particularly late in pregnancy, options for management are based on the approaches described in case reports. Thus, it is impossible to quantify the risk to the pregnancy from these procedures, but it is probably low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Incarceration before 20 weeks of gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis and treatment before 20 weeks of gestation are important for successful management of uterine incarceration. When a retroverted uterus is noted during the first trimester, bimanual examination should be repeated at 16 weeks to determine whether the fundus has ascended into the abdominal cavity.",
"   </p>",
"   <p>",
"    If the uterus remains retroverted, intervention is indicated for relief of maternal symptoms, if present. Even in the absence of symptoms, we suggest correction between 16 and 20 weeks to prevent development of complications related to incarceration. Many techniques have been utilized for freeing the uterus: the simplest maneuvers should be attempted first.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Passive reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The woman is instructed to empty her bladder and assume the knee-chest position for 10 minutes at least three times per day for one week. If spontaneous voiding is impaired, a catheter is placed to decompress the bladder.",
"   </p>",
"   <p>",
"    Although described in the literature, this approach is unlikely to be successful in symptomatic cases. If it fails to relieve the incarceration, manual reduction is attempted [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Manual reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manual reduction can be attempted in the office or performed in a setting where conscious sedation or regional or general anesthesia can be administered if pain management is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/18\">",
"     18",
"    </a>",
"    ]. Disadvantages of anesthesia are that it precludes use of some maternal positions and removes pain as a sign of excessive force during the reduction. Some clinicians administer a tocolytic drug (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    ) before the procedure to relax the uterus.",
"   </p>",
"   <p>",
"    After emptying her bladder, the patient is placed in the dorsal lithotomy position with her feet in stirrups. The clinician uses",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    fingertips to apply mild to moderate cephalad pressure to the uterine fundus through the posterior fornix until it is released from the cul-de-sac; a finger in the rectum can also be used to apply pressure. If these maneuvers are unsuccessful, the patient is placed in knee-chest (Sims) or all fours position and the procedure is repeated.",
"   </p>",
"   <p>",
"    A ring forceps can be applied to the cervix and gently pulled toward the introitus to provide countertraction while the fundus is being pushed cephalad. Use of sonographic guidance during manipulation of the uterus may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the initial attempt at correction fails, these maneuvers can be repeated in one week [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Colonoscopic reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A colonoscope can be used to reduce uterine incarceration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/14,20\">",
"     14,20",
"    </a>",
"    ]. In one report, five gravid patients with an incarcerated uterus refractory to manual reduction underwent a simple bowel prep with one to two enemas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/20\">",
"     20",
"    </a>",
"    ]. Under conscious sedation, a colonoscope was passed through the sigmoid colon to above the level of the uterine fundus. The investigators hypothesized that as the flexible colonoscope passed through the rectum to the proximal descending colon, forming a loop while advancing through the sigmoid colon, it generated sufficient external forces to dislodge the uterus from beneath the sacral promontory. In this small series, all of the procedures were successful and uncomplicated, although one patient required a second procedure because of recurrent incarceration.",
"   </p>",
"   <p>",
"    A second series described four cases of incarcerated uterus between the 15th and 25th week of gestation; three underwent successful manual reposition by colonoscopic insufflation without complication [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/14\">",
"     14",
"    </a>",
"    ]. The authors hypothesized that air insufflation during the procedure together with the formation of the loop had a synergistic effect by creating anterior pressure through the wall of the rectum on the uterine fundus.",
"   </p>",
"   <p>",
"    Colonoscopy should only be performed by an experienced endoscopist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Laparoscopic reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Release of the incarcerated uterus can be approached laparoscopically under general anesthesia. After pneumoperitoneum is achieved, vaginal maneuvers for manual reduction are again attempted. If unsuccessful, the round ligaments are grasped with atraumatic instruments by an assistant and pulled to free the fundus, concurrently with manual pressure on the fundus from below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8727?source=see_link\">",
"     \"Laparoscopic surgery in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299877\">",
"    <span class=\"h3\">",
"     Laparotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparotomy is rarely needed. However, if incarceration is due to the presence of dense adhesions, treatment must be individualized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36766070\">",
"    <span class=\"h3\">",
"     Post-reduction care",
"    </span>",
"    &nbsp;&mdash;&nbsp;A postprocedure ultrasound examination is useful to confirm uterine position and fetal well-being. Once the uterus is freed, it almost always remains in the correct abdominal location without further support; however, some authors suggest placing a Hodge pessary in the vagina for five to seven days to help ensure that the uterus maintains its upright anterior position [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Incarceration after 20 weeks of gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is generally recommended that reduction be avoided if the diagnosis of uterine incarceration is made after 20 weeks of gestation and the patient is asymptomatic or has only mild symptoms. Attempts at uterine release in the second half of pregnancy are unlikely to be successful and can cause serious complications (eg, pregnancy loss [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/3,17\">",
"     3,17",
"    </a>",
"    ]), although at least one successful case has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In these cases, the pregnancy is monitored for preterm labor, premature rupture of membranes, oligohydramnios, and fetal growth restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/4\">",
"     4",
"    </a>",
"    ]. Urinary retention commonly occurs and is treated by self-catheterization, if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/5,21\">",
"     5,21",
"    </a>",
"    ]. Otherwise, an indwelling catheter is placed.",
"   </p>",
"   <p>",
"    Analgesia can be provided as a comfort measure to enable prolongation of the pregnancy. However, severe pain may be indicative of a significant complication, such as uterine wall necrosis, impending uterine rupture, or rectal gangrene, and thus may require prompt laparotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Displacement of the cervix impedes normal progression of labor and increases the risk of intrapartum uterine rupture; vaginal delivery is always contraindicated when the uterus is incarcerated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/7,10\">",
"     7,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the very rare cases that persist to the third trimester, we suggest cesarean delivery at 36 weeks of gestation to avoid exposing the uterus to labor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/9\">",
"     9",
"    </a>",
"    ]. We do not test amniotic fluid for fetal lung maturity because, in our opinion, the risk of labor and uterine rupture at this point exceeds potential prematurity-related risks.",
"   </p>",
"   <p>",
"    Anatomical relationships at cesarean delivery are severely distorted [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/6,12\">",
"     6,12",
"    </a>",
"    ]. The anatomic posterior uterine wall may be located ventrally. The bladder, vagina, and elongated cervix are stretched ventrally and cephalad, thus if the surgeon makes the uterine incision where the lower uterine segment is normally located,",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    can transect the bladder, cervix, or vagina, resulting in supracervical hysterectomy. Preoperative magnetic resonance imaging provides detailed images of the pelvic anatomy, and thus may facilitate surgical planning [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/12,16\">",
"     12,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest a vertical supraumbilical skin incision, rather than a low vertical or Pfannenstiel incision. It can be extended caudally after entering the peritoneal cavity, if needed to allow adequate exposure of the distorted anatomy. The uterus should not be incised before the anatomic relationships are ascertained and restored to normal, if possible, by mobilization of the uterus from the pelvic cavity. In preterm gestations, where there is still a relatively large amount of amniotic fluid present, amnioreduction by amniocentesis may facilitate repositioning of the uterus.",
"   </p>",
"   <p>",
"    If the fundus cannot be released and restored to its correct position, the uterine incision should be made as cephalad as possible on the anterior wall of the uterus, where the uterus bends back on itself, so as not to enter the bladder, vagina, or cervix.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RECURRENCE RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21334/abstract/4,22\">",
"     4,22",
"    </a>",
"    ]. Predisposing conditions, such as uterine abnormalities or pelvic adhesions, may confer a higher risk of recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An incarcerated uterus is a rare complication of pregnancy in which the uterine fundus remains retroverted and entrapped below the sacral promontory after the first trimester. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for incarcerated uterus include pelvic adhesions and anatomic abnormalities. (See",
"      <a class=\"local\" href=\"#H299734\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations are due to pressure on the anatomic structures adjacent to the entrapped enlarging uterus. The most common symptoms are pain and voiding problems. Urinary retention is a frequent complication. Rectal pressure may cause worsening constipation and tenesmus. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H41500140\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is based on physical and ultrasound findings. In addition to palpation of a large firm mass in the cul-de-sac, a key finding is severe anterior displacement of the cervix so that it is located behind the pubic symphysis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H41499667\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the uterus remains retroverted after the first trimester, intervention is indicated for relief of maternal symptoms, if present, and to prevent complications related to incarcerated uterus. We suggest beginning with simple methods (trial of knee-chest position, manual reduction) before attempting more invasive methods (colonoscopy, laparoscopy) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Displacement of the cervix impedes normal progression of labor and increases the risk of intrapartum uterine rupture. For the very rare cases of incarcerated uterus that progress to the third trimester, we suggest cesarean delivery at 36 weeks of gestation rather than at term to avoid exposing the uterus to labor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The uterus should not be incised before the anatomic relationships are ascertained. If the fundus cannot be released and restored to its correct position, the uterine incision should be made as cephalad as possible on the anterior wall of the uterus, where the uterus bends back on itself, so as not to enter the bladder, vagina, or cervix. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Delivery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/1\">",
"      van Beekhuizen HJ, Bodewes HW, Tepe EM, et al. Role of magnetic resonance imaging in the diagnosis of incarceration of the gravid uterus. Obstet Gynecol 2003; 102:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/2\">",
"      Feusner AH, Mueller PD. Incarceration of a gravid fibroid uterus. Ann Emerg Med 1997; 30:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/3\">",
"      Gibbons JM Jr, Paley WB. The incarcerated gravid uterus. Obstet Gynecol 1969; 33:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/4\">",
"      Jacobsson B, Wide-Swensson D. Incarceration of the retroverted gravid uterus--a review. Acta Obstet Gynecol Scand 1999; 78:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/5\">",
"      Gottschalk EM, Siedentopf JP, Schoenborn I, et al. Prenatal sonographic and MRI findings in a pregnancy complicated by uterine sacculation: case report and review of the literature. Ultrasound Obstet Gynecol 2008; 32:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/6\">",
"      Lettieri L, Rodis JF, McLean DA, et al. Incarceration of the gravid uterus. Obstet Gynecol Surv 1994; 49:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/7\">",
"      Singh MN, Payappagoudar J, Lo J, Prashar S. Incarcerated retroverted uterus in the third trimester complicated by postpartum pulmonary embolism. Obstet Gynecol 2007; 109:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/8\">",
"      O'Connell MP, Ivory CM, Hunter RW. Incarcerated retroverted uterus--a non recurring complication of pregnancy. J Obstet Gynaecol 1999; 19:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/9\">",
"      Van Winter JT, Ogburn PL Jr, Ney JA, Hetzel DJ. Uterine incarceration during the third trimester: a rare complication of pregnancy. Mayo Clin Proc 1991; 66:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/10\">",
"      Renaud MC, Bazin S, Blanchet P. Asymptomatic uterine incarceration at term. Obstet Gynecol 1996; 88:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/11\">",
"      Matsushita H, Kurabayashi T, Higashino M, et al. Incarceration of the retroverted uterus at term gestation. Am J Perinatol 2004; 21:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/12\">",
"      Al Wadi K, Helewa M, Sabeski L. Asymptomatic uterine incarceration at term: a rare complication of pregnancy. J Obstet Gynaecol Can 2011; 33:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/13\">",
"      Haylen BT, Cerqui AJ. Postpartum uterine retroversion causing bladder outflow obstruction: cure by laparoscopic ventrosuspension. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/14\">",
"      Dierickx I, Van Holsbeke C, Mesens T, et al. Colonoscopy-assisted reposition of the incarcerated uterus in mid-pregnancy: a report of four cases and a literature review. Eur J Obstet Gynecol Reprod Biol 2011; 158:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/15\">",
"      Gottschalk S. Zur Lehre von der Retroversio uteri gravidi. Arch Gynecol Obstet 1894; 46:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/16\">",
"      Hachisuga N, Hidaka N, Fujita Y, et al. Significance of pelvic magnetic resonance imaging in preoperative diagnosis of incarcerated retroverted gravid uterus with a large anterior leiomyoma: a case report. J Reprod Med 2012; 57:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/17\">",
"      Hess LW, Nolan TE, Martin RW, et al. Incarceration of the retroverted gravid uterus: report of four patients managed with uterine reduction. South Med J 1989; 82:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/18\">",
"      Algra LJ, Fogel ST, Norris MC. Anesthesia for reduction of uterine incarceration: report of two cases. Int J Obstet Anesth 1999; 8:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/19\">",
"      Grossenburg NJ, Delaney AA, Berg TG. Treatment of a late second-trimester incarcerated uterus using ultrasound-guided manual reduction. Obstet Gynecol 2011; 118:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/20\">",
"      Seubert DE, Puder KS, Goldmeier P, Gonik B. Colonoscopic release of the incarcerated gravid uterus. Obstet Gynecol 1999; 94:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/21\">",
"      Hamod H, Chamberlain PF, Moore NR, Mackenzie IZ. Conservative treatment of an incarcerated gravid uterus. BJOG 2002; 109:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21334/abstract/22\">",
"      van der Tuuk K, Krenning RA, Krenning G, Monincx WM. Recurrent incarceration of the retroverted gravid uterus at term - two times transvaginal caesarean section: a case report. J Med Case Rep 2009; 3:103.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6747 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_53_21334=[""].join("\n");
var outline_f20_53_21334=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H299648\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H299734\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41499271\">",
"      Patient presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41499667\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36765994\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41499621\">",
"      - Ultrasound examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H300081\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41500140\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Incarceration before 20 weeks of gestation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Passive reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Manual reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Colonoscopic reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Laparoscopic reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H299877\">",
"      - Laparotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36766070\">",
"      - Post-reduction care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Incarceration after 20 weeks of gestation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RECURRENCE RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6747\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6747|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/44/28357\" title=\"diagnostic image 1\">",
"      Ultrasound image incarcerated gravid uterus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/49/39698\" title=\"diagnostic image 2\">",
"      Ultrasound of incarcerated uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6747|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/26/2468\" title=\"figure 1A\">",
"      Normal uterine position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/39/42611\" title=\"figure 1B\">",
"      Incarcerated uterus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8727?source=related_link\">",
"      Laparoscopic surgery in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_53_21335="Denosumab: Drug information";
var content_f20_53_21335=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Denosumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/38/3685?source=see_link\">",
"    see \"Denosumab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14384138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Health Canada Issues Update Regarding Atypical Femur Fractures",
"     </span>",
"     <span class=\"collapsible-date\">",
"      November 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Amgen Canada, Inc, in consultation with Health Canada, has issued an update for Canadian healthcare professionals in regards to the risk of atypical femur fractures associated with denosumab treatment. Rare cases of atypical femoral fracture have occurred in an ongoing, open label extension study called Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months (FREEDOM). These fractures are subtrochanteric or proximal diaphyseal fractures that may occur in both legs without any significant trauma being reported.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       There are no confirmed cases in Canada to date; however, Canadian healthcare professionals are being reminded to be aware of this possible risk for fracture and to evaluate and rule out femur fracture in patients reporting new or unusual hip, thigh, or groin pain. Patients should not discontinue denosumab therapy without consulting a healthcare professional and should be encouraged to report dull, unusual aching pain in the hip, thigh, or groin.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at file://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2012/index-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Reports of Severe Hypocalcemia Including Fatalities, Health Canada Issues Notice",
"     </span>",
"     <span class=\"collapsible-date\">",
"      June 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Amgen Canada Inc, in conjunction with Health Canada, has issued notice to healthcare professionals regarding reports of severe symptomatic hypocalcemia (including fatalities) in patients receiving denosumab (XGEVA&reg;). Severe hypocalcemia with symptoms including altered mental status, tetany, seizures and QT",
"       <sub>",
"        c",
"       </sub>",
"       prolongation has been reported at an estimated incidence of 1% to 2%. During clinical trials, the incidence of severe hypocalcemia (corrected serum calcium &lt;7 mg/dL) was ~3%. The Canadian product monograph will be updated with this important safety information.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       To reduce the risk of severe hypocalcemia, healthcare professionals are reminded to:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       - Correct pre-existing hypocalcemia prior to initiating denosumab therapy.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       - Identify patients at high risk of developing hypocalcemia, such as patients with severe renal impairment and/or receiving dialysis.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       - Supplement with calcium and vitamin D unless hypercalcemia is present.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       - Monitor calcium levels during therapy.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       - If severe hypocalcemia occurs, assess the risk versus benefit of continued treatment.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at file://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2012/xgeva_hpc-cps-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10267890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prolia&trade;;",
"     </li>",
"     <li>",
"      Xgeva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10890558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Prolia&reg;;",
"     </li>",
"     <li>",
"      Xgeva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10267529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Bone-Modifying Agent;",
"     </li>",
"     <li>",
"      Monoclonal Antibody",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10267929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prevention of skeletal-related events in bone metastases from solid tumors (Xgeva&reg;):",
"     </b>",
"     SubQ: 120 mg every 4 weeks (Fizazi, 2011; Henry, 2011; Stopeck, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of androgen deprivation-induced bone loss in men with prostate cancer (Prolia&reg;):",
"     </b>",
"     SubQ: 60 mg as a single dose, once every 6 months (Smith, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of aromatase inhibitor-induced bone loss in women with breast cancer (Prolia&reg;):",
"     </b>",
"     SubQ: 60 mg as a single dose, once every 6 months (ELlis, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of osteoporosis in men or postmenopausal women (Prolia&reg;):",
"     </b>",
"     SubQ: 60 mg as a single dose, once every 6 months",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F10267930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10267931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute (including dialysis-dependent): No adjustment necessary when administered every 6 months (Prolia&reg;); once-monthly dosing has not been evaluated in patients with renal impairment (Xgeva&reg;). Monitor patients with severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute or on dialysis) due to increased risk of hypocalcemia.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14295272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10267951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prolia&trade;: 60 mg/mL (1 mL) [contains natural rubber/natural latex in packaging]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xgeva&reg;: 70 mg/mL (1.7 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10267527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10267524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prolia&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM214385.pd\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM214385.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10267946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Prior to administration, bring to room temperature in original container (allow to stand ~15-30 minutes); do not warm by any other method. Solution may contain trace amounts of translucent to white protein particles; do not use if cloudy, discolored (normal solution should be clear and colorless to pale yellow), or contains excessive particles or foreign matter. Avoid vigorous shaking. Administer via SubQ injection in the upper arm, upper thigh, or abdomen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prolia&reg;: If a dose is missed, administer as soon as possible, then continue dosing every 6 months from the date of the last injection.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10267530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of osteoporosis in men and in postmenopausal women at high risk for fracture; treatment of bone loss in men receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer; treatment of bone loss in women receiving aromatase inhibitor (AI) therapy for breast cancer; prevention of skeletal-related events (eg, fracture, spinal cord compression, bone pain requiring surgery/radiation therapy) in patients with bone metastases from solid tumors",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13254953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bone destruction caused by rheumatoid arthritis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13254398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Xgeva&reg; may be confused with Jevtana&reg;, Xtandi&reg;, Zometa&reg;, Zytiga&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: Prolia&reg; contains denosumab, which is the same ingredient contained in Xgeva&reg;; patients receiving Xgeva&reg; should not be treated with Prolia&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10267894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A postmarketing safety program for Prolia&reg; is available to collect information on adverse events; more information is available at file://www.proliasafety.com. To report adverse events for either Prolia&reg; or Xgeva&reg;, prescribers may also call Amgen at 800-772-6436 or FDA at 800-332-1088.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Percentages noted with Prolia&reg; (60 mg every 6 months) unless specified as Xgeva&reg; (120 mg every 4 weeks):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (Xgeva&reg;: 45%), headache (Xgeva&reg;: 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Dermatitis (4% to 11%), eczema (4% to 11%), rash (3% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypophosphatemia (Xgeva&reg;: 32%; grade 3: 15%), hypocalcemia (2%; Xgeva&reg;: 18%; grade 3: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (Xgeva&reg;: 31%), diarrhea (Xgeva&reg;: 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (Xgeva&reg;: 45%), arthralgia (7% to 14%), limb pain (10% to 12%), back pain (8% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (Xgeva&reg;: 21%), cough (Xgeva&reg;: 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (5%), angina (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Flatulence (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain (6%), sciatica (5%), bone pain (4%), myalgia (3%), osteonecrosis of the jaw (ONJ; &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Cataracts (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (7%), upper respiratory tract infection (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: New malignancies (3% to 5%), infections (nonfatal, serious;  4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Antibody formation, constipation, cystitis, diaphyseal femur fracture, endocarditis, erythema, facial swelling, GERD, hypertension, hypocalcemia (severe symptomatic), influenza, pancreatitis, subtrochanteric femur fracture, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10267537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prolia&reg;: Hypersensitivity to denosumab or any component of the formulation; pre-existing hypocalcemia; pregnancy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Xgeva&reg;: There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10267891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bone fractures: Atypical femur fractures have been reported in patients receiving denosumab. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if denosumab therapy is the cause for these fractures. Consider interrupting therapy in patients who develop an atypical femoral fracture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dermatologic reactions: Dermatitis, eczema, and rash (which are not necessarily specific to the injection site) have been reported. Consider discontinuing if severe symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypocalcemia: Denosumab may cause or exacerbate hypocalcemia; severe symptomatic cases (including fatalities) have been reported.  Monitor calcium levels; correct pre-existing hypocalcemia prior to therapy. Use caution in patients with a history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment/dialysis or other conditions which would predispose the patient to hypocalcemia; monitor calcium, phosphorus, and magnesium closely during therapy. Ensure adequate calcium and vitamin D intake; calcium and vitamin D supplementation is recommended; magnesium supplementation may also be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infection: Incidence of infections may be increased, including serious skin infections, abdominal, urinary, ear, or periodontal infections. Endocarditis has also been reported following use. Patients should be advised to contact healthcare provider if signs or symptoms of severe infection or cellulitis develop. Use with caution in patients with impaired immune systems or using concomitant immunosuppressive therapy; may be at increased risk for serious infections. Evaluate the need for continued treatment with serious infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Osteonecrosis of the jaw (ONJ): ONJ has been reported in patients receiving denosumab. ONJ may manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth/periodontal infection, toothache, gingival ulceration/erosion. Risk factors include invasive dental procedures (eg, tooth extraction, dental implants, boney surgery); a diagnosis of cancer, concomitant chemotherapy or corticosteroids, poor oral hygiene, ill-fitting dentures; and comorbid disorders (anemia, coagulopathy, infection, pre-existing dental disease). Patients should maintain good oral hygiene during treatment. A dental exam and preventative dentistry should be performed prior to therapy. The benefit/risk must be assessed by the treating physician and/or dentist/surgeon prior to any invasive dental procedure; avoid invasive procedures in patients with bone metastases receiving for prevention of skeletal-related events. Patients developing ONJ while on denosumab therapy should receive care by a dentist or oral surgeon; extensive dental surgery to treat ONJ may exacerbate ONJ; evaluate individually and consider discontinuing if extensive dental surgery is necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Multiple myeloma: Denosumab is not indicated for the prevention of skeletal-related events in patients with multiple myeloma. In trials of with multiple myeloma patients, denosumab was noninferior to zoledronic acid in delaying time to first skeletal&ndash;related event and mortality was increased in a subset of the denosumab-treated group.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) or patients on dialysis; risk of hypocalcemia is increased. Dose adjustment is not needed when administered at 60 mg every 6 months (Prolia&reg;); once-monthly dosing has not been evaluated in patients with renal impairment (Xgeva&reg;).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Latex: Packaging may contain natural latex rubber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: May impair bone growth in children with open growth plates or inhibit eruption of dentition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Postmenopausal osteoporosis: For use in women at high risk for fracture which is defined as a history of osteoporotic fracture or multiple risk factors for fracture. May also be used in women who failed or did not tolerate other therapies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Duplicate therapy: Do not administer Prolia&reg; and Xgeva&reg; to the same patient for different indications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Long-term therapy: Denosumab therapy results in significant suppression of bone turnover; the long-term effects of treatment are not known, but may contribute to adverse outcomes such as ONJ, atypical fractures, or delayed fracture healing; monitor.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10327798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: Denosumab may enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10267898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase risk of osteoporosis).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10267532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (Xgeva&reg;)/X (Prolia&reg;) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10267533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Specifically, increased fetal loss, stillbirths, postnatal mortality, absent lymph nodes, abnormal bone growth, and decreased neonatal growth was observed in cynomolgus monkeys exposed to denosumab throughout pregnancy. Denosumab was measurable in the offspring at one month of age. Fetal exposure to monoclonal antibodies is expected to increase as pregnancy progresses. Women should be advised to avoid pregnancy during denosumab treatment. If a pregnant woman is exposed, patients or their prescribers may contact the Amgen Pregnancy Surveillance Program (800-772-6436). In addition, there is potential for a fetus to be exposed to denosumab when a pregnant woman has unprotected sex with a man treated with denosumab. It is unknown the extent that denosumab is present in seminal fluid; however, the risk of harm to the fetus is expected to be low. Men receiving denosumab who have pregnant partners should be counseled regarding this potential risk.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10267535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10267536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to discontinue denosumab or discontinue breast-feeding should take into account the benefits of treatment to the mother. In some animal studies, mammary gland development was impaired following exposure to denosumab during pregnancy, resulting in impaired lactation postpartum.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F10267899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ensure adequate calcium and vitamin D intake to prevent or treat hypocalcemia. Calcium 1000 mg/day and vitamin D &ge;400 units/day is recommended in product labeling (Prolia&reg;).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Women and men &gt;50 years of age should consume elemental calcium 1200-1500 mg/day and vitamin D 800-1000 units/day (National Osteoporosis Foundation Guidelines, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Prolia Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg/mL (1 mL): $990.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Xgeva Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg/1.7 mL (1.7 mL): $1980.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10267948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommend monitoring of serum creatinine, serum calcium, phosphorus and magnesium, signs and symptoms of hypocalcemia, especially  in patients predisposed to hypocalcemia (severe renal impairment, thyroid/parathyroid surgery, malabsorption syndromes, hypoparathyroidism); infection, or dermatologic reactions; routine oral exam (prior to treatment); dental exam if risk factors for ONJ",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Osteoporosis: Bone mineral density as measured by central dual-energy x-ray absorptiometry (DXA) of the hip or spine (prior to initiation of therapy and at least every 2 years; annual measurements of height and weight, assessment of chronic back pain; serum calcium and 25(OH)D; may consider monitoring biochemical markers of bone turnover (National Osteoporosis Foundation Guidelines, 2010)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Prolia (AR, AT, AU, BE, CH, CZ, DE, DK, EE, FR, GB, HK, HN, NL, NO, PL, SE, SG, TW);",
"     </li>",
"     <li>",
"      Xgeva (AR, AU, GB, IE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10267944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Denosumab is a monoclonal antibody with affinity for nuclear factor-kappa ligand (RANKL). Osteoblasts secrete RANKL; RANKL activates osteoclast precursors and subsequent osteolysis which promotes release of bone-derived growth factors, such as insulin-like growth factor-1 (IGF1) and transforming growth factor-beta (TGF-beta), and increases serum calcium levels. Denosumab binds to RANKL, blocks the interaction between RANKL and RANK (a receptor located on osteoclast surfaces), and prevents osteoclast formation, leading to decreased bone resorption and increased bone mass in osteoporosis. In solid tumors with bony metastases, RANKL inhibition decreases osteoclastic activity leading to decreased skeletal related events and tumor-induced bone destruction.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10267902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Decreases markers of bone resorption by ~85% within 3 days; maximal reductions observed within 1 month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Markers of bone resorption return to baseline within 12 months of discontinuing therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: SubQ: 62%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~25-28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, serum: 10 days (range: 3-21 days)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Block GA, Bone HG, Fang L, et al, &ldquo;A Single-Dose Study of Denosumab in Patients With Various Degrees of Renal Impairment,&rdquo;",
"      <i>",
"       J Bone Miner Res",
"      </i>",
"      , 2012, 27(7):1471-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/22461041/pubmed\" id=\"22461041\" target=\"_blank\">",
"        22461041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Body JJ, Lipton A, Gralow J, et al, &ldquo;Effects of Denosumab in Patients With Bone Metastases With and Without Previous Bisphosphonate Exposure,&rdquo;",
"      <i>",
"       J Bone Miner Res",
"      </i>",
"      , 2010, 25(3):440-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/19653815/pubmed\" id=\"19653815\" target=\"_blank\">",
"        19653815",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bone HG, Bolognese MA, Yuen CK, et al, &ldquo;Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women With Low Bone Mass,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2011, 96(4):972-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/21289258/pubmed\" id=\"21289258\" target=\"_blank\">",
"        21289258",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boonen S, Adachi JD, Man Z, et al, &ldquo;Treatment With Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2011, 96(6):1727-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/21411557/pubmed\" id=\"21411557\" target=\"_blank\">",
"        21411557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown JP, Prince RL, Deal C, et al, &ldquo;Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial,&rdquo;",
"      <i>",
"       J Bone Miner Res",
"      </i>",
"      , 2009, 24(1):153-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/18767928/pubmed\" id=\"18767928\" target=\"_blank\">",
"        18767928",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen SB, Dore RK, Lane NE, et al, &ldquo;Denosumab Treatment Effects on Structural Damage, Bone Mineral Density, and Bone Turnover in Rheumatoid Arthritis: A Twelve-Month, Multicenter, Randomized, Double-Blind Placebo-Controlled, Phase II Clinical Trial,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2008, 58(5):1299-309.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/18438830/pubmed\" id=\"18438830\" target=\"_blank\">",
"        18438830",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cummings SR, San Martin J, McClung MR, et al, &ldquo;FREEDOM Trial. Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 361(8):756-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/19671655/pubmed\" id=\"19671655\" target=\"_blank\">",
"        19671655",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dore RK, Cohen SB, Lane NE, et al, &ldquo;Effects of Denosumab on Bone Mineral Density and Bone Turnover in Patients With Rheumatoid Arthritis Receiving Concurrent Glucocorticoids or Bisphosphonates,&rdquo;",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2010, 69(5):872-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/19734132/pubmed\" id=\"19734132\" target=\"_blank\">",
"        19734132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ellis GK, Bone HG, Chlebowski R, et al, &ldquo;Randomized Trial of Denosumab in Patients receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(30):4875-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/18725648/pubmed\" id=\"18725648\" target=\"_blank\">",
"        18725648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fizazi K, Carducci M, Smith M, et al, &ldquo;Denosumab Versus Zoledronic Acid for Treatment of Bone Metastases in Men With Castration-Resistant Prostate Cancer:  A Randomised, Double-Blind Study,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2011, 377(9768):813-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/21353695/pubmed\" id=\"21353695\" target=\"_blank\">",
"        21353695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Henry DH, Costa L, Goldwasser F, et al, &ldquo;Randomized, Double-Blind Study of Denosumab Verses Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(9):1125-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/21343556/pubmed\" id=\"21343556\" target=\"_blank\">",
"        21343556",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kendler DL, Roux C, Benhamou CL, et al, &ldquo;Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women Transitioning from Alendronate Therapy,&rdquo;",
"      <i>",
"       J Bone Miner Res",
"      </i>",
"      , 2010, 25(1):72-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/19594293/pubmed\" id=\"19594293\" target=\"_blank\">",
"        19594293",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kyrgidis A and Toulis KA, \"Denosumab-Related Osteonecrosis of the Jaws,\"",
"      <i>",
"       Osteoporos Int",
"      </i>",
"      , 2011, 22(1):369-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/20306021/pubmed\" id=\"20306021\" target=\"_blank\">",
"        20306021",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lewiecki EM, Miller PD, McClung MR, et al, &ldquo;Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD,&rdquo;",
"      <i>",
"       J Bone Miner Res",
"      </i>",
"      , 2007, 22(12):1832-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/17708711/pubmed\" id=\"17708711\" target=\"_blank\">",
"        17708711",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipton A, Steger GG, Figueroa J, et al, &ldquo;Extended Efficacy and Safety of Denosumab in Breast Cancer Patients With Bone Metastases Not Receiving Prior Bisphosphonate Therapy,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2008, 14(20):6690-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/18927312/pubmed\" id=\"18927312\" target=\"_blank\">",
"        18927312",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipton A, Steger GG, Figueroa J, et al, &ldquo;Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(28):4431-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/17785705/pubmed\" id=\"17785705\" target=\"_blank\">",
"        17785705",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McClung MR, Lewiecki EM, Cohen SB, et al, &ldquo;Denosumab in Postmenopausal Women With Low Bone Mineral Density,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(8):821-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/16495394/pubmed\" id=\"16495394\" target=\"_blank\">",
"        16495394",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Osteoporosis Foundation, &ldquo;Clinician&rsquo;s Guide to Prevention and Treatment of Osteoporosis,&rdquo; Washington, DC, 2010. Available at file://www.nof.org/files/nof/public/content/file/344/upload/159.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pageau SC, &ldquo;Denosumab,&rdquo;",
"      <i>",
"       MAbs",
"      </i>",
"      , 2009, 1(3):210-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/20065634/pubmed\" id=\"20065634\" target=\"_blank\">",
"        20065634",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith MR, Egerdie B, Hern&aacute;ndez Toriz N, et al, &ldquo;Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 361(8):745-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/19671656/pubmed\" id=\"19671656\" target=\"_blank\">",
"        19671656",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith MR, Saad F, Coleman R, et al, &ldquo;Denosumab and Bone-Metastasis-Free Survival in Men With Castration-Resistant Prostate Cancer: Results of a Phase 3, Randomised, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2012, 379(9810):39-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/22093187/pubmed\" id=\"22093187\" target=\"_blank\">",
"        22093187",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stopeck AT, Lipton A, Body JJ, et al, &ldquo;Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(35):5132-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/21060033/pubmed\" id=\"21060033\" target=\"_blank\">",
"        21060033",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor KH, Middlefell LS, and Mizen KD, \"Osteonecrosis of the Jaws Induced by Anti-RANK Ligand Therapy,\"",
"      <i>",
"       Br J Oral Maxillofac Surg",
"      </i>",
"      , 2010, 48(3):221-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/19836866/pubmed\" id=\"19836866\" target=\"_blank\">",
"        19836866",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Poznak CH, Temin S, Yee GC, et al, &ldquo;American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(9):1221-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/53/21335/abstract-text/21343561/pubmed\" id=\"21343561\" target=\"_blank\">",
"        21343561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15575 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-F17749F6BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_53_21335=[""].join("\n");
var outline_f20_53_21335=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14384138\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267890\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10890558\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267529\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267929\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267930\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267931\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14295272\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267951\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267527\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267524\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267946\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267530\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13254953\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13254398\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267894\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267537\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267891\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299134\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10327798\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267898\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267532\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267533\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267535\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267536\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267899\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322854\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267948\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962022\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267944\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267902\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15575\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15575|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/38/3685?source=related_link\">",
"      Denosumab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_53_21336="Peripheral blood MCL";
var content_f20_53_21336=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F86530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F86530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Peripheral blood smear of mantle cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear shows many lymphoma cells with variable sizes, irregular configuration, high nuclear-cytoplasm ratio, and prominent nucleoli. Wright-Giemsa stain, 60x magnification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_53_21336=[""].join("\n");
var outline_f20_53_21336=null;
var title_f20_53_21337="Classification of the hematopoietic neoplasms";
var content_f20_53_21337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification of the hematopoietic neoplasms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/53/21337/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/53/21337/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/53/21337/contributors\">",
"     Jonathan W Friedberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/53/21337/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/53/21337/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/53/21337/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/53/21337/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/53/21337/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/53/21337/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancies of the hematopoietic and lymphoid tissues include the lymphomas, leukemias, myeloproliferative neoplasms, plasma cell dyscrasias, histiocytic tumors, and dendritic cell neoplasms. Multiple classification schemes have been employed for these diseases over the years. These have included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gall and Mallory classification",
"     </li>",
"     <li>",
"      Rappaport classification",
"     </li>",
"     <li>",
"      Kiel classification",
"     </li>",
"     <li>",
"      Lukes-Collins classification",
"     </li>",
"     <li>",
"      Working Formulation",
"     </li>",
"     <li>",
"      Revised European-American classification (REAL)",
"     </li>",
"     <li>",
"      French-American-British system",
"     </li>",
"     <li>",
"      World Health Organization (WHO) classification 2001",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The earliest classification systems were based upon tissue architecture and the cytologic appearances of the neoplastic cells. For a few entities (eg, follicular lymphoma), these morphologic features are often sufficient to establish the diagnosis. However, with the development and application of immunophenotyping and cytogenetic and molecular genetic testing, it was recognized that many distinct entities existed that could not be distinguished reliably by morphology alone. This appreciation led to the incorporation of immunophenotype and genetic criteria into the REAL classification of lymphoid neoplasms in 1994. Numerous subsequent analyses demonstrated that the REAL classification had \"added value\" over older systems for determining prognosis and patient stratification. In 2001, immunophenotype and genetic findings were incorporated into a new WHO classification, which subsumed the REAL classification and included tumors of myeloid or mixed lineage origin.",
"   </p>",
"   <p>",
"    The latest WHO classification, updated in 2008, further refined and expanded upon the use of objective diagnostic criteria (eg, particular molecular markers) for clearly defined entities and is widely used and accepted [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21337/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, it remains important for clinicians to be familiar with prior classification systems in order to interpret the older literature and to care for patients who were previously treated for hematopoietic neoplasms with now outdated names. A nested classification of lymphoid neoplasms proposed by the Pathology Working Group of the International Lymphoma Epidemiology Consortium, which is based on the WHO classification and the third edition of the International Classification of Diseases-Oncology, provides a guide for translation of previous classification systems into the present [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21337/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss the current classification system, the 2008 World Health Organization (WHO) classification, the biology of which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2008 WHO classification of tumors of the hematopoietic and lymphoid tissues uses morphologic, immunophenotypic, genetic, and clinical features to define distinct diagnoses. In addition, it has created borderline categories for cases that do not fit into a defined entity. This approach has been adapted to improve the accurate assessment of patient outcomes in \"typical\" disease and to enable the study of borderline cases.",
"   </p>",
"   <p>",
"    When possible, the different tumor types are grouped by lineage into (",
"    <a class=\"graphic graphic_figure graphicRef56283 \" href=\"UTD.htm?24/16/24835\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myeloid neoplasms &mdash; derived from those bone marrow progenitor cells that normally develop into erythrocytes, granulocytes (neutrophils, basophils, and eosinophils), monocytes, or megakaryocytes.",
"     </li>",
"     <li>",
"      Lymphoid neoplasms &mdash; derived variously from B cell progenitors (bone marrow derived), T cell progenitors (thymus-derived), mature T lymphocytes (cytotoxic T cells, helper T cells, or T regulatory cells) or mature B lymphocytes (B cells or plasma cells).",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Histiocytic/dendritic",
"      </span>",
"      neoplasms &mdash; derived from cells that normally develop into \"professional\" antigen presenting cells (dendritic cells) or tissue macrophages (histiocytes).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also neoplasms that show evidence of both myeloid and lymphoid differentiation, presumably because they are derived from multipotent progenitor cells. Such cases are given their own category, neoplasms of myeloid and lymphoid lineage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MYELOID NEOPLASMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myeloid neoplasms are usually derived from bone marrow progenitors that are restricted to developing into erythrocytes, granulocytes (neutrophils, basophils, and eosinophils), monocytes, or megakaryocytes. An exception is chronic myeloid leukemia (CML), in which the cell of origin is a pluripotent hematopoietic stem cell capable of giving rise to lymphoid cells as well. These neoplasms can be subgrouped into three broad clinicopathologic classes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute myeloid leukemias (AML)",
"     </li>",
"     <li>",
"      Myeloproliferative neoplasms (MPN)",
"     </li>",
"     <li>",
"      Myelodysplastic syndromes (MDS)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, it must be appreciated that some cases show features that overlap between those of a MPN and a MDS, and that all MPN and MDS have the potential to transform into AML.",
"   </p>",
"   <p>",
"    AML and related entities inevitably pursue a very aggressive course and need immediate therapy, whereas the clinical behavior of MPN and MDS is varied and can be quite indolent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute myeloid leukemia and related aggressive myeloid neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute myeloid leukemia (AML) is defined by greater than 20 percent myeloid blasts in the bone marrow or peripheral blood, or the presence of particular cytogenetic abnormalities, regardless of the blast count. This group of entities includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AML with recurrent genetic abnormalities",
"     </li>",
"     <li>",
"      AML with myelodysplasia-related changes",
"     </li>",
"     <li>",
"      Therapy-related myeloid neoplasms",
"     </li>",
"     <li>",
"      AML, not otherwise specified",
"     </li>",
"     <li>",
"      Myeloid sarcoma",
"     </li>",
"     <li>",
"      Myeloid proliferations related to Down syndrome &mdash; this includes transient abnormal myelopoiesis and myeloid leukemia associated with Down syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical features and diagnosis of Down syndrome\", section on 'Transient leukemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blastic plasmacytoid dendritic cell neoplasms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Details on the biology, cytogenetics, clinical presentation, and diagnosis of AML are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link\">",
"     \"Cytogenetics in acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Myeloproliferative neoplasms (disorders)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myeloproliferative neoplasms (MPN) are a group of clonal stem cell disorders associated with the proliferation of one or more of the myeloid lineages (eg, granulocytic, erythroid, megakaryocytic, or mast cells). There is increasing recognition that these diseases are often associated with mutations that cause abnormal increases in tyrosine kinase activity and growth factor-independent proliferation of bone marrow progenitors. Bone marrow cellularity is usually increased, but may be normal. The percentage of blasts in the bone marrow is normal or slightly increased, but always less than 20 percent. There is usually effective hematopoiesis, which results in increases in the numbers of one or more formed elements in the peripheral blood.",
"   </p>",
"   <p>",
"    The following entities are included under the category of MPN:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic myeloid leukemia (CML) &mdash; CML demonstrates overproliferation of the granulocytic lineage at all stages of maturation and is always associated with the presence of a BCR-ABL fusion gene, which is usually created by a reciprocal translocation that results in the formation of the Philadelphia chromosome (9;22). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=see_link\">",
"       \"Clinical manifestations and diagnosis of chronic myeloid leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic neutrophilic leukemia (CNL) &mdash; CNL is rare entity characterized by the overproduction of mature granulocytes and the absence of the BCR-ABL fusion gene. Previously, the name CNL was also applied to an unusual MPN associated with a variant BCR-ABL fusion gene and pure neutrophilia, but in the updated WHO classification, such cases are considered to be forms of CML. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=see_link\">",
"       \"Clinical manifestations and diagnosis of chronic myeloid leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Polycythemia vera (PCV) &mdash; PCV presents with an otherwise unexplained increased",
"      <span class=\"nowrap\">",
"       hematocrit/red",
"      </span>",
"      blood cell mass and is associated in virtually all cases with gain-of-function mutations in the gene encoding the tyrosine kinase JAK2. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link\">",
"       \"Diagnostic approach to the patient with suspected polycythemia vera\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Essential thrombocythemia (ET) &mdash; ET demonstrates clonal or autonomous thrombocytosis and is associated with JAK2 mutations in about 50 percent of cases and mutations in a different tyrosine kinase, MPL, in about 5 percent of cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=see_link\">",
"       \"Diagnosis and clinical manifestations of essential thrombocythemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary myelofibrosis (PMF) &mdash; PMF (previously agnogenic myeloid metaplasia, chronic idiopathic myelofibrosis) is characterized by otherwise unexplained bone marrow fibrosis. Like ET, it is associated with mutations in JAK2 and MPL in approximately 50 and 5 percent, respectively. Some data suggest that PMF may be best viewed as a stage of MPD progression, rather than a distinct entity. Indeed, CML, PCV, and ET can all evolve to a picture that mimics PMF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=see_link\">",
"       \"Clinical manifestations and diagnosis of primary myelofibrosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic eosinophilic leukemia (CEL) &mdash; CEL is characterized by eosinophilia, anemia, thrombocytopenia, hepatomegaly, and splenomegaly. It is often associated with mutations that activate the tyrosine kinase activity of either the PDGFR-alpha or PDGFR-beta receptor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mastocytosis refers to a group of disorders characterized by excessive mast cell accumulation in one or multiple tissues. It is often associated with mutations that activate the tyrosine kinase activity of the c-KIT receptor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link\">",
"       \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myeloproliferative neoplasm, unclassifiable &mdash; Although most of the MPNs are classifiable, some are difficult to categorize; these may also be referred to as atypical MPNs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further discussion of the classification of MPN is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link\">",
"     \"Overview of the myeloproliferative neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Myelodysplastic syndromes (MDS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myelodysplastic syndrome (MDS) refers to disorders that exhibit dysplasia and ineffective blood cell production with a variable risk of transformation to acute leukemia. Bone marrow cellularity is often increased, but may be normocellular or hypocellular. The percentage of blasts in the bone marrow is normal or increased, but less than 20 percent. Maturation is present, but dysplasia is noted in one or more myeloid lineages. Hematopoiesis is ineffective and results in cytopenias.",
"   </p>",
"   <p>",
"    The following entities are included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Refractory cytopenia with unilineage dysplasia &mdash; includes refractory anemia, refractory neutropenia, and refractory thrombocytopenia",
"     </li>",
"     <li>",
"      Refractory anemia with ring sideroblasts",
"     </li>",
"     <li>",
"      Refractory cytopenia with multilineage dysplasia",
"     </li>",
"     <li>",
"      Refractory anemia with excess blasts",
"     </li>",
"     <li>",
"      MDS with isolated del(5q)",
"     </li>",
"     <li>",
"      MDS, unclassifiable",
"     </li>",
"     <li>",
"      Childhood MDS &mdash; includes a provisional entity called refractory cytopenia of childhood",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The classification of MDS is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H359854#H359854\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'WHO Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     MDS/MPN syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     myelodysplastic/myeloproliferative",
"    </span>",
"    neoplasms",
"    <span class=\"nowrap\">",
"     (MDS/MPN)",
"    </span>",
"    include disorders where both dysplastic and proliferative features co-exist. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic myelomonocytic leukemia",
"     </li>",
"     <li>",
"      Atypical chronic myeloid leukemia, BCR-ABL negative",
"     </li>",
"     <li>",
"      Juvenile myelomonocytic leukemia",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       MDS/MPN,",
"      </span>",
"      unclassifiable",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is a provisional entity of refractory anemia with ring sideroblasts and thrombocytosis. The classification of",
"    <span class=\"nowrap\">",
"     MDS/MPN",
"    </span>",
"    is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H359854#H359854\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'WHO Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LYMPHOID NEOPLASMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoid neoplasms are those derived from cells that normally develop into T lymphocytes (cytotoxic T lymphocytes, helper T lymphocytes, or regulatory T lymphocytes) or B lymphocytes (lymphocytes or plasma cells). In general, the lymphoid neoplasms are divided into neoplasms derived from lymphoid precursors (eg, acute lymphoblastic",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma)",
"    </span>",
"    and neoplasms of mature lymphocytes and plasma cells. These are further grouped depending upon whether they are of B or T cell derivation.",
"   </p>",
"   <p>",
"    Historically, lymphoid neoplasms that present with bone marrow and blood involvement (leukemia) have been segregated from those that present as a mass (lymphoma). However, it is now appreciated that any \"lymphoma\" can present with or evolve to a leukemic picture, and any \"leukemia\" can occasionally present with a mass lesion. In the WHO classification, the diagnosis of the various lymphoid neoplasms depends not on the anatomic location of tumor cells, but rather on the cell of origin of the tumor, as judged by morphology, immunophenotype, and genetic findings. As a result, several entities previously considered distinct are now grouped together under single diagnostic categories. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic lymphocytic leukemia and small lymphocytic lymphoma",
"     </li>",
"     <li>",
"      Precursor B cell lymphoblastic leukemia and pre-B Cell lymphoblastic lymphoma",
"     </li>",
"     <li>",
"      Pre-T cell lymphoblastic leukemia and pre-T cell lymphoblastic lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The WHO classification makes no effort to order lymphoid neoplasm according to their aggressiveness, in part due to recognition that the natural history of these tumors shows significant patient-to-patient variability. However, some clinical trials have separated histologic subtypes according to the usual clinical behavior of each of the lymphoid neoplasms, which can be roughly segregated into three groups, as follows (",
"    <a class=\"graphic graphic_table graphicRef59978 \" href=\"UTD.htm?41/26/42412\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21337/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indolent &mdash; Survival of untreated indolent lymphoid neoplasms is generally measured in years. Indolent lymphomas represent 35 to 40 percent of the non-Hodgkin lymphomas (NHLs). The most common histologic subtypes include follicular lymphoma, chronic lymphocytic",
"      <span class=\"nowrap\">",
"       leukemia/small",
"      </span>",
"      lymphocytic lymphoma, some cases of mantle cell lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, mycosis fungoides, and splenic marginal zone lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21337/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Aggressive &mdash; Survival of untreated aggressive lymphoid neoplasms is usually measured in months. About half of the NHLs are aggressive [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21337/abstract/4\">",
"       4",
"      </a>",
"      ]. The most common subtypes include diffuse large B cell lymphoma, peripheral T cell lymphoma, and anaplastic large cell lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21337/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Highly aggressive &mdash; Survival of untreated highly aggressive lymphoid neoplasms is measured in weeks. Highly aggressive lymphomas, as a group, represent about 5 percent of the NHLs. These diseases are all uncommon. The highly aggressive lymphomas can arise from B cells or T cells.",
"     </li>",
"     <li>",
"      Hodgkin lymphoma, although a lymphoid malignancy, is pathologically and clinically distinct from the other lymphoid neoplasms and is considered a distinct entity with a generally excellent prognosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whenever possible, we try to avoid grouping these lymphomas into indolent, aggressive, and highly aggressive histologies in our discussions and instead focus on the individual lymphoma histologies as defined by the WHO.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Precursor lymphoid neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The highly aggressive precursor lymphoid neoplasms are those that are comprised of immature B or T cells. There are two main categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The precursor B lymphoblastic",
"      <span class=\"nowrap\">",
"       leukemia/lymphomas",
"      </span>",
"      are neoplastic disorders of immature lymphoblasts committed to the B cell lineage. Precursor B cells arise in the bone marrow, and most patients with this tumor present with bone marrow involvement and a leukemic peripheral blood picture (ie, precursor B cell acute lymphoblastic leukemia). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26007?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The precursor T lymphoblastic",
"      <span class=\"nowrap\">",
"       leukemia/lymphomas",
"      </span>",
"      are neoplastic disorders of immature lymphoblasts committed to the T cell lineage that may arise within the thymus or the bone marrow. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mature B cell neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoid neoplasms of mature B cells are classified in part based upon a comparison of the immunophenotype and genotype of the tumor cells to normal stages of B cell development as well as other characteristic immunophenotypic and genetic features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These tumors can be derived from any stage of mature B cell development, including naive B cells, germinal center B cells, post-germinal center memory B cells, or plasma cells. Of note, the most common B cell neoplasms derive from cells that have experienced a germinal center reaction, which is initiated when antigen stimulated B cells migrate into the germinal centers (or follicles) of secondary lymphoid organs (eg, lymph nodes, spleen, and mucosa associated lymphoid tissues) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21337/abstract/7\">",
"     7",
"    </a>",
"    ]. Germinal center B cells proliferate and undergo two events that permit the diversification of immunoglobulin (Ig) genes, somatic hypermutation and heavy chain class switching. Most tumors of mature B cells, including plasma cell neoplasms, show evidence of somatic hypermutation, and it is thought that \"mistakes\" that occur during somatic hypermutation and class switching may be responsible for many of the acquired mutations that lead to B cell transformation.",
"   </p>",
"   <p>",
"    Specific diagnostic entities derived from mature B cells include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic lymphocytic",
"      <span class=\"nowrap\">",
"       leukemia/small",
"      </span>",
"      lymphocytic lymphoma",
"      <span class=\"nowrap\">",
"       (CLL/SLL)",
"      </span>",
"      &mdash;",
"      <span class=\"nowrap\">",
"       CLL/SLL",
"      </span>",
"      is the most common leukemia in Western countries, accounting for approximately 30 percent of all leukemias in the United States. It is a malignancy of small, mature-appearing lymphocytes, presenting primarily either as a leukemia (CLL) or a lymphoma (SLL). In roughly 60 percent of cases, the Ig genes are somatically hypermutated; the remaining cases appear to derive from naive B cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link\">",
"       \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18887?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lymphoplasmacytic lymphoma (LPL) &mdash; LPL is a neoplasm derived from post-germinal center B cells that is comprised of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. It is usually associated with the presence of a serum monoclonal protein. Waldenstrom macroglobulinemia is a clinicopathologic entity usually associated with LPL and levels of IgM monoclonal gammopathy that are sufficiently high to produce symptoms related to hyperviscosity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38872?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link\">",
"       \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mantle cell lymphoma (MCL) &mdash; MCL has been previously referred to as intermediate lymphocytic lymphoma, mantle zone lymphoma, centrocytic lymphoma; and lymphocytic lymphoma of intermediate differentiation. MCL comprises about 7 percent of adult NHLs in the United States and Europe. In about 80 percent of cases, the cell of origin is a naive B cell, but the remaining cases are somatically hypermutated and apparently derived from antigen-stimulated B cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      B cell prolymphocytic leukemia (B-PLL) &mdash; B-PLL is a rare B cell neoplasm characterized by a predominance of activated lymphocytes referred to as prolymphocytes in the bone marrow. B-PLL can present de novo or can arise through transformation of previously diagnosed",
"      <span class=\"nowrap\">",
"       CLL/SLL.",
"      </span>",
"      Roughly 50 to 60 percent of cases are somatically hypermutated while the remainder may arise from naive B cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20358?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of B cell prolymphocytic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Follicular lymphoma (FL) &mdash; FL, previously called follicle center lymphoma, is the second most common lymphoma in the United States and Western Europe. Patients usually present with painless peripheral adenopathy. FL is comprised of neoplastic germinal center B cells and recapitulates the appearance of normal germinal centers of secondary lymphoid follicles. Primary cutaneous follicle center lymphoma resembles FL morphologically, but is usually confined to the skin and has distinctive immunophenotypic and genotypic features. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link\">",
"       \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=see_link\">",
"       \"Primary cutaneous follicle center lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diffuse large B cell lymphoma (DLBCL) &mdash; DLBCL, previously diffuse histiocytic lymphoma, is the most common histologic subtype of NHL accounting for approximately 25 percent of cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    DLBCL encompasses a heterogeneous group of tumors that have as a common feature the diffuse proliferation of large neoplastic B cells. Essentially all cases are somatically hypermutated indicating a germinal center or post-germinal center B cell origin. In addition to typical DLBCLs, the WHO classification includes several special subtypes:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intravascular large B cell lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13511?source=see_link\">",
"       \"Intravascular large cell lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Primary mediastinal (thymic) large B cell lymphoma, lymphoma with distinct clinicopathologic features that may be derived from an unusual subset of B cells that are resident in the thymus.",
"     </li>",
"     <li>",
"      Large B cell lymphoma, lymphomatoid granulomatosis type, an EBV-associated large cell lymphoma that usually presents at extranodal sites.",
"     </li>",
"     <li>",
"      T cell",
"      <span class=\"nowrap\">",
"       rich/histiocyte-rich",
"      </span>",
"      large B cell lymphoma.",
"     </li>",
"     <li>",
"      Primary DLBCL of the central nervous system (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link\">",
"       \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Primary cutaneous DLBCL, leg type (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26391?source=see_link\">",
"       \"Primary cutaneous large B cell lymphoma, leg type\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Epstein Barr virus (EBV) positive DLBCL of the elderly (defined as those over age 50 years).",
"     </li>",
"     <li>",
"      Plasmablastic lymphoma &mdash; This is a distinctive type of AIDS-related large cell lymphoma, usually presenting in the oral cavity and jaws, which is always EBV-associated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=see_link\">",
"       \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary effusion lymphoma (PEL) &mdash; PEL is an uncommon large cell lymphoma associated with AIDS and other immunodeficiency states. Latent gene products of human herpesvirus-8 (HHV-8) appear to play a role in the pathogenesis. Occasionally, a similar HHV8-positive lymphoma arises out of a background of multicentric Castleman's disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link\">",
"       \"AIDS-related lymphomas: Primary effusion lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=see_link\">",
"       \"Castleman's disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ALK positive large B cell lymphoma &mdash; This is a rare B cell lymphoma with plasmablastic features associated with translocations or rearrangements of the ALK (anaplastic lymphoma kinase) gene.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Burkitt",
"      <span class=\"nowrap\">",
"       lymphoma/leukemia",
"      </span>",
"      (BL) &mdash; BL is a highly aggressive B cell neoplasm of germinal center B cell origin that can present in one of three distinct clinical forms: endemic, sporadic, and immunodeficiency-associated. Patients present with rapidly growing tumor masses and often have evidence of tumor lysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Marginal zone B cell lymphoma (MZL) &mdash; The MZL usually arise from post-germinal center marginal zone B cells surrounding normal lymphoid follicles. Three subtypes are recognized:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Extranodal MZL of mucosa-associated lymphoid tissue (MALT) or MALT-type lymphoma, most commonly involves the gastrointestinal tract. This condition refers only to the low-grade tumor and not to DLBCL, which can also occur in these tissues. Primary cutaneous marginal zone lymphoma is included in this broader category. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26776?source=see_link\">",
"       \"Primary cutaneous marginal zone lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Splenic MZL is the tissue counterpart of splenic lymphoma with circulating villous lymphocytes. Patients typically present with splenomegaly, lymphocytosis, and cytopenias (most often due to hypersplenism). Unlike most other NHLs, lymphadenopathy and involvement of extralymphatic organs is uncommon. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nodal MZL tumor cells cytologically resemble \"normal\" monocytoid B cells and often involve lymph node sinuses. They phenotypically resemble hairy cell leukemias. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hairy cell leukemia (HCL) &mdash; HCL, previously called \"leukemic reticuloendotheliosis\", is an uncommon indolent B cell lymphoproliferative disorder that usually has a post-germinal center B cell origin. The tumor cells in the blood have characteristic prominent irregular (\"hairy\") cytoplasmic projections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20841?source=see_link\">",
"       \"Clinical features and diagnosis of hairy cell leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Plasma cell",
"      <span class=\"nowrap\">",
"       myeloma/plasmacytoma",
"      </span>",
"      &mdash; Plasma cell myeloma, which can present as a single lesion (plasmacytoma) or multiple lesions (multiple myeloma), is characterized by the neoplastic proliferation of plasma cells producing a monoclonal immunoglobulin. The cell of origin is a germinal center-derived, bone marrow-homing plasma cell. In the bone marrow, these cells proliferate and often produce extensive skeletal destruction, osteolytic lesions, osteopenia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fractures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"       \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44535?source=see_link\">",
"       \"Diagnosis and management of solitary plasmacytoma of bone\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16662?source=see_link\">",
"       \"Diagnosis and management of solitary extramedullary plasmacytoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      AL (primary) amyloidosis and light and heavy chain deposition diseases are clonal plasma cell dyscrasias characterized by tissue deposits of light chain or heavy chain fragments, leading to organ dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"       \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hodgkin lymphoma (HL)",
"    </span>",
"    &nbsp;&mdash;&nbsp;HL, formerly called Hodgkin's disease, arises from germinal center or post-germinal center B cells. HL has a unique cellular composition, containing a minority of neoplastic cells (Reed-Sternberg cells and their variants) in an inflammatory background. It is separated from the other B cell lymphomas based on its unique clinicopathologic features, and can be divided into two major sub-groups, based on the appearance and immunophenotype of the tumor cells:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nodular lymphocyte predominant HL &mdash; The tumor cells in this subtype retain the immunophenotypic features of germinal center B cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33432?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Classical HL &mdash; The tumor cells in this group are also derived from germinal center B cells, but typically fail to express many of the genes and gene products that define normal germinal center B cells. Based on differences in the appearance of the tumor cells and the composition of the reactive background, classical HL is further divided into the following four subtypes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nodular sclerosis classical HL",
"     </li>",
"     <li>",
"      Mixed cellularity classical HL",
"     </li>",
"     <li>",
"      Lymphocyte-rich classical HL",
"     </li>",
"     <li>",
"      Lymphocyte depleted classical HL",
"      <br/>",
"      <br/>",
"      A significant minority of cases of classical HL are EBV-associated, particularly the lymphocyte depleted and mixed cellularity types, whereas nodular lymphocyte-predominant HL is never EBV-associated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The classification of HL is presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=see_link\">",
"     \"Initial evaluation and diagnosis of Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mature T cell or NK cell lineage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoid neoplasms of mature T cells or NK cells include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral T cell lymphoma (PTCL) &mdash; PTCL are a heterogeneous group of generally aggressive neoplasms that constitute less than 15 percent of all NHLs in adults:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Peripheral T cell lymphoma, unspecified &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35400?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Angioimmunoblastic T cell lymphoma &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34023?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell nasal type lymphoma &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Subcutaneous panniculitis-like T cell lymphoma &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35126?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T-cell lymphoma\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hepatosplenic T cell lymphoma &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4119?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of hepatosplenic T cell lymphoma\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Enteropathy-associated T cell lymphoma, previously called intestinal T cell lymphoma &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5256?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anaplastic large cell lymphoma (ALCL) &mdash; ALCL is characterized by large lymphoid cells with pleomorphic nuclei. There are two clinical subtypes: cutaneous and systemic. Primary systemic ALCL is then further subcategorized into tumors that have or do not have rearrangements involving the Anaplastic Lymphoma Kinase (ALK) gene. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary cutaneous peripheral T cell lymphomas &mdash; There are numerous cutaneous T cell lymphomas. Mycosis fungoides (MF) is the most common of these. S&eacute;zary syndrome is an erythrodermic, leukemic variant of MF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adult T cell leukemia-lymphoma (ATL) &mdash; ATL is a highly aggressive peripheral T cell neoplasm most often comprised of highly pleomorphic lymphoid cells. It is caused by infection with the human T cell leukemia virus (HTLV), type 1 and often presents with generalized lymphadenopathy, hepatosplenomegaly, immunosuppression, hypercalcemia, lytic bone lesions, and skin lesions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      T cell large granular lymphocyte leukemia (LGL) &mdash; The term T cell LGL leukemia is a disorder of clonally expanded T cell large granular lymphocytes that invade the bone marrow, spleen, and liver. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2793?source=see_link\">",
"       \"Treatment of large granular lymphocyte leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      T cell prolymphocytic leukemia (T-PLL) &mdash; T cell prolymphocytic leukemia is an aggressive tumor comprised of small to medium-sized mature T cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10102?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Natural killer (NK) cell large granular lymphocyte leukemia (LGL) &mdash; NK cell LGL leukemia, also called chronic lymphoproliferative disorder of NK cells, is an indolent NHL variant involving malignant NK cells. Its clinical presentation is more aggressive than that of T cell LGL leukemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20040?source=see_link\">",
"       \"Natural killer (NK) cell large granular lymphocyte leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aggressive natural killer cell leukemia &mdash; Aggressive NK cell leukemia is a very rare aggressive leukemia derived from NK cells. The highest prevalence is among Asians.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NEOPLASMS WITH MYELOID AND LYMPHOID LINEAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some neoplasms express markers of both myeloid and lymphoid lineages or neither of these:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Myeloid/lymphoid",
"      </span>",
"      neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute leukemias of ambiguous lineage &mdash; The acute leukemias of ambiguous lineage include leukemias that either have no features of lymphoid or myeloid lineage (eg, acute undifferentiated leukemia) or features of both lymphoid and myeloid lineages (eg, mixed phenotype or mixed lineage acute leukemia)",
"      <span class=\"nowrap\">",
"       [",
"       <a class=\"abstract\" href=\"UTD.htm?20/53/21337/abstract/8\">",
"        8",
"       </a>",
"       ].",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     HISTIOCYTIC/DENDRITIC NEOPLASMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histiocytic/dendritic",
"    neoplasms are those derived from those cells that normally develop into accessory antigen presenting cells (dendritic cells) or connective tissue macrophages (histiocytes):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Histiocytic sarcoma",
"     </li>",
"     <li>",
"      Tumors derived from Langerhans cells",
"     </li>",
"     <li>",
"      Interdigitating dendritic cell sarcoma",
"     </li>",
"     <li>",
"      Follicular dendritic cell sarcoma",
"     </li>",
"     <li>",
"      Other rare dendritic cell tumors",
"     </li>",
"     <li>",
"      Disseminated juvenile xanthogranuloma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most malignancies of the hematopoietic and lymphoid tissues fall into distinct diagnostic categories that are defined by morphologic, immunophenotypic, genetic, and clinical features. Malignancies that do not fit defined entities are placed in categories that capture diverse tumors (eg, peripheral T cell lymphoma, not otherwise specified) or in borderline categories that are used for cases that share features of more than one entity (eg, Burkitt lymphoma and diffuse large B cell lymphoma, or Hodgkin lymphoma and diffuse large B cell lymphoma). When possible, the different tumor types are grouped by lineage as follows (",
"    <a class=\"graphic graphic_figure graphicRef56283 \" href=\"UTD.htm?24/16/24835\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myeloid neoplasms &mdash; derived from those bone marrow progenitor cells that normally develop into erythrocytes, granulocytes (neutrophils, basophils, and eosinophils), monocytes, or megakaryocytes. These neoplasms can be subgrouped into three broad clinicopathologic classes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute myeloid leukemias (AML) &mdash; AML is defined by greater than 20 percent myeloid blasts in the bone marrow or peripheral blood, or the presence of particular cytogenetic abnormalities, regardless of the blast count. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Acute myeloid leukemia and related aggressive myeloid neoplasms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myeloproliferative neoplasms (MPN) &mdash; clonal stem cell disorders associated with the proliferation of one or more of the myeloid lineages (eg, granulocytic, erythroid, megakaryocytic, or mast cells). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Myeloproliferative neoplasms (disorders)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myelodysplastic syndromes (MDS) &mdash; disorders that exhibit dysplasia and ineffective blood cell production. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Myelodysplastic syndromes (MDS)'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Of note, some cases show features that overlap between those of a MPN and a MDS, and all MPN and MDS have the potential to transform into AML. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'MDS/MPN syndromes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphoid neoplasms &mdash; derived variously from B cell progenitors (bone marrow derived), T cell progenitors (thymus-derived), mature T lymphocytes (cytotoxic T cells, helper T cells, or T regulatory cells) or mature B lymphocytes (B cells or plasma cells). Historically, lymphoid neoplasms that present with bone marrow and blood involvement (leukemia) have been segregated from those that present as a mass (lymphoma). However, it is now appreciated that any \"lymphoma\" can present with or evolve to a leukemic picture, and any \"leukemia\" can occasionally present as a mass. Lymphoid neoplasms are mainly grouped depending upon whether they are of B, T, or natural killer (NK) cell derivation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Lymphoid neoplasms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Histiocytic/dendritic",
"      </span>",
"      neoplasms &mdash; derived from cells that normally develop into \"professional\" antigen presenting cells (dendritic cells) or tissue macrophages (histiocytes). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Histiocytic/dendritic neoplasms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also neoplasms that show evidence of both myeloid and lymphoid differentiation, presumably because they are derived from multipotent progenitor cells. Such cases are given their own category, neoplasms of myeloid and lymphoid lineage. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Neoplasms with myeloid and lymphoid lineage'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21337/abstract/2\">",
"      Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21337/abstract/3\">",
"      Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007; 110:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21337/abstract/4\">",
"      Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.",
"     </a>",
"    </li>",
"    <li>",
"     Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21337/abstract/6\">",
"      Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21337/abstract/7\">",
"      Carbone A, Gloghini A, Cabras A, Elia G. The Germinal centre-derived lymphomas seen through their cellular microenvironment. Br J Haematol 2009; 145:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21337/abstract/8\">",
"      Matutes E, Pickl WF, Van't Veer M, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood 2011; 117:3163.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4716 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-393BA8AD0C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_53_21337=[""].join("\n");
var outline_f20_53_21337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MYELOID NEOPLASMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute myeloid leukemia and related aggressive myeloid neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Myeloproliferative neoplasms (disorders)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Myelodysplastic syndromes (MDS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MDS/MPN syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LYMPHOID NEOPLASMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Precursor lymphoid neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mature B cell neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hodgkin lymphoma (HL)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mature T cell or NK cell lineage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NEOPLASMS WITH MYELOID AND LYMPHOID LINEAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HISTIOCYTIC/DENDRITIC NEOPLASMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4716\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4716|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/16/24835\" title=\"figure 1\">",
"      Organiz heme malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4716|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/26/42412\" title=\"table 1\">",
"      Classification of NHL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=related_link\">",
"      AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=related_link\">",
"      AIDS-related lymphomas: Primary effusion lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=related_link\">",
"      Castleman's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20841?source=related_link\">",
"      Clinical features and diagnosis of hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=related_link\">",
"      Clinical manifestations and diagnosis of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20358?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of B cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10102?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34023?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5256?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4119?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of hepatosplenic T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38872?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33432?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35400?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26007?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18887?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35126?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T-cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=related_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=related_link\">",
"      Diagnosis and clinical manifestations of essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16662?source=related_link\">",
"      Diagnosis and management of solitary extramedullary plasmacytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44535?source=related_link\">",
"      Diagnosis and management of solitary plasmacytoma of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=related_link\">",
"      Diagnostic approach to the patient with suspected polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=related_link\">",
"      Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=related_link\">",
"      Initial evaluation and diagnosis of Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13511?source=related_link\">",
"      Intravascular large cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20040?source=related_link\">",
"      Natural killer (NK) cell large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=related_link\">",
"      Primary cutaneous follicle center lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26391?source=related_link\">",
"      Primary cutaneous large B cell lymphoma, leg type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26776?source=related_link\">",
"      Primary cutaneous marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2793?source=related_link\">",
"      Treatment of large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_53_21338="Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis";
var content_f20_53_21338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/53/21338/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/53/21338/contributors\">",
"     Kenneth L McClain, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/53/21338/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/53/21338/contributors\">",
"     Laurence A Boxer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/53/21338/contributors\">",
"     Julie R Park, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/53/21338/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/53/21338/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/53/21338/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Langerhans cell histiocytosis (LCH) is a rare histiocytic disorder most commonly characterized by single or multiple osteolytic bone lesions demonstrating infiltration with histiocytes having bean-shaped nuclei on biopsy with or without histiocytic infiltration of extraskeletal lesions (most notably the skin, lymph nodes, lungs, thymus, liver, spleen, bone marrow, or central nervous system).",
"   </p>",
"   <p>",
"    Histocytic disorders are derived from mononuclear phagocytic cells (macrophages) and dendritic cells, which have several different origins and locations. This group has generally been divided into Langerhans cell histiocytosis and non-Langerhans histiocytosis. LCH is so named because the morphology and immunophenotype of the abnormal cells is similar to that of Langerhans cells, which are specialized dendritic cells found in the skin and mucosa. Gene expression array data on LCH have shown that the skin Langerhans cell is not the cell of origin for LCH. Rather, it is a myeloid dendritic cell that expresses the same antigens (CD1a, CD207) as the skin Langerhans cell. In contrast, non-Langerhans histiocytoses are thought to be derived from other dendritic cells that ultimately produce the monocyte-macrophage lineage.",
"   </p>",
"   <p>",
"    For now, \"Langerhans cell histiocytosis\" remains the preferred nomenclature, although new terminology may evolve when the precise origin of the CD-207+ cells in LCH is fully understood. The historical terms histiocytosis-X, Letterer-Siwe disease, Hand-Sch&uuml;ller-Christian disease, and diffuse reticuloendotheliosis should be abandoned. The term &ldquo;eosinophilic granuloma&rdquo; is sometimes used to describe the pathology of an individual lesion, particularly isolated lytic processes in bone.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, pathologic features, diagnosis, and differential diagnosis of LCH will be presented here. The management of LCH is presented separately, as are specific discussions of solitary LCH involving lung or bone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28378?source=see_link\">",
"     \"Treatment of Langerhans cell histiocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=see_link\">",
"     \"Pulmonary Langerhans cell histiocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32551?source=see_link\">",
"     \"Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The generic term \"histiocyte\" refers to several types of cells, including Langerhans cells,",
"    <span class=\"nowrap\">",
"     monocytes/macrophages,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     dermal/interstitial",
"    </span>",
"    dendritic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/1\">",
"     1",
"    </a>",
"    ]. The World Health Organization classification of hematopoietic and lymphoid tumors divides disorders of these cells into the following three categories [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dendritic cell disorders",
"      </strong>",
"      &mdash; This grouping includes Langerhans cell histiocytosis, secondary dendritic cell processes, juvenile xanthogranuloma, solitary histiocytomas with a dendritic phenotype, and Erdheim-Chester Disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20680?source=see_link\">",
"       \"Erdheim-Chester disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1495?source=see_link\">",
"       \"Juvenile xanthogranuloma (JXG)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Macrophage-related disorders",
"      </strong>",
"      &mdash; This grouping includes primary and secondary hemophagocytic syndromes, sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease), and solitary histiocytoma with a macrophage phenotype. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link\">",
"       \"Hemophagocytic lymphohistiocytosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=see_link&amp;anchor=H28#H28\">",
"       \"Causes of peripheral lymphadenopathy in children\", section on 'Rosai-Dorfman disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Malignant histiocytic disorders",
"      </strong>",
"      &mdash; This grouping includes monocyte-related leukemias (eg, acute monocytic leukemia, acute myelomonocytic leukemia), extramedullary monocytic tumor, and dendritic cell or macrophage-related histiocytic sarcoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38934?source=see_link\">",
"       \"Histiocytic sarcoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452648790\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;LCH is a rare histiocytic disorder and the true incidence is unknown. Large published studies usually are from referral centers and the disorder is likely under-diagnosed in the general population. LCH has been diagnosed in all age groups, but is most common in children from one to three years old. The incidence appears to be three to five cases per million children and one to two cases per million adults [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A male predominance has been described in some case series, but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. The incidence appears to be higher in whites of northern European descent than in blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/2\">",
"     2",
"    </a>",
"    ]. An epidemiologic study from the United States suggested a connection between solvent exposure in parents, as well as perinatal infections, but no increased incidence after viral epidemics [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/10\">",
"     10",
"    </a>",
"    ]. Pulmonary LCH is a rare disorder occurring in adults that is nearly universally associated with cigarette smoking, whereas extrapulmonary LCH does not appear to have any association with smoking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=see_link&amp;anchor=H4#H4\">",
"     \"Pulmonary Langerhans cell histiocytosis\", section on 'Role of cigarette smoking'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The genetics of LCH have not been well elucidated. Very rarely are twins or singleton siblings concordantly affected, despite a few reported cases with early disease presentation and similar organs affected in presumed monozygotic twins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/11\">",
"     11",
"    </a>",
"    ]. One report described three cases with skin and bone involvement in one Iranian family [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/12\">",
"     12",
"    </a>",
"    ]. Another study noted an association with a family history of thyroid disease, but the meaning of this finding is not understood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/13\">",
"     13",
"    </a>",
"    ]. Rarely, LCH has been described in patients with other concomitant histiocytic disorders, such as Erdheim-Chester Disease and Rosai Dorfman Disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452648797\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;LCH is so named because of a presumed derivation from the morphologically similar Langerhans cells, which are specialized dendritic cells found in the skin and mucosa. However, gene expression array data have shown that the skin Langerhans cell is not the cell of origin for LCH. Rather, it is a myeloid dendritic cell that expresses the same antigens (CD1a, CD207) as the skin Langerhans cell. Peripheral monocytes found in normal blood can differentiate into macrophages and interstitial dendritic cells that may travel through lymphatics to draining lymph nodes. There are probably two populations of circulating myeloid dendritic cells that can differentiate into committed dendritic cells. Expression array results support the notion that one of these could become the pathologic dendritic cell in LCH [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a few studies have purported to show evidence of viruses in LCH lesion, the weight of evidence does not support a viral etiology of LCH [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Debate continues regarding whether the disorder is reactive or neoplastic [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/19\">",
"     19",
"    </a>",
"    ]. Arguments for each are presented below. Some, but not all, cases of LCH are clonal. The Langerhans cells in biopsies of children with single system or multisystem disease are caused by proliferation of a single clone, as judged by analysis of methylation-specific restriction enzyme sites on the human androgen receptor gene in specimens from female patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. On the other hand, pulmonary LCH in adults is non-clonal in origin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/22\">",
"     22",
"    </a>",
"    ]. Clonal rearrangements of the T-cell receptor gamma gene, immunoglobulin heavy chain and kappa light chain genes are seen in approximately one-quarter of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/23\">",
"     23",
"    </a>",
"    ]. Although clonal proliferation is a hallmark of neoplastic conditions, it can also be consistent with a reactive process.",
"   </p>",
"   <p>",
"    Support for LCH as a reactive condition due to immunologic dysfunction comes from the finding of regulatory T cell expansion in LCH and a lack of mutations in tumor suppressor genes. Initial support for this hypothesis came from studies that noted increases in the levels of various cytokines (IL-17, IL-2) or growth factors in the blood of patients with LCH [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. However, none of these genes were up-regulated in subsequent gene expression array studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/16\">",
"     16",
"    </a>",
"    ]. Elevated levels of these proteins may reflect a systemic inflammatory response, with the",
"    <span class=\"nowrap\">",
"     cytokines/growth",
"    </span>",
"    factors being produced by cells outside the LCH lesions. Comprehensive gene expression array experiments have identified over 2000 genes that are differentially expressed in CD207+, CD3+ cells from LCH biopsies when compared with CD207+ cells from the skin and CD3+ T cells from the peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/16\">",
"     16",
"    </a>",
"    ]. Of 65 genes previously reported to be associated with LCH, only 11 were found to be up-regulated in the array results. Among the genes found not to be relevant in LCH were interferon gamma, TNF alpha, IL-10, CCR6, and CCR7. Genes confirmed to be upregulated included TGF-beta, BCL2, ICAM, CD14, and CD2. The most highly upregulated genes were those genes that activate and recruit T cells to sites of inflammation. The expression profile of the T cells was that of an activated regulatory T cell. These findings support other studies that have reported the expansion of regulatory T cell in LCH [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/29\">",
"     29",
"    </a>",
"    ]. Complementary studies using comparative genomic hybridization have failed to identify mutations in tumor suppressor genes in LCH [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. These data, as well as the failure of LCH biopsy specimens to grow in culture or in immune deficient mice, suggest that LCH is not a malignant neoplasm in the classic sense.",
"   </p>",
"   <p>",
"    Support for LCH as a neoplasm comes from the finding of a cancer-associated proto-oncogene mutation in a high percentage of LCH [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. A mass spectrometric method was used to analyze for a large number of cancer-associated gene mutations in DNA retrieved from paraffin-embedded biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/33\">",
"     33",
"    </a>",
"    ]. The oncogenic BRAF V600E mutation was found in 35 of 61 (57 percent) cases of LCH. Interestingly, in all cases (BRAF mutated or not), the downstream BRAF targets MEK and ERK were phosphorylated, suggesting a common mechanism of activation of the signal transduction pathway regardless of BRAF mutation status. Patients with mutations were younger than those without, but disease site and stage were no different. The BRAF V600E mutation was also detected in 40 percent of adult pulmonary LCH specimens tested.",
"   </p>",
"   <p>",
"    Further study is needed to elucidate the pathogenesis of LCH. It is likely that the pathogenesis differs between pulmonary LCH in adults and LCH in children. Langerhans cells in adult lung lesions were shown to be mature dendritic cells expressing high levels of the accessory molecules B7-1 and B7-2, unlike LC found in other lung disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, pulmonary LCH in adults is more likely to be polyclonal, although one study found evidence of clonal proliferation in 29 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452648804\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452648812\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of patients with LCH varies depending upon the sites and extent of involvement. The disease is limited to one organ system (eg, bone) in approximately 55 percent of patients, while the remainder presents with multisystem disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/36\">",
"     36",
"    </a>",
"    ]. As an example, a retrospective analysis of 1741 patients with LCH registered in prospective trials reported involvement of the following areas at the time of diagnosis, in order of decreasing frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bone &mdash; 77 percent",
"     </li>",
"     <li>",
"      Skin &mdash; 39 percent",
"     </li>",
"     <li>",
"      Lymph nodes &mdash; 19 percent",
"     </li>",
"     <li>",
"      Liver &mdash; 16 percent",
"     </li>",
"     <li>",
"      Spleen &mdash; 13 percent",
"     </li>",
"     <li>",
"      Oral mucosa &mdash; 13 percent",
"     </li>",
"     <li>",
"      Lung &mdash; 10 percent",
"     </li>",
"     <li>",
"      Central nervous system &mdash; 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The areas of involvement and the extent of disease vary at least partially with patient age. Acute disseminated multisystem disease is most commonly seen in children less than three years, while a more indolent disease involving a single organ is more common in older children and adults. Presenting symptoms in adults from published studies are (in order of decreasing frequency): skin rash, dyspnea or tachypnea, polydipsia and polyuria, bone pain, lymphadenopathy, weight loss, fever, gingival hypertrophy, ataxia, and memory problems [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. In general, patients can be divided into two groups based upon the extent of involvement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Single system LCH &mdash; Patients may be of any age and typically do not have systemic symptoms (eg, weight loss or fever). Unifocal or multifocal involvement can be found in one of the following",
"      <span class=\"nowrap\">",
"       organs/systems:",
"      </span>",
"      bone, skin, lymph node (excluding draining lymph node of another LCH lesion), lungs, central nervous system, or other rare locations (eg, thyroid, thymus).",
"     </li>",
"     <li>",
"      Multisystem LCH &mdash; Two or more",
"      <span class=\"nowrap\">",
"       organs/systems",
"      </span>",
"      are involved with or without involvement of &ldquo;risk organs&rdquo;. Risk organs include the hematopoietic system, liver,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      spleen and denote a worse prognosis. Although the lung has been considered a &ldquo;risk organ&rdquo;, more recent studies have suggested that it has less of an effect on prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. In contrast &ldquo;CNS-risk&rdquo; areas include the sphenoid, orbital, ethmoid, or temporal bones and denote an increased risk of involvement of the central nervous system [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disease tempo is variable and the length of time from the first symptom(s) to diagnosis can be frustratingly long. Many adults wait one to four years before the correct diagnosis is made, and some have symptoms for 5 to 20 years. In this setting, diabetes insipidus is often the initial symptom, sometimes starting in childhood and not recognized as being caused by LCH until other symptoms occur later in the course of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452648841\">",
"    <span class=\"h2\">",
"     Lytic bone lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone involvement occurs in the majority of patients with LCH. Although some lesions are asymptomatic, the patient may complain of pain in a localized area of bone; examination usually reveals a raised, soft, tender spot. Radiologic studies typically demonstrate a lytic, &ldquo;punched out&rdquo; appearance, sometimes with an accompanying soft tissue mass (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56235 \" href=\"UTD.htm?20/13/20703\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32551?source=see_link&amp;anchor=H5#H5\">",
"     \"Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children\", section on 'Imaging characteristics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    LCH can involve any bone of the body, and the most common sites differ depending upon the patient&rsquo;s age. In children, the most frequent sites of involvement are the skull (40 percent), femur, rib, vertebra, and humerus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/39\">",
"     39",
"    </a>",
"    ]. The digits are involved only in the most diffuse cases. In contrast, the primary sites of bone involvement in adults in one study were jaw (30 percent), skull (21 percent), vertebra (13 percent), pelvis (13 percent), extremity (17 percent), and rib (6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/4\">",
"     4",
"    </a>",
"    ]. Involvement of certain bones can cause problems with nearby organ systems. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spine lesions in children are most often located in the cervical vertebrae and are frequently associated with other bone lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/40\">",
"       40",
"      </a>",
"      ]. Although vertebra plana (symmetrical vertebral flattening) may develop in some, others have stabilization of the vertebrae after treatment and spinal deformity is rare. In a series of adults with LCH of the spine, neurologic defects occurred in 21 of 30 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/41\">",
"       41",
"      </a>",
"      ]. Asymmetric collapse as opposed to vertebra plana was more common in adults. Of 33 vertebral lesions, 21 were in the cervical spine, seven in the thoracic, and five in the lumbar spine.",
"     </li>",
"     <li>",
"      Involvement of the calvaria, base of the skull, maxillofacial bones, and hypothalamic-pituitary axis is common. Resulting complaints include scalp",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      facial swelling, seizures, hearing loss, recurrent otitis media, gingival bleeding, proptosis, diabetes insipidus, and cranial nerve palsies [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/42\">",
"       42",
"      </a>",
"      ]. Pain in the jaw and loose teeth may be a presenting symptom. Although bone lesions may be asymptomatic in some areas, those in the mouth are especially troublesome because of tooth loss and a high recurrence rate. Posterior regions of the jawbones are affected more often than anterior regions [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some skull lesions are not only lytic but may have an accompanying mass that impinges on the dura. Lesions of the facial bones or anterior or middle cranial fossae (eg, temporal, sphenoid, ethmoid, zygomatic) with intracranial tumor extension are part of a \"CNS-risk\" group. Patients with these lesions have a threefold increased risk for developing diabetes insipidus and an increased risk of other central nervous system (CNS) disease. (See",
"    <a class=\"local\" href=\"#H452648890\">",
"     'Diabetes insipidus and other endocrinopathies'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H452662508\">",
"     'Central nervous system'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452648848\">",
"    <span class=\"h2\">",
"     Skin and oral mucosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin involvement is seen in approximately 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/36\">",
"     36",
"    </a>",
"    ]. The most common skin manifestations are brown to purplish papules referred to as congenital self-healing reticulohistiocytosis and an eczematous rash resembling a candidal infection. Other skin lesions may be pustular, purpuric, petechial, vesicular, or papulo-nodular [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Brown to purplish papules",
"      </strong>",
"      &mdash; Infants may present with brown to purplish papules over any part of their body (congenital self-healing reticulohistiocytosis, Hashimoto-Pritzker disease) (",
"      <a class=\"graphic graphic_picture graphicRef75074 \" href=\"UTD.htm?29/28/30146\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. If solitary, this manifestation is benign and the lesions disappear during the first year of life with no therapy. However, neonates with apparently isolated skin involvement need thorough evaluation to confirm that no other sites are involved, as well as close follow-up for later risk organ involvement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6840?source=see_link&amp;anchor=H11#H11\">",
"       \"Skin nodules in newborns and infants\", section on 'Congenital self-healing reticulohistiocytosis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The importance of a thorough evaluation was demonstrated in a series of 19 neonatal LCH cases with skin involvement in which 12 of the 19 also had multisystem disease with 7 (21 percent) of these affecting risk organs (ie, liver, spleen, lung, or bone marrow) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/47\">",
"       47",
"      </a>",
"      ]. In another report of 61 neonatal cases from 1069 patients in the Histiocyte Society database, 36 of 61 (59 percent) had multisystem disease and 25 of 61 (42 percent) had risk organ involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/48\">",
"       48",
"      </a>",
"      ]. In a separate study, 40 percent of neonates who had solitary skin LCH at presentation proceeded to have multisystem involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Eczematous rash",
"      </strong>",
"      &mdash; LCH can manifest in children and adults as a red papular rash that occurs in the groin, abdomen, back, or chest and resembles a diffuse candida diaper rash (",
"      <a class=\"graphic graphic_picture graphicRef57722 graphicRef69504 \" href=\"UTD.htm?38/9/39064\">",
"       picture 2A-B",
"      </a>",
"      ). Lesions range in size from a pin head to dime-sized. Seborrheic involvement of the scalp may be mistaken for prolonged \"cradle cap\" in infants or a severe case of seborrheic dermatitis in older individuals. Ulcerative lesions behind the ears, in the scalp, genitalia, or perianal region are especially troublesome, as they often are misdiagnosed as bacterial or fungal lesions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=see_link&amp;anchor=H15#H15\">",
"       \"Overview of diaper dermatitis in infants and children\", section on 'Langerhans cell histiocytosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37318?source=see_link&amp;anchor=H12#H12\">",
"       \"Approach to the patient with a scalp eruption\", section on 'Seborrheic dermatitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Oral lesions",
"      </strong>",
"      &mdash; The most common oral manifestations of LCH are intraoral mass, gingivitis, mucosal ulcers, and loose teeth [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/43,50\">",
"       43,50",
"      </a>",
"      ]. Pain and mass effects can derive from lesions of the bones or soft tissues.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H536268105\">",
"    <span class=\"h2\">",
"     Lymph nodes and bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphadenopathy is seen in approximately 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/36\">",
"     36",
"    </a>",
"    ]. Cervical nodes are most commonly involved. On physical examination, involved nodes are usually soft and matted. An enlarged thymus or mediastinal nodes can mimic lymphoma or an infection and may cause asthma-like symptoms due to compression of local structures. Accordingly, biopsy with culture and histological examination is mandatory for these presentations.",
"   </p>",
"   <p>",
"    There are less data regarding the incidence of bone marrow involvement in patients with LCH, but one study found it to be 34 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/51\">",
"     51",
"    </a>",
"    ]. Most patients with bone marrow involvement are young children with diffuse disease in the liver, spleen, lymph nodes, and skin. A longstanding assumption has been that LCH is found in the bone marrow only when significant thrombocytopenia, anemia, or neutropenia is present [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/52\">",
"     52",
"    </a>",
"    ]. However, analyses of bone marrow specimens stained with anti-CD1a have shown the presence of Langerhans cell histiocytes in patients with multifocal bone disease and normal blood counts, as well as in low-risk patients with single-site involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of LCH patients under two years of age with two or more &ldquo;risk organs&rdquo; (ie, hematopoietic system, liver, spleen, and perhaps lung) involved showed that anemia with thrombocytopenia and hypoalbuminemia were prognostic for a poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/53\">",
"     53",
"    </a>",
"    ]. When compared with those with anemia alone, patients with anemia and thrombocytopenia had an inferior five-year survival rate (19 percent versus 87 percent). Similarly, when compared with those with normal albumin, patients with low albumin had a significantly lower rate of survival at five years (16 versus 65 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452648869\">",
"    <span class=\"h2\">",
"     Liver and spleen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver and spleen are both &ldquo;risk organs&rdquo; and involvement denotes a worse prognosis. Hepatic involvement can include tumor-like or cystic lesions, or overall hepatomegaly, and can be accompanied by elevated liver enzymes, hepatic dysfunction, leading to hypoalbuminemia with ascites, hyperbilirubinemia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clotting factor deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/53-57\">",
"     53-57",
"    </a>",
"    ]. Sclerosing cholangitis is an especially serious complication of LCH, marked by elevated alkaline phosphatase, liver transaminases and gamma glutamyl transpeptidase; it may be progressive, even when other manifestations of LCH respond to treatment, and require eventual liver transplantation.",
"   </p>",
"   <p>",
"    Ultrasound (US), computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen can be used to assess for involvement of the liver",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spleen in patients who have hepato-splenomegaly. Findings of liver involvement include low echogenicity along the biliary tract by US and low T1 or high T2 signal intensity along the portal vein and portal triads [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Massive splenomegaly may lead to cytopenias because of hypersplenism and may also result in respiratory compromise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12840?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to the child with an enlarged spleen\", section on 'Causes of a massively enlarged spleen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452648876\">",
"    <span class=\"h2\">",
"     Lungs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung involvement is seen in approximately 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/36\">",
"     36",
"    </a>",
"    ]. It is less frequent in children than in adults, in whom smoking is a key etiologic factor (",
"    <a class=\"graphic graphic_figure graphicRef69932 \" href=\"UTD.htm?18/34/18989\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/60\">",
"     60",
"    </a>",
"    ]. Although the lung has been considered a &ldquo;risk organ&rdquo;, more recent studies have suggested that it has less of an effect on prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Patients with lung involvement may present following a spontaneous pneumothorax or with a nonproductive cough, dyspnea, chest pain, or constitutional symptoms, especially fever or weight loss. Recurrent spontaneous pneumothorax occurs in 15 to 25 percent of patients. Nearly 20 percent of adults with lung involvement have no symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=see_link\">",
"     \"Pulmonary Langerhans cell histiocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28378?source=see_link&amp;anchor=H42641525#H42641525\">",
"     \"Treatment of Langerhans cell histiocytosis\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary function tests may be normal or may show reduced lung volumes and a reduced diffusing capacity. Airflow limitation and hyperinflation occur in a minority of patients, typically in patients with more advanced, cystic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=see_link&amp;anchor=H11#H11\">",
"     \"Pulmonary Langerhans cell histiocytosis\", section on 'Physiologic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most sensitive diagnostic test is a high-resolution computed tomography (CT) scan, which reveals cysts and nodules characteristic of LCH. A high resolution CT scan of the chest showing a combination of multiple cysts and nodules, with a mid to upper zone predominance, and interstitial thickening in a young smoker is so characteristic that it can be diagnostic of pulmonary LCH (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58182 graphicRef69891 graphicRef72698 \" href=\"UTD.htm?16/61/17368\">",
"     image 2A-C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=see_link&amp;anchor=H8#H8\">",
"     \"Pulmonary Langerhans cell histiocytosis\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the radiographic pattern is nondiagnostic, the combination of transbronchial lung biopsy and bronchoalveolar lavage (BAL) showing an increase in the number of CD-1a positive cells strongly suggests pulmonary LCH, especially when more than 5 percent of BAL cells are CD1a positive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=see_link&amp;anchor=H14#H14\">",
"     \"Pulmonary Langerhans cell histiocytosis\", section on 'Tissue confirmation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452662508\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;LCH involves the central nervous system (CNS) in approximately 6 percent of patients at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/36\">",
"     36",
"    </a>",
"    ]. However, the risk of CNS involvement varies with the location of bone involvement. Lesions of facial bones or bones of the anterior or middle cranial fossae are \"CNS-risk\" lesions with an almost 25 percent incidence of CNS involvement. Symptoms related to CNS involvement vary depending upon the site of disease. The most common manifestations are diabetes insipidus and symptoms of neurodegeneration (ataxia, cognitive dysfunction). Patients may also have proptosis due to soft-tissue masses in the orbital area.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetes insipidus usually presents with polydipsia and polyuria and occurs secondary to infiltration of the posterior pituitary. (See",
"      <a class=\"local\" href=\"#H452648890\">",
"       'Diabetes insipidus and other endocrinopathies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Neurodegeneration is characterized by bilateral symmetric lesions on magnetic resonance imaging (MRI) in the dentate nucleus of the cerebellum or basal ganglia (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51191 \" href=\"UTD.htm?41/12/42177\">",
"       image 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]. Affected patients may have devastating problems with ataxia and behavioral and cognitive dysfunction, which may not be reversible and may not be manifest clinically for over a decade following the initial diagnosis of LCH [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/61,63-67\">",
"       61,63-67",
"      </a>",
"      ]. Patients with hypothalamic-pituitary involvement are at high risk for eventual development of neurodegenerative changes and neuropsychological deficits [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/68\">",
"       68",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H452648841\">",
"       'Lytic bone lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 1 percent develop mass lesions or granulomas in the brain parenchyma or choroid plexus, with the latter leading to blockage of cerebral spinal fluid flow [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=see_link\">",
"       \"Clinical features and diagnosis of leptomeningeal metastases from solid tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"       \"Evaluation and management of elevated intracranial pressure in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"       \"Elevated intracranial pressure in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MRI is the imaging modality of choice to visual CNS involvement. Findings on MRI include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enhancement of the pons, basal ganglia, and white matter of the cerebellum, as well as mass lesions or meningeal enhancement [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report of 163 patients, meningeal lesions were found in 29 percent and choroid-plexus involvement in 6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/67\">",
"       67",
"      </a>",
"      ]. Paranasal-sinus or mastoid lesions were found in over 50 percent versus 20 percent of controls, and accentuated Virchow-Robin spaces (perivascular space) in 70 percent of patients versus 27 percent of controls. These latter findings are hypothesized to indicate modes of entry for pathologic cells into the brain from the \"CNS Risk\" areas.",
"      <br/>",
"      <br/>",
"      In another study, pineal glands were larger in LCH patients than in the controls and often had cystic changes [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/70\">",
"       70",
"      </a>",
"      ]. However, there were no differences in the melatonin levels of LCH patients with or without these changes, making the significance of these findings unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452648890\">",
"    <span class=\"h2\">",
"     Diabetes insipidus and other endocrinopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes insipidus (DI) is the most frequent endocrine abnormality in LCH and typically presents with polyuria, nocturia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    polydipsia. Other endocrine manifestations of LCH include hypogonadism, growth failure, abnormalities of glucose metabolism (eg, impaired glucose tolerance, diabetes mellitus), and an enlarged thyroid gland [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and causes of central diabetes insipidus\", section on 'Infiltrative disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The identification of DI can occur prior to (4 percent), concomitant with (18 percent), or after the diagnosis of LCH [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/63,73\">",
"     63,73",
"    </a>",
"    ]. Among patients with LCH, approximately one-quarter of patients will be diagnosed with pituitary involvement within 10 years of LCH diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/72\">",
"     72",
"    </a>",
"    ]. DI follows initial LCH diagnosis by a mean of one year, and growth hormone deficiency five years later.",
"   </p>",
"   <p>",
"    LCH must be considered in the differential diagnosis of patients with apparently &ldquo;isolated&rdquo; DI and such patients should be carefully observed for later onset of other LCH symptoms. In two studies, 15 percent of patients with \"isolated\" DI were found to have LCH [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/7,72\">",
"     7,72",
"    </a>",
"    ]. Of patients initially presenting with DI, approximately half are diagnosed with LCH within one year of DI diagnosis, and over 80 percent by two years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/63,73\">",
"     63,73",
"    </a>",
"    ], but in some, LCH may be diagnosed many years after DI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/71\">",
"     71",
"    </a>",
"    ]. In a Mayo Clinic series of children and adults with LCH presenting as isolated DI, 42 of 44 patients with DI had involvement of other organ systems: bone (68 percent), skin (57 percent), lung (39 percent), and lymph nodes (18 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients presenting with DI may demonstrate deficiencies of other pituitary hormones. In two series of patients initially presenting with DI, 80 percent had a deficiency in another pituitary hormone within five years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/7,73\">",
"     7,73",
"    </a>",
"    ]. In another series, 28 percent of patients with DI had anterior pituitary deficiencies by the time they were diagnosed with LCH and half had anterior pituitary hormone abnormalities within a year of DI diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=see_link\">",
"     \"Clinical manifestations of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for the development of DI were identified in a study of 1741 children registered in several large LCH trials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/36\">",
"     36",
"    </a>",
"    ]. When compared with those having only single system involvement, patients with multisystem disease and craniofacial involvement at the time of diagnosis, particularly of the ear, eye, and oral region, carried a significantly increased risk of developing DI during their course (relative risk 4.6). This risk was augmented when the disease remained active for a longer period of time, or reactivated. The risk for development of DI in this population was 20 percent at 15 years after diagnosis.",
"   </p>",
"   <p>",
"    While not diagnostic, CNS involvement of LCH is classically seen on magnetic resonance imaging (MRI) as a loss of the posterior bright spot of the pituitary gland [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. The pituitary stalk is thickened in over 70 percent of patients with DI and remains thickened in 24 percent five years later [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/76\">",
"     76",
"    </a>",
"    ]. An enlarged pituitary may be biopsied for a definitive diagnosis, but total removal should be avoided because the resulting total pituitary dysfunction results in difficult management problems.",
"   </p>",
"   <p>",
"    Despite treatment of LCH, anterior pituitary hormone deficiency persists indefinitely [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452648897\">",
"    <span class=\"h2\">",
"     Gastrointestinal system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal involvement of LCH is uncommon. Approximately 2 percent of patients present with diarrhea or malabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/77\">",
"     77",
"    </a>",
"    ]. Diagnosing gastrointestinal involvement is difficult because of intermittent involvement of LCH lesions in the gastrointestinal tract. Careful endoscopic examination with biopsies is needed. A case report and literature review of gastrointestinal LCH involvement found that LCH was diagnosed by endoscopy in 91 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/78\">",
"     78",
"    </a>",
"    ]. Of these patients, 86 percent had LCH in the duodenum and 64 percent in the rectal, sigmoid, or colon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link&amp;anchor=H9#H9\">",
"     \"Eosinophilic gastroenteritis\", section on 'Diagnosis and differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13609?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations of peptic ulcer disease\", section on 'Infiltrative or granulomatous diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ten adult patients with gastrointestinal (GI) involvement with LCH have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/79\">",
"     79",
"    </a>",
"    ]. Half of these were asymptomatic with a mean age of 58 years and 75 percent being female. Most of the adults had a solitary, small, intramucosal polyp in the colorectum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452652235\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsies of involved tissue usually demonstrate heterogeneous collections of Langerhans cells with eosinophils, neutrophils, small lymphocytes, and histiocytes (which may form multinucleated giant cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/2\">",
"     2",
"    </a>",
"    ]. Eosinophilic abscesses may be present demonstrating central necrosis with or without Charcot-Leyden crystals.",
"   </p>",
"   <p>",
"    Morphologically, Langerhans cells are large oval mononuclear cells with few cytoplasmic vacuoles, little or no phagocytic material, and moderately abundant, slightly eosinophilic cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef67142 \" href=\"UTD.htm?24/10/24742\">",
"     picture 3",
"    </a>",
"    ). The nucleus is prominent with fine chromatin and thin nuclear membranes with grooved, folded, or indented nuclear contours, imparting a &ldquo;twisted towel&rdquo; or &ldquo;coffee bean&rdquo; appearance. Nucleoli are not prominent. Unlike dermal Langerhans cells, these cells do not have dendritic cell processes.",
"   </p>",
"   <p>",
"    Similar to dermal Langerhans cells, those in LCH express the histiocyte markers CD1a, S100, and CD207 (langerin) and contain Birbeck granules (",
"    <a class=\"graphic graphic_picture graphicRef55261 \" href=\"UTD.htm?30/34/31273\">",
"     picture 4",
"    </a>",
"    ). Birbeck granules are intracytoplasmic rod-shaped organelles with central striation that can be demonstrated on electron microscopy (",
"    <a class=\"graphic graphic_picture graphicRef60620 \" href=\"UTD.htm?2/32/2570\">",
"     picture 5",
"    </a>",
"    ). Occasionally, there is terminal vesicular dilation giving the Birbeck granule the appearance of a &ldquo;tennis racket&rdquo;.",
"   </p>",
"   <p>",
"    Pathologic findings may vary depending upon the site of biopsy. Bone and skin lesions as well as mass lesions in the cerebrum, hypothalamus, and pituitary have classic CD1a-reactive Langerhans cells and CD8-positive T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/2,80\">",
"     2,80",
"    </a>",
"    ]. Lesions in the cerebellum primarily contain CD8+ T cells rather than CD1a-expressing Langerhans cells. Neuronal and axonal destruction with demyelination is prominent. Liver biopsies may show no CD1a-positive cells, but many lymphocytes clustered around bile ducts.",
"   </p>",
"   <p>",
"    Other pathologic features that are not diagnostic of LCH but are sometimes seen include hemophagocytosis on bone marrow specimens and myelodysplastic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Macrophage activation seen in LCH patients may be a result of excessive cytokine expression in these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link\">",
"     \"Hemophagocytic lymphohistiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No cytogenetic findings are characteristic or diagnostic. Although monoclonality can be established in the majority of cases, these studies are not used routinely for diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452648918\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;LCH is diagnosed based upon biopsy with the pathologic evaluation of involved tissue interpreted within the clinical context. A biopsy of an osteolytic bone lesion or skin lesion is generally preferred. Biopsy of the pituitary may be required for the definitive diagnosis of a solitary pituitary lesion, but is more invasive and dependent upon the size of the lesion and comfort of the neurosurgeon. While Langerhans cells can be recognized on the basis of morphologic criteria, their identity must be confirmed either by positive immunohistochemical staining for CD1a and CD207 or by the identification of Birbeck granules by electron microscopy. Electron microscopy to identify Birbeck granules is performed less frequently because of time and expense.",
"   </p>",
"   <p>",
"    LCH can be difficult to diagnose since it is an uncommon disease that can affect many organ systems. LCH in bone, lymph nodes, thymus, liver or spleen can be confused with lymphomas, solid tumors, or primary CNS tumors including germinoma and meningioma. Cutaneous involvement can mimic vasculitis, cutaneous lymphoma, or cutaneous involvement with Erdheim-Chester disease (see below). Pulmonary involvement can have the clinical appearance of any number of interstitial lung diseases. LCH must be distinguished histologically and immuno-phenotypically from other histiocytic and dendritic cell disorders, metastatic solid or hematopoietic neoplasms, and hemophagocytic lymphohistiocytic and macrophage activation syndromes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erdheim-Chester disease (ECD) &mdash; ECD is a rare multisystem histiocytic disorder, most often seen in adults, that may be confused with LCH. Histiocytic infiltration leads to xanthogranulomatous infiltrates of multiple organ systems (eg, skin, lung, bone, cerebral, facial, orbital and retro-orbital tissue, pituitary, retroperitoneum, cardiovascular system). These cells may be very similar to those of juvenile xanthogranuloma, as both diseases most likely derive from the same lineage of",
"      <span class=\"nowrap\">",
"       dermal/interstitial",
"      </span>",
"      dendrocyte [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/1\">",
"       1",
"      </a>",
"      ]. Long bone pain and symmetric osteosclerotic lesions suggest this diagnosis, which is confirmed by tissue biopsies showing histiocytes with non-Langerhans features (eg, negative for CD1a and S-100 protein). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20680?source=see_link&amp;anchor=H801440#H801440\">",
"       \"Erdheim-Chester disease\", section on 'Diagnosis and differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Juvenile xanthogranuloma (JXG) &mdash; JXG is a benign proliferative disorder of histiocytic cells of the dermal dendrocyte phenotype. JXG belongs to the broad group of non-Langerhans cell histiocytoses and is typically a disorder of early childhood. JXG presents in the first two years of life as a solitary reddish or yellowish skin papule or nodule (",
"      <a class=\"graphic graphic_picture graphicRef69122 \" href=\"UTD.htm?28/52/29504\">",
"       picture 6",
"      </a>",
"      ), most often on the head, neck, and upper trunk. Histologically, JXG is characterized by the presence of foamy or Touton giant cells. JXG generally follows a benign course with spontaneous resolution over a period of a few years. Less commonly, skin lesions can be multiple (",
"      <a class=\"graphic graphic_picture graphicRef81058 \" href=\"UTD.htm?1/2/1061\">",
"       picture 7",
"      </a>",
"      ). Extracutaneous or systemic forms (brain, lung, kidney, spleen, liver, bone marrow, and retro-orbital tumors) are exceedingly rare and can be associated with considerable morbidity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1495?source=see_link\">",
"       \"Juvenile xanthogranuloma (JXG)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiple myeloma &mdash; The osteolytic lesions of bone in LCH can be confused with those seen in multiple myeloma. LCH can readily be distinguished from multiple myeloma by histologic and immunophenotypic findings on biopsy and the presence of a monoclonal protein in the serum of patient with multiple myeloma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H25#H25\">",
"       \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemophagocytic lymphohistiocytosis (HLH) &mdash; HLH and the related macrophage activation syndrome are systemic disorders that demonstrate tissue infiltration by non-neoplastic histiocytes. Unlike LCH, these disorders demonstrate prominent hemophagocytic activity in the bone marrow, and are characterized by fever, hypertriglyceridemia, hypofibrinogenemia, hyperferritinemia, and one or more cytopenias. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link\">",
"       \"Hemophagocytic lymphohistiocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rosai-Dorfman disease (sinus histiocytosis with massive lymphadenopathy) is a macrophage-related disorder that most often presents as a systemic disorder involving lymph nodes and other organs [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/83-85\">",
"       83-85",
"      </a>",
"      ], or can rarely be limited to the skin [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/86,87\">",
"       86,87",
"      </a>",
"      ]. Although the pathologic cells in RDD and HLH are the macrophages (CD14+, CD1a-,",
"      <span class=\"nowrap\">",
"       S100+/-,",
"      </span>",
"      CD68+), RDD is histologically distinct from the other histiocytic diseases because the macrophages have normal-appearing lymphocytes residing in the macrophage cytoplasm (emperipolesis) unlike the hemophagocytosis of HLH [",
"      <a class=\"abstract\" href=\"UTD.htm?20/53/21338/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=see_link&amp;anchor=H28#H28\">",
"       \"Causes of peripheral lymphadenopathy in children\", section on 'Rosai-Dorfman disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452650421\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Langerhans cell histiocytosis (LCH) is a rare histiocytic disorder that may be seen in all age groups, but is most common in children from one to three years old. (See",
"      <a class=\"local\" href=\"#H452648790\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of patients with LCH varies depending upon the sites and extent of involvement. The disease is limited to one organ system (eg, bone) in approximately half of patients. Acute disseminated multisystem disease is most commonly seen in children less than three years, while a more indolent disease involving a single organ is more common in older children and adults. (See",
"      <a class=\"local\" href=\"#H452648812\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bone involvement occurs in the majority of patients and can involve any bone of the body. Although some lesions are asymptomatic, the patient may complain of pain in a localized area of bone; examination usually reveals a raised, soft, tender spot. Radiologic studies typically demonstrate a lytic, &ldquo;punched out&rdquo; appearance, sometimes with an accompanying soft tissue mass (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56235 \" href=\"UTD.htm?20/13/20703\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H452648841\">",
"       'Lytic bone lesions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32551?source=see_link&amp;anchor=H5#H5\">",
"       \"Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children\", section on 'Imaging characteristics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skin involvement is seen in approximately 40 percent of patients. The most common skin manifestations are an eczematous rash resembling a candidal infection (",
"      <a class=\"graphic graphic_picture graphicRef75074 \" href=\"UTD.htm?29/28/30146\">",
"       picture 1",
"      </a>",
"      ) or ulcerative lesions in the axillae, inguinal folds, genitalia, or peri-anal regions. A much less common manifestation is the &ldquo;self-healing&rdquo; or Hashimoto-Pritzker variant rash, which consists of brown to purplish papules in infants (",
"      <a class=\"graphic graphic_picture graphicRef57722 \" href=\"UTD.htm?33/62/34786\">",
"       picture 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H452648848\">",
"       'Skin and oral mucosa'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lung involvement occurs in approximately 10 percent of cases. It is less frequent in children than in adults, in whom smoking is a key etiologic factor. Patients with lung involvement may be asymptomatic or present following a spontaneous pneumothorax or with nonproductive cough, dyspnea, chest pain, or constitutional symptoms. The most sensitive diagnostic test is a high-resolution computed tomography (CT) scan, which reveals cysts and nodules characteristic of LCH (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69891 \" href=\"UTD.htm?2/51/2864\">",
"       image 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H452648876\">",
"       'Lungs'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=see_link\">",
"       \"Pulmonary Langerhans cell histiocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of central nervous system (CNS) involvement varies with the location of bone involvement. Lesions of facial bones or bones of the anterior or middle cranial fossae are \"CNS-risk\" lesions with an almost 25 percent incidence of CNS involvement. The most common symptoms of CNS involvement are diabetes insipidus and symptoms of neurodegeneration (ataxia, cognitive dysfunction). Findings on magnetic resonance imaging include thickening of the pituitary stalk; enhancement of the pons, basal ganglia, and white matter of the cerebellum; mass lesions; and meningeal enhancement. (See",
"      <a class=\"local\" href=\"#H452662508\">",
"       'Central nervous system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LCH is diagnosed based upon the pathologic evaluation of involved tissue interpreted within the clinical context. A biopsy of an osteolytic bone lesion or skin lesion is generally preferred, when possible. While Langerhans cell histiocytes can be suspected based upon morphologic criteria, their identity must be confirmed either by positive immunohistochemical staining for CD1a (",
"      <a class=\"graphic graphic_picture graphicRef55261 \" href=\"UTD.htm?30/34/31273\">",
"       picture 4",
"      </a>",
"      ) and CD207 or by the identification of Birbeck granules (",
"      <a class=\"graphic graphic_picture graphicRef60620 \" href=\"UTD.htm?2/32/2570\">",
"       picture 5",
"      </a>",
"      ) by electron microscopy. (See",
"      <a class=\"local\" href=\"#H452652235\">",
"       'Pathologic features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H452648918\">",
"       'Diagnosis and differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LCH can be difficult to diagnose since it is an uncommon disease that can affect many organ systems. LCH must be distinguished histologically and immuno-phenotypically from other histiocytic and dendritic cell disorders, metastatic solid or hematopoietic neoplasms, and hemophagocytic lymphohistiocytic and macrophage activation syndromes. (See",
"      <a class=\"local\" href=\"#H452648918\">",
"       'Diagnosis and differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Jaffe R. The diagnostic histopathology of Langerhans cell histiocytosis. In: Histiocytic Disorders of Children and Adults. Basic Science, Clinical Features, and Therapy, Weitzman S, Egeler RM (Eds), Cambridge University Press, Cambridge 2005. p.14.",
"    </li>",
"    <li>",
"     Jaffe R, Weiss LM, Facchetti F. Tumours derived from Langerhans cells. In: World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al (Eds), IARC Press, Lyon 2008. p.358.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/3\">",
"      Carstensen H, Ornvold K. The epidemiology of LCH in children in Denmark, 1975-89. Med Pediatr Oncol 1993; 21:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/4\">",
"      Baumgartner I, von Hochstetter A, Baumert B, et al. Langerhans'-cell histiocytosis in adults. Med Pediatr Oncol 1997; 28:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/5\">",
"      Malpas JS, Norton AJ. Langerhans cell histiocytosis in the adult. Med Pediatr Oncol 1996; 27:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/6\">",
"      Howarth DM, Gilchrist GS, Mullan BP, et al. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer 1999; 85:2278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/7\">",
"      Islinger RB, Kuklo TR, Owens BD, et al. Langerhans' cell histiocytosis in patients older than 21 years. Clin Orthop Relat Res 2000; :231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/8\">",
"      G&ouml;tz G, Fichter J. Langerhans'-cell histiocytosis in 58 adults. Eur J Med Res 2004; 9:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/9\">",
"      Aric&ograve; M, Girschikofsky M, G&eacute;n&eacute;reau T, et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003; 39:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/10\">",
"      Nicholson HS, Egeler RM, Nesbit ME. The epidemiology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/11\">",
"      Aric&ograve; M, Nichols K, Whitlock JA, et al. Familial clustering of Langerhans cell histiocytosis. Br J Haematol 1999; 107:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/12\">",
"      Shahla A, Parvaneh V, Hossein HD. Langerhans cells histiocytosis in one family. Pediatr Hematol Oncol 2004; 21:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/13\">",
"      Bhatia S, Nesbit ME Jr, Egeler RM, et al. Epidemiologic study of Langerhans cell histiocytosis in children. J Pediatr 1997; 130:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/14\">",
"      Pineles SL, Liu GT, Acebes X, et al. Presence of Erdheim-Chester disease and Langerhans cell histiocytosis in the same patient: a report of 2 cases. J Neuroophthalmol 2011; 31:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/15\">",
"      Wang KH, Cheng CJ, Hu CH, Lee WR. Coexistence of localized Langerhans cell histiocytosis and cutaneous Rosai-Dorfman disease. Br J Dermatol 2002; 147:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/16\">",
"      Allen CE, Li L, Peters TL, et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol 2010; 184:4557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/17\">",
"      McClain K, Jin H, Gresik V, Favara B. Langerhans cell histiocytosis: lack of a viral etiology. Am J Hematol 1994; 47:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/18\">",
"      Jeziorski E, Senechal B, Molina TJ, et al. Herpes-virus infection in patients with Langerhans cell histiocytosis: a case-controlled sero-epidemiological study, and in situ analysis. PLoS One 2008; 3:e3262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/19\">",
"      Abla O, Egeler RM, Weitzman S. Langerhans cell histiocytosis: Current concepts and treatments. Cancer Treat Rev 2010; 36:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/20\">",
"      Willman CL, Busque L, Griffith BB, et al. Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med 1994; 331:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/21\">",
"      Yu RC, Chu C, Buluwela L, Chu AC. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet 1994; 343:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/22\">",
"      Yousem SA, Colby TV, Chen YY, et al. Pulmonary Langerhans' cell histiocytosis: molecular analysis of clonality. Am J Surg Pathol 2001; 25:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/23\">",
"      Chen W, Wang J, Wang E, et al. Detection of clonal lymphoid receptor gene rearrangements in langerhans cell histiocytosis. Am J Surg Pathol 2010; 34:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/24\">",
"      Rolland A, Guyon L, Gill M, et al. Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. J Immunol 2005; 174:3067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/25\">",
"      Coury F, Annels N, Rivollier A, et al. Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med 2008; 14:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/26\">",
"      Allen CE, McClain KL. Interleukin-17A is not expressed by CD207(+) cells in Langerhans cell histiocytosis lesions. Nat Med 2009; 15:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/27\">",
"      Peters TL, McClain KL, Allen CE. Neither IL-17A mRNA nor IL-17A protein are detectable in Langerhans cell histiocytosis lesions. Mol Ther 2011; 19:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/28\">",
"      Ishii R, Morimoto A, Ikushima S, et al. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis. Pediatr Blood Cancer 2006; 47:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/29\">",
"      Senechal B, Elain G, Jeziorski E, et al. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med 2007; 4:e253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/30\">",
"      Chikwava KR, Hunt JL, Mantha GS, et al. Analysis of loss of heterozygosity in single-system and multisystem Langerhans' cell histiocytosis. Pediatr Dev Pathol 2007; 10:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/31\">",
"      Murakami I, Gogusev J, Fournet JC, et al. Detection of molecular cytogenetic aberrations in langerhans cell histiocytosis of bone. Hum Pathol 2002; 33:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/32\">",
"      da Costa CE, Szuhai K, van Eijk R, et al. No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes Cancer 2009; 48:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/33\">",
"      Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010; 116:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/34\">",
"      Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 120:2700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/35\">",
"      Tazi A, Moreau J, Bergeron A, et al. Evidence that Langerhans cells in adult pulmonary Langerhans cell histiocytosis are mature dendritic cells: importance of the cytokine microenvironment. J Immunol 1999; 163:3511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/36\">",
"      Grois N, P&ouml;tschger U, Prosch H, et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer 2006; 46:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/37\">",
"      Braier J, Latella A, Balancini B, et al. Outcome in children with pulmonary Langerhans cell Histiocytosis. Pediatr Blood Cancer 2004; 43:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/38\">",
"      Odame I, Li P, Lau L, et al. Pulmonary Langerhans cell histiocytosis: a variable disease in childhood. Pediatr Blood Cancer 2006; 47:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/39\">",
"      Slater JM, Swarm OJ. Eosinophilic granuloma of bone. Med Pediatr Oncol 1980; 8:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/40\">",
"      Garg S, Mehta S, Dormans JP. Langerhans cell histiocytosis of the spine in children. Long-term follow-up. J Bone Joint Surg Am 2004; 86-A:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/41\">",
"      Huang W, Yang X, Cao D, et al. Eosinophilic granuloma of spine in adults: a report of 30 cases and outcome. Acta Neurochir (Wien) 2010; 152:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/42\">",
"      D'Ambrosio N, Soohoo S, Warshall C, et al. Craniofacial and intracranial manifestations of langerhans cell histiocytosis: report of findings in 100 patients. AJR Am J Roentgenol 2008; 191:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/43\">",
"      Annibali S, Cristalli MP, Solidani M, et al. Langerhans cell histiocytosis: oral/periodontal involvement in adult patients. Oral Dis 2009; 15:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/44\">",
"      Newman B, Hu W, Nigro K, Gilliam AC. Aggressive histiocytic disorders that can involve the skin. J Am Acad Dermatol 2007; 56:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/45\">",
"      Munn S, Chu AC. Langerhans cell histiocytosis of the skin. Hematol Oncol Clin North Am 1998; 12:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/46\">",
"      Kapur P, Erickson C, Rakheja D, et al. Congenital self-healing reticulohistiocytosis (Hashimoto-Pritzker disease): ten-year experience at Dallas Children's Medical Center. J Am Acad Dermatol 2007; 56:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/47\">",
"      Stein SL, Paller AS, Haut PR, Mancini AJ. Langerhans cell histiocytosis presenting in the neonatal period: a retrospective case series. Arch Pediatr Adolesc Med 2001; 155:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/48\">",
"      Minkov M, Prosch H, Steiner M, et al. Langerhans cell histiocytosis in neonates. Pediatr Blood Cancer 2005; 45:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/49\">",
"      Lau L, Krafchik B, Trebo MM, Weitzman S. Cutaneous Langerhans cell histiocytosis in children under one year. Pediatr Blood Cancer 2006; 46:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/50\">",
"      Hicks J, Flaitz CM. Langerhans cell histiocytosis: current insights in a molecular age with emphasis on clinical oral and maxillofacial pathology practice. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100:S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/51\">",
"      Minkov M, P&ouml;tschger U, Grois N, et al. Bone marrow assessment in Langerhans cell histiocytosis. Pediatr Blood Cancer 2007; 49:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/52\">",
"      McClain K, Ramsay NK, Robison L, et al. Bone marrow involvement in histiocytosis X. Med Pediatr Oncol 1983; 11:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/53\">",
"      Braier JL, Rosso D, Latella A, et al. Importance of multi-lineage hematologic involvement and hypoalbuminemia at diagnosis in patients with \"risk-organ\" multi-system Langerhans cell histiocytosis. J Pediatr Hematol Oncol 2010; 32:e122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/54\">",
"      Kaplan KJ, Goodman ZD, Ishak KG. Liver involvement in Langerhans' cell histiocytosis: a study of nine cases. Mod Pathol 1999; 12:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/55\">",
"      K&ouml;nig CW, Pfannenberg C, Tr&uuml;benbach J, et al. MR cholangiography in the diagnosis of sclerosing cholangitis in Langerhans' cell histiocytosis. Eur Radiol 2001; 11:2516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/56\">",
"      Haas S, Theuerkauf I, K&uuml;hnen A, et al. [Langerhans' cell histiocytosis of the liver. Differential diagnosis of a rare chronic destructive sclerosing cholangitis]. Pathologe 2003; 24:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/57\">",
"      Braier J, Ciocca M, Latella A, et al. Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell Histiocytosis. Med Pediatr Oncol 2002; 38:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/58\">",
"      Prasad SR, Wang H, Rosas H, et al. Fat-containing lesions of the liver: radiologic-pathologic correlation. Radiographics 2005; 25:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/59\">",
"      Wong A, Ortiz-Neira CL, Reslan WA, et al. Liver involvement in Langerhans cell histiocytosis. Pediatr Radiol 2006; 36:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/60\">",
"      Nondahl SR, Finlay JL, Farrell PM, et al. A case report and literature review of \"primary\" pulmonary histiocytosis X of childhood. Med Pediatr Oncol 1986; 14:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/61\">",
"      Grois NG, Favara BE, Mostbeck GH, Prayer D. Central nervous system disease in Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/62\">",
"      Grois N, Fahrner B, Arceci RJ, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr 2010; 156:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/63\">",
"      Prosch H, Grois N, Prayer D, et al. Central diabetes insipidus as presenting symptom of Langerhans cell histiocytosis. Pediatr Blood Cancer 2004; 43:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/64\">",
"      Wnorowski M, Prosch H, Prayer D, et al. Pattern and course of neurodegeneration in Langerhans cell histiocytosis. J Pediatr 2008; 153:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/65\">",
"      Mittheisz E, Seidl R, Prayer D, et al. Central nervous system-related permanent consequences in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 2007; 48:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/66\">",
"      van der Knaap MS, Arts WF, Garbern JY, et al. Cerebellar leukoencephalopathy: most likely histiocytosis-related. Neurology 2008; 71:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/67\">",
"      Prayer D, Grois N, Prosch H, et al. MR imaging presentation of intracranial disease associated with Langerhans cell histiocytosis. AJNR Am J Neuroradiol 2004; 25:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/68\">",
"      Fahrner B, Prosch H, Minkov M, et al. Long-term outcome of hypothalamic pituitary tumors in Langerhans cell histiocytosis. Pediatr Blood Cancer 2012; 58:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/69\">",
"      Laurencikas E, Gavhed D, St&aring;lemark H, et al. Incidence and pattern of radiological central nervous system Langerhans cell histiocytosis in children: a population based study. Pediatr Blood Cancer 2011; 56:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/70\">",
"      Grois N, Prosch H, Waldhauser F, et al. Pineal gland abnormalities in Langerhans cell histiocytosis. Pediatr Blood Cancer 2004; 43:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/71\">",
"      Garc&iacute;a Gallo MS, Mart&iacute;nez MP, Abalovich MS, et al. Endocrine manifestations of Langerhans cell histiocytosis diagnosed in adults. Pituitary 2010; 13:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/72\">",
"      Donadieu J, Rolon MA, Thomas C, et al. Endocrine involvement in pediatric-onset Langerhans' cell histiocytosis: a population-based study. J Pediatr 2004; 144:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/73\">",
"      Maghnie M, Cosi G, Genovese E, et al. Central diabetes insipidus in children and young adults. N Engl J Med 2000; 343:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/74\">",
"      Maghnie M, Bossi G, Klersy C, et al. Dynamic endocrine testing and magnetic resonance imaging in the long-term follow-up of childhood langerhans cell histiocytosis. J Clin Endocrinol Metab 1998; 83:3089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/75\">",
"      Kaltsas GA, Powles TB, Evanson J, et al. Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab 2000; 85:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/76\">",
"      Grois N, Prayer D, Prosch H, et al. Course and clinical impact of magnetic resonance imaging findings in diabetes insipidus associated with Langerhans cell histiocytosis. Pediatr Blood Cancer 2004; 43:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/77\">",
"      Geissmann F, Thomas C, Emile JF, et al. Digestive tract involvement in Langerhans cell histiocytosis. The French Langerhans Cell Histiocytosis Study Group. J Pediatr 1996; 129:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/78\">",
"      Hait E, Liang M, Degar B, et al. Gastrointestinal tract involvement in Langerhans cell histiocytosis: case report and literature review. Pediatrics 2006; 118:e1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/79\">",
"      Singhi AD, Montgomery EA. Gastrointestinal tract langerhans cell histiocytosis: A clinicopathologic study of 12 patients. Am J Surg Pathol 2011; 35:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/80\">",
"      Grois N, Prayer D, Prosch H, et al. Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain 2005; 128:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/81\">",
"      Surico G, Muggeo P, Rigillo N, Gadner H. Concurrent Langerhans cell histiocytosis and myelodysplasia in children. Med Pediatr Oncol 2000; 35:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/82\">",
"      Favara BE, Jaffe R, Egeler RM. Macrophage activation and hemophagocytic syndrome in langerhans cell histiocytosis: report of 30 cases. Pediatr Dev Pathol 2002; 5:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/83\">",
"      Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol 1990; 7:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/84\">",
"      Pulsoni A, Anghel G, Falcucci P, et al. Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case and literature review. Am J Hematol 2002; 69:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/85\">",
"      Utikal J, Ugurel S, Kurzen H, et al. Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. Arch Dermatol 2007; 143:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/86\">",
"      Frater JL, Maddox JS, Obadiah JM, Hurley MY. Cutaneous Rosai-Dorfman disease: comprehensive review of cases reported in the medical literature since 1990 and presentation of an illustrative case. J Cutan Med Surg 2006; 10:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/53/21338/abstract/87\">",
"      Wang KH, Chen WY, Liu HN, et al. Cutaneous Rosai-Dorfman disease: clinicopathological profiles, spectrum and evolution of 21 lesions in six patients. Br J Dermatol 2006; 154:277.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8385 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-3D6454D7D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_53_21338=[""].join("\n");
var outline_f20_53_21338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H452650421\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H452648790\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H452648797\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H452648804\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H452648812\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H452648841\">",
"      Lytic bone lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H452648848\">",
"      Skin and oral mucosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H536268105\">",
"      Lymph nodes and bone marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H452648869\">",
"      Liver and spleen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H452648876\">",
"      Lungs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H452662508\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H452648890\">",
"      Diabetes insipidus and other endocrinopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H452648897\">",
"      Gastrointestinal system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H452652235\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H452648918\">",
"      DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H452650421\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8385\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8385|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/13/20703\" title=\"diagnostic image 1\">",
"      Langerhans sternum CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/29/34271\" title=\"diagnostic image 2A\">",
"      Langerhans histiocytosis CT I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/51/2864\" title=\"diagnostic image 2B\">",
"      Langerhans histiocytosis CT II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/37/21074\" title=\"diagnostic image 2C\">",
"      Pulmonary histiocytosis X CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/12/42177\" title=\"diagnostic image 3\">",
"      Neurodegenerative CNS LCH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8385|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/34/18989\" title=\"figure 1\">",
"      Age pulmonary histiocytosis X",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8385|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/28/30146\" title=\"picture 1\">",
"      Congenital histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/62/34786\" title=\"picture 2A\">",
"      Langerhans histiocytosis skin 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/56/4997\" title=\"picture 2B\">",
"      Langerhans histiocytosis skin 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/10/24742\" title=\"picture 3\">",
"      Lymph node LCH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/34/31273\" title=\"picture 4\">",
"      CD1a stain LCH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/32/2570\" title=\"picture 5\">",
"      Birbeck granules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/52/29504\" title=\"picture 6\">",
"      JXG solitary lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/2/1061\" title=\"picture 7\">",
"      JXG multiple lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12840?source=related_link\">",
"      Approach to the child with an enlarged spleen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37318?source=related_link\">",
"      Approach to the patient with a scalp eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=related_link\">",
"      Causes of peripheral lymphadenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=related_link\">",
"      Clinical features and diagnosis of leptomeningeal metastases from solid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=related_link\">",
"      Clinical manifestations and causes of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=related_link\">",
"      Clinical manifestations of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13609?source=related_link\">",
"      Clinical manifestations of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=related_link\">",
"      Eosinophilic gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20680?source=related_link\">",
"      Erdheim-Chester disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38934?source=related_link\">",
"      Histiocytic sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1495?source=related_link\">",
"      Juvenile xanthogranuloma (JXG)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32551?source=related_link\">",
"      Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=related_link\">",
"      Overview of diaper dermatitis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=related_link\">",
"      Pulmonary Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6840?source=related_link\">",
"      Skin nodules in newborns and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28378?source=related_link\">",
"      Treatment of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_53_21339="Survival in DAH";
var content_f20_53_21339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Outcome of diffuse alveolar hemorrhage syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"60%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Early mortality",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        5-year survival",
"        <br/>",
"        (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microscopic polyangiitis",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Goodpasture's syndrome",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        &lt;20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic pulmonary hemosiderosis",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        &gt;50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolated pulmonary capillaritis",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        &gt;50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_53_21339=[""].join("\n");
var outline_f20_53_21339=null;
var title_f20_53_21340="Drugs that can induce Brugada-like ECG patterns";
var content_f20_53_21340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs that can induce Brugada-like patters on the surface electrocardiogram (ECG)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Antiarrhythmic or antianginal drugs drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Cardiac sodium channel blockers (some have been used for drug challenge in patients with Brugada type 2 or 3 ECG pattern)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Class IC drugs (flecainide, pilsicainide, propafenone)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Class IA drugs (ajmaline, procainamide, disopyramide, cibenzoline)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lithium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium channel blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beta blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitrates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nicorandil (a potassium channel opener)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Psychotropic drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Tricyclic antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Amitriptyline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nortriptyline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Desipramine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Clomipramine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Tetracyclic antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Maprotiline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Phenothiazines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Perphenazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cyamemazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Selective serotonin reuptake inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fluoxetine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dimenhydrinate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cocaine intoxication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol intoxication",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111:659.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_53_21340=[""].join("\n");
var outline_f20_53_21340=null;
var title_f20_53_21341="Postop surv ASCO NCCN rec";
var content_f20_53_21341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of updated 2005 colorectal cancer surveillance guidelines from the American Society of Clinical Oncology (ASCO) and from the National Comprehensive Cancer Network (NCCN)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        American Society of Clinical Oncology (ASCO)",
"       </td>",
"       <td class=\"subtitle1\">",
"        National Comprehensive Cancer Network (NCCN)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        History and physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Every three to six months for the first three years; every six months during years 4 and 5, then annually thereafter.",
"       </td>",
"       <td>",
"        Every three to six months for the first two years; then every six months for a total of five years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Carcinoembryonic antigen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum CEA testing should be performed every three months for at least three years in patients with stage II or III colon or rectal cancer if they would otherwise be candidates for surgery or systemic therapy. Since adjuvant 5-FU-based therapy can falsely elevate the serum CEA, waiting until adjuvant therapy is finished to initiate surveillance is advised.",
"       </td>",
"       <td>",
"        Every three to six months for the first two years, then every six months for a total of five years for T2 or higher stage disease, if patient is a potential candidate for resection of isolated metastases.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Liver function tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not recommended",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Complete blood cell count",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not recommended",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Fecal occult blood test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The data are sufficient to recommend against periodic FOBTs in surveillance for colorectal cancer recurrence*.",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Chest x-ray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not recommended",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Computed tomography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patients with colon or rectal cancer at higher risk of recurrence (stage III or stage II with multiple poor risk features) should undergo annual CT of the chest and abdomen for three years if they would otherwise be eligible for curative intent surgery.",
"       </td>",
"       <td>",
"        Annual CT of the chest, abdomen, and pelvis for three years for patients at high risk of recurrence (lymphatic or venous invasion, or poorly differentiated tumors).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Annual pelvic CT for three years should be considered for rectal cancer surveillance, particularly if the patient has not been treated with pelvic radiation therapy.",
"       </td>",
"       <td>",
"        For resected stage IV disease: CT every three to six months for two years then every six to 12 months for a total of five years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Colonoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All patients with colon or rectal cancer should have a full colonoscopy in the preoperative or perioperative setting to document a cancer-free and polyp-free colon. Patients who present with an obstructing cancer should undergo full colonoscopy within six months of surgery. Repeat colonoscopy is recommended at three years, and if normal, every five years thereafter. For patients with high-risk genetic syndromes, the panel recommended that the screening guidelines of the American Gastroenterology Association be followed",
"        <sup>",
"         &bull;",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Colonoscopy in one year. If year one study shows advanced adenoma (villous polyp, any polyp &gt;1 cm, or high-grade dysplasia), repeat in one year. If negative for polyps or not advanced adenoma, repeat in three years then every five years. If no preoperative colonoscopy due to obstructing lesion, colonoscopy in three to six months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Flexible proctosigmoidoscopy, rectal cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        For patients who have not received pelvic radiation therapy, direct visualization of the rectum with flexible proctosigmoidoscopy is recommended every six months for five years.",
"       </td>",
"       <td>",
"        Proctosigmoidoscopy every six months for five years if status post low anterior resection for rectal cancer.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Addressed in the year 2000 guidelines (Benson AB, et al. J Clin Oncol 2000; 18:3586).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     American Gastroenterology Association guidelines available from Winawer S, et al. Gastroenterology 2003; 124:544.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Desch, et al. J Clin Oncol 2005; 23:8512.",
"     <br/>",
"     NCCN guidelines available online at www.nccn.org/professionals/physician_gls/default.asp.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_53_21341=[""].join("\n");
var outline_f20_53_21341=null;
var title_f20_53_21342="GISSI risk index post MI";
var content_f20_53_21342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59209%7ECARD%2F82205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59209%7ECARD%2F82205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    GISSI-prevenzione risk of death assessment scoring",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Risk points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Females",
"       </td>",
"       <td class=\"subtitle2\">",
"        Males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Age, Years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        &lt;45",
"       </td>",
"       <td>",
"        -2",
"       </td>",
"       <td>",
"        -11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        45 to 49",
"       </td>",
"       <td>",
"        -2",
"       </td>",
"       <td>",
"        -4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        50 to 54",
"       </td>",
"       <td>",
"        -1",
"       </td>",
"       <td>",
"        -4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        55 to 59",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        60 to 64",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        65 to 69",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        70 to 74",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        75",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Complications after myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left ventricular dysfunction",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrical instability",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Residual myocardial ischaernia",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Diabetes",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Hypertension",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Smoker",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Intermittent claudication",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Leukocyte count ( x 1000/&micro;L)",
"       </td>",
"       <td>",
"        &lt;7.0",
"       </td>",
"       <td>",
"        -4",
"       </td>",
"       <td>",
"        -3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7.0 to 7.9",
"       </td>",
"       <td>",
"        -1",
"       </td>",
"       <td>",
"        -1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8.0 to 8.9",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;9.0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Fibrinogen (mg /dL)",
"       </td>",
"       <td>",
"        &lt;400",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;400",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        HDL-cholesterol (mg/dL)",
"       </td>",
"       <td>",
"        &gt;55",
"       </td>",
"       <td>",
"        -3",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        41 to 55",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36 to 40",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;35",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Heart rate (beats/min)",
"       </td>",
"       <td>",
"        &le;64",
"       </td>",
"       <td>",
"        -2",
"       </td>",
"       <td>",
"        -1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        65 to 69",
"       </td>",
"       <td>",
"        -3",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70 to 74",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;75",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Marchioli R, Avanzini F, Barzi F. Eur Heart J 2001; 22:2085.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    GISSI predictive model for risk of death after acute myocardial infarction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Men",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Points",
"       </td>",
"       <td class=\"subtitle2\">",
"        Absolute risk of death, number",
"       </td>",
"       <td class=\"subtitle2\">",
"        Points",
"       </td>",
"       <td class=\"subtitle2\">",
"        Absolute risk of death, number",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &le;-11",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"       <td>",
"        &le;-8",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -10 to -6",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        -7 to -3",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -5 to 0",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"       <td>",
"        -2 to 0",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 3",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        1 to 3",
"       </td>",
"       <td>",
"        2.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 to 6",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"       <td>",
"        4 to 6",
"       </td>",
"       <td>",
"        2.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7 to 9",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"       <td>",
"        7 to 9",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10 to 12",
"       </td>",
"       <td>",
"        9.6",
"       </td>",
"       <td>",
"        10 to 12",
"       </td>",
"       <td>",
"        5.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13 to 15",
"       </td>",
"       <td>",
"        12.8",
"       </td>",
"       <td>",
"        13 to 15",
"       </td>",
"       <td>",
"        6.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16 to 18",
"       </td>",
"       <td>",
"        16.6",
"       </td>",
"       <td>",
"        16 to 18",
"       </td>",
"       <td>",
"        9.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        19 to 21",
"       </td>",
"       <td>",
"        22.0",
"       </td>",
"       <td>",
"        19 to 21",
"       </td>",
"       <td>",
"        12.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22 to 24",
"       </td>",
"       <td>",
"        28.5",
"       </td>",
"       <td>",
"        22 to 24",
"       </td>",
"       <td>",
"        16.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25 to 27",
"       </td>",
"       <td>",
"        36.4",
"       </td>",
"       <td>",
"        25 to 27",
"       </td>",
"       <td>",
"        21.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28 to 30",
"       </td>",
"       <td>",
"        45.7",
"       </td>",
"       <td>",
"        28 to 30",
"       </td>",
"       <td>",
"        27.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        31 to 33",
"       </td>",
"       <td>",
"        56.1",
"       </td>",
"       <td>",
"        31 to 33",
"       </td>",
"       <td>",
"        35.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        34 to 36",
"       </td>",
"       <td>",
"        67.0",
"       </td>",
"       <td>",
"        34 to 36",
"       </td>",
"       <td>",
"        44.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        37 to 39",
"       </td>",
"       <td>",
"        77.5",
"       </td>",
"       <td>",
"        37 to 39",
"       </td>",
"       <td>",
"        54.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;40",
"       </td>",
"       <td>",
"        83.9",
"       </td>",
"       <td>",
"        &ge;40",
"       </td>",
"       <td>",
"        61.6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Marchioli R, Avanzini F, Barzi F. Eur Heart J 2001; 22:2085.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_53_21342=[""].join("\n");
var outline_f20_53_21342=null;
var title_f20_53_21343="Mirena IUD insertion kit";
var content_f20_53_21343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mirena IUD&reg; insertion kit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 492px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Berlex. Copyright &copy; Berlex.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_53_21343=[""].join("\n");
var outline_f20_53_21343=null;
